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i 
Abstract 
 
Sodium handling properties of left atria (LA) were compared to those of left 
ventricle (LV), with the aim to understand the atria’s susceptibility to arrhythmia 
and improve therapy. Mouse LA sodium channels displayed distinctive 
activation, inactivation and recovery kinetics compared to LV sodium channels. 
Distinctive voltage dependence of LA sodium channel inactivation was 
instrumental in reducing INa in LA compared to LV, when initiated from 
physiological holding potentials. Flecainide sodium channel inhibition was 
greater in LA than LV, likely also due to differences in kinetic properties of the 
sodium channels between chambers. Additionally, the greater inhibitory effect 
of flecainide at more positive membrane potentials could result in even greater 
LA sodium channel inhibition in vivo. 
 
Activation and inactivation distinctions observed between LA and LV sodium 
channels were conserved between chambers in the Plako+/- mouse. However, 
there was no difference in physiological INa density, sodium channel recovery or 
flecainide inhibition between Plako+/- LA and LV chambers. 
 
The novel Langendorff-free isolation method produced high yields of viable 
mouse cardiomyocytes comparable in morphology, signalling, calcium handling 
and sodium channel electrophysiology to cardiomyocytes isolated using the 
traditional Langendorff method. This maintained that injection isolation is a 
valuable method for obtaining cardiomyocytes for cardiac research.   
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1 
1.#Introduction#
1.1.#Summative#overview#
Intracellular Na+ concentration [Na+]i  is an essential modulator of action 
potential (AP) waveform, calcium cycling and impulse propagation throughout 
the myocardium (1). To enable cell excitability a Na+ gradient across 
cardiomyocyte membranes must be maintained. Therefore, [Na+]i is regulated 
by a balance between the influx and efflux of Na+ via a number of 
transmembrane pumps, channels and transporters (2). Over the last few 
decades there has been increasing interest in the regulation of [Na+]i, as 
deregulation is associated with cardiac disease and may contribute to 
pathophysiology (3). The processes driving physiological regulation of [Na+]i in 
health and disease are relatively well studied in the ventricles. However, the 
fundamental difficulties in studying the atria and atrial cardiomyocytes have 
resulted in few direct comparisons of the way Na+ is handled between the 
ventricles and atria. As isolation of workable cardiomyocytes is a key issue for 
the study of the atria, this thesis outlines a new method for ventricular isolation 
that can be utilised for atrial isolation and describes the viability of cells 
compared to those that have been isolated using the more classical method. 
 
Studying Na+ handling specifically in the atria could aid in understanding the 
atria’s susceptibility to arrhythmia and also potentially highlight atrial specific 
targets for treatment of atrial fibrillation (AF). Distinctions between atrial and 
 
 
2 
ventricular sodium channel kinetics have been identified in several mammalian 
species (4-6). However, it is essential that these findings be considered in 
physiological context. Consequently, results presented in this study aim to 
develop an understanding of the clinical relevance/importance of Na+ handling 
distinctions between cardiac chambers. A number of sodium channel inhibiting 
drugs have been used in the treatment of AF (7) and this thesis also aims to 
characterise inhibitor effects on sodium channels in the atria compared to the 
ventricles. 
 
Additionally, it is essential to establish whether distinctions shown in this study 
and previous mammalian studies are representative of what would be observed 
between human atria and ventricles, in order to consider the clinical relevance 
of findings. Molecular experiments described within this thesis identify 
differences in the proteins associated with the sodium channels between 
human atrial and ventricular chambers and between healthy and diseased 
cardiac tissues. Therefore, a discussion into what the consequences of these 
molecular distinctions are, in terms of the effect of disease on Na+ handling 
within the different chambers of the heart, is contained within this thesis. 
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1.2.#Cardiac#physiology#
1.2.1.#Basic#anatomy#and#function#of#the#heart#
The mammalian heart is a muscular organ that lies inside the thoracic cavity 
surrounded by a fluid filled sac called the pericardium, which serves as 
protection. The circulatory system is defined as the heart and the system of 
blood vessels that carry blood around the body. Circulation of blood with 
adequate perfusion of the organs and tissues is essential to sustain life, by 
delivering oxygen and nutrients, alongside carrying away waste products (8). 
 
The wall of the heart consists of three layers of tissue. The epicardium is the 
outer layer and is primarily composed of connective tissue, including elastic 
fibers and adipose tissue. It acts as a protective layer and assists in the 
production of the pericardial fluid that fills the pericardial cavity and aids in 
reducing friction between pericardial membranes. The coronary blood vessels 
that supply the heart wall with blood are also found in this layer of heart. The 
myocardium is the middle and the thickest layer of the heart, consisting of the 
cardiac muscle fibers that enable contraction. The endocardium is the layer that 
lines the inner heart chambers, covers heart valves and is continuous with the 
endothelium of the large blood vessels, providing a smooth surface, enabling 
blood to flow freely (9). 
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The heart consists of four distinct hollow chambers. The two upper chambers 
are the right and left atrium and the two lower chambers are right and left 
ventricles (Figure 1.1). The septum is a muscular wall that separates the left 
chambers from the right chambers. The right atrium (RA) receives 
deoxygenated (carbon-dioxide enriched) blood via the inferior and superior 
vena cava from the systemic circulation. The RA contracts and the blood flows 
into the right ventricle (RV), which contracts to eject blood into the pulmonary 
artery, delivering it to the lungs. In the lungs the blood is oxygenated. The left 
atrium (LA) receives this oxygenated blood from the lungs via the pulmonary 
veins and contracts, filling the left ventricle (LV), which contracts to eject blood 
into the aorta and systemic arterial system of the body. There are four valves 
that insure the flow of blood is unidirectional by preventing backflow. The aortic 
valve is found between the LV and aorta, the mitral valve between the LA and 
LV, the pulmonary valve between the RV and pulmonary artery and tricuspid 
valve between the RA and RV (9).  
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Figure 1.1. Structure and blood flow though the heart. 
The arrows show the direction of blood flow. The blue denotes the circulation of 
deoxygenated blood and the red denotes the circulation of oxygenated blood. 
Image extracted from (10). 
 
1.2.2.#Cardiomyocytes#
The myocardium is an organised tissue comprised of immune cells, smooth 
muscle cells, fibroblasts and cardiomyocytes (the fundamental contractile cells). 
Cardiomyocytes have a striated subcellular structure and are connected to 
neighbouring cardiomyocytes by intercalated discs consisting of desmosomes, 
providing structural attachment of myocytes and an electrical connection via 
gap junctions (11). Gap junctions are essential in conducting the electrical 
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impulse throughout the myocardium, by providing low resistance pathways 
between cardiomyocytes. As desmosomes link intracellularly to the intermediate 
filament cytoskeleton, it is the network of adhesive bonds they form that gives 
the heart its mechanical strength. Therefore, if cardiac desmosomal adhesion 
breaks down, as with particular autoimmune and genetic diseases, the heart 
cannot uphold mechanical stress and integrity of the myocardium can be lost 
(12). Desmosomes are also important for signalling, regulating the availability of 
signalling molecules, participating in cell proliferation, differentiation and 
morphogenesis (12). 
 
Atrial and ventricular cardiomyocytes develop their distinctive, cell-specific 
characteristics at an early embryonic stage by regulated gene expression. 
Ventricular cardiomyocytes are elongated rectangular shaped cells with many 
myofibrils and mitochondria (for ATP production). Myofibrils are repeating units 
(sarcomeres) composed of thin actin filaments and anchored at the Z-disks at 
the end of the sarcomere and thick myosin filaments, which interlock and 
interact with the thin filaments. Atrial cardiomyocytes differ from ventricular 
cardiomyocytes, having a thinner smaller shape with fewer transverse tubules 
(T-tubules), which are 20-450nm extensions of the membrane that penetrate 
into the cell (13). Atrial cardiomyocytes have more caveolae, 50-100nm lipid raft 
invaginations of the plasma membrane. Unlike ventricular cardiomyocytes, 
which are multinucleated, atrial cardiomyocytes typically have only one central 
elongated nucleus (14, 15). 
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1.2.3.#Cardiac#conduction#system#
The contracting chambers of the heart are controlled by the cardiac conduction 
system. This system generates electrical impulses known as action potentials 
(APs) and conducts them throughout the myocardium, stimulating the heart to 
contract. APs are a result of transient changes in ion conductance across 
cardiomyocyte membranes. Ion channels and transporters are membrane-
embedded proteins that selectively allow passage of ions, which is the primary 
cause of changes in conductance (8). 
 
The normal cardiac conduction system pathway starts at the sinoatrial (SA) 
node, the dominant pacemaker that generates an impulse at the junction of the 
superior vena cava and RA. The cells within the SA node are characterised as 
having no true resting membrane potential, instead they produce regular, 
spontaneous APs. Although pacemaker activity is spontaneously generated by 
SA nodal cells, the rate of this activity can be changed considerably by external 
factors; including autonomic nerves, hormones, ion concentrations, medication 
and ischemia/hypoxia. From the SA node the electrical impulse spreads 
throughout the RA and LA via cell-to-cell conduction at a velocity of around 
0.5m/sec. The wave of APs depolarises the atrial myocardium, initiating atrial 
muscular contraction and resultant filling of the ventricles (8). 
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The impulse is conducted via the atrial myocardium, towards the atrioventricular 
(AV) node, which is a specialised region of cells located in the inferior-posterior 
region of the interatrial septum. At the AV node, conduction is slowed 
considerably to around 0.05m/sec to allow sufficient time for complete atrial 
depolarisation and contraction before depolarisation progresses to the 
ventricles. The impulse then enters the apex of the ventricles and spreads 
throughout the ventricles via the specialised Bundle of His conduction system. 
The impulse then streams down the left and right bundle branches along the 
interventricular septum, at a rapid velocity of around 2m/sec. The bundle 
branches then divide into the extensive Purkinje fibers system that conduct the 
impulses throughout the ventricles at a velocity of around 4m/sec. This rapid 
spread of electrical impulse across the ventricles enables a coordinated 
depolarisation of the ventricular myocardium and uniform contraction (16). 
 
A synchronised conduction system within the heart is essential to ensure the 
rapid and organised depolarisation of cardiomyocytes, required for efficient and 
accurate contraction. Electrical conduction across the heart is influenced by 
autonomic nerve activity. Autonomic control is most apparent at the AV node as 
sympathetic activation increases conduction velocity by increasing the rate of 
depolarisation, reducing the normal delay of conduction, therefore reducing the 
time between atrial and ventricular contraction. Conversely, parasympathetic 
activation decreases conduction velocity at the AV, increasing time between 
atrial and ventricular contraction (16). 
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1.2.4.#Cardiomyocyte#resting#membrane#potential#
The intracellular voltage potential with respect to the extracellular voltage 
potential under resting conditions is known as the resting membrane potential 
(RMP). With stimulation, the normally negative voltage potential inside the cell 
(negative membrane potential), can temporarily become more positive, resulting 
in the generation of an AP. Membrane potentials are established by an 
asymmetric distribution of ions on each side of the cardiomyocyte membrane, 
selective permeability of the cell by specific ion channels and the activity of 
electrogenic pumps that maintain ion concentrations across the membrane (8). 
 
Cardiomyocytes have distinctive concentrations of ions across their membrane, 
the most significant being K+, Na+, Cl- and Ca2+. Inside a cardiomyocyte the 
concentration of K+ is high but low on the outside of the cell, resulting in a 
chemical gradient for K+ to diffuse out of the cell. Whereas, Ca2+ and Na+ 
concentrations are higher outside of the cell, favouring inward diffusion of those 
ions (17).  
 
Cardiomyocytes have channels that allow K+ to move across the cell membrane 
so that it diffuses down its chemical gradient out of the cell. The negative 
charge across the membrane that would be required to oppose the movement 
of K+ out of the cells is termed the equilibrium potential for K+ (EK).  In 
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electrochemistry, the Nernst equation is an equation that defines the 
relationship between the concentrations of an ion on either side of a perfectly 
selective membrane and so the potential difference (voltage) that would be 
measured across the membrane under equilibrium conditions. Therefore, the 
Nernst equation can provide a value for the voltage that must exist across the 
membrane in or order to balance a chemical gradient (17). The EK can be 
calculated using the Nernst equations as follows: 
EK = 
!!"!" !" !! !!! ! = !−96!"! 
Where R= universal gas constant (8.314 J.K−1.mol−1), T= temperature in Kelvin, 
z=1 as K+ is monovalent, F= Faraday’s constant (96,485 C.mol−1), [K+]o 
(extracellular K+ concentration) =4mM and [K+]i (intracellular K+ concentration) 
=150mM. 
 
Contrasting to the pacemaker cells in the nodal tissue of the heart, non-
pacemaker cells have a stable RMP that rarely depolarises spontaneously. The 
RMP for a ventricular myocyte is around -80 to -90mV, near to the equilibrium 
potential for K+, as cardiomyocytes are most permeable to K+ compared to 
other ions. The key current that sets the RMP is the inward rectifier K+ current 
(IK1). As Ek is -96mV there is a net electrochemical outward driving force of 
around 6-16mV acting on K+. This small net outward driving force and finite 
permeability of cardiomyocytes to K+, results in a slow outward leak of K+ from 
the cells. However, regardless of the leaking K+, the chemical gradient is 
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maintained due to Na+/K+-ATPase pumps that actively transport K+ back into 
cardiomyocytes. The Kir2.1 potassium channel is the major channel responsible 
for IK1 and it has a lower expression in the atria compared to the ventricles. 
Therefore, atrial cardiomyocytes have lower density of IK1 (around 5-6 fold less) 
than ventricular cardiomyocytes, and this explains their resulting depolarised 
RMP of at around -65 to -80mV(18-20). 
 
1.2.5.#Pacemaker#action#potential#
An AP results from the rapid depolarisation of the myocyte membrane followed 
by repolarisation back to RMP of the cell. The AP in nodal cells differs to the AP 
generated in cardiomyocytes of the atria and ventricles. The SA node is the 
primary pacemaker site within the heart and characterised as having no true 
RMP, generating regular spontaneous APs. Distinctive to pacemaker cells, the 
AP depolarising current is caused by the relatively slow influx of Ca2+, with no 
fast Na+ currents. This causes the SA nodal cells to have relatively slower 
depolarisation and therefore slower APs. Therefore, APs in SA and AV 
pacemaker cells as known as “slow response” APs, as they have a slower rate 
of depolarisation than non-pacemaker cells. Non-pacemaker APs, inversely 
referred as “fast response” AP’s, due to more rapid depolarisation, are found 
throughout the myocardium (21). Although pacemaker activity is spontaneously 
generated by the SA nodal cells it can be modified by autonomic nerves, drugs, 
hormones, ischemia and hypoxia. 
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SA nodal cell APs has 3 phases. The ions responsible for change in membrane 
potential during the AP are predominantly Ca2+ and K+, and to a lesser extent 
Na+ (Figure 1.2). When the membrane is repolarised, Na+ channels open, 
conducting a slow inward Na+ current called the “funny current” (If) (If is a mixed 
Na+-K+ current, therefore it can also occur as a result of K+ influx). The If results 
in the membrane potential depolarising, initiating phase 4 of the AP that 
consists of this spontaneous depolarisation. As the membrane potential 
reaches -50mV transient (T-type) calcium channels open, enabling inward Ca2+ 
current (ICaT) down its electrochemical gradient, further depolarising the cell. 
When the membrane potential depolarises to approximately -40mV the long-
lasting (L-type) calcium channels open with a resulting inward Ca2+ current 
(ICaL). This further depolarises the cell until the AP threshold of -40 to 30mV is 
reached and phase 0 commences. Also, during phase 4 there is a slow decline 
in K+ efflux (IK) as the K+ channels responsible for phase 3 close, contributing to 
the depolarising pacemaker potential. 
 
Phase 0 is the AP depolarisation phase, caused by increased ICaL. The If and 
ICaT declines during this phase as their respective channels close. As Ca2+ influx 
is slow the rate of depolarisation is much slower than that of cardiac cells. This 
is followed by repolarisation in phase 3, as K+ channels open, resulting in IK and 
L-type calcium channel inactivation and closure. The subsequent 
hyperpolarised state is essential for pacemaker channels to activate. Therefore, 
once the nodal cell is repolarised to approximately -60mV in phase 3, the AP 
phase cycle is spontaneously repeated. 
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In SA nodal pacemaker cells during depolarisation the membrane potential 
moves towards the equilibrium potential for Ca2+, about +134mV. During 
repolarisation Ca2+ conductance decreases and K+ conductance increases, 
resulting in membrane potential becoming closer toward the equilibrium 
potential of K+, as stated above -96mV, according to the Nernst equation. AV 
nodal cell APs also have intrinsic pacemaker activity produced by the same 
ionic currents as the SA nodal cells, determined by changes in slow inward Ca2+ 
and K+ current, with no fast Na+ currents. 
 
Spontaneously released Ca2+ from the SR (known as a Ca2+ spark) into the 
cytosol is involved in the “calcium clock” mechanism that also determines 
pacemaker potential. The rise in intracellular Ca2+ activates the NCX to extrude 
one Ca2+ out of the cell in exchange for three Na+ into the cell, depolarising the 
membrane potential. The extruded Ca2+ is later pumped back into the cell via 
Ca2+ channels on the cell surface and SR membranes, allowing a flow of Ca2+ 
into the cell, continuously depolarising the membrane potential (22). 
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Figure 1.2. SA node action potential. 
The numbers refer to the phase of the AP. The respective membrane potential 
is shown to the left of the AP. Figure adapted from (23). 
 
1.2.6.#Human#ventricular#action#potential#
Atrial and ventricular cardiomyocytes are examples of cells that generate non-
pacemaker AP’s. The type of ion channels responsible for determining the AP 
in ventricular and atrial cardiomyocytes are mostly the same (21). However, the 
expression and regulation differ in some of the ion channels and this is what 
results in the AP of a ventricular cardiomyocyte having different morphology to 
that of an atrial cardiomyocyte (24). 
 
A normal human ventricular cardiomyocyte AP has five phases (Figure 1.3). 
Phase 4 is the RMP phase (-90mV for ventricular cardiomyocytes) and is 
associated with high K+ currents (IK1), in which K+ ions are leaving the cell and 
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making the membrane potential negative. At the same time, fast sodium 
channels and L-type calcium channels are closed. Phase 0 occurs when cells 
are rapidly depolarised by an AP at a neighbouring cell, to a threshold voltage 
of around -70mV. 
 
Phase 0 is classified by a rapid upstroke with a large and fast depolarisation of 
the cardiomyocyte membrane, due to the rapid influx of Na+ ions along their 
electrochemical gradient, generating the “fast-response” AP. This inward Na+ 
current (INa) generates the initiation and propagation of APs from cardiomyocyte 
to neighbouring cardiomyocyte throughout the myocardium, consequently 
assuming a central role in the excitability of the myocardial cells and accurate 
conduction of the electrical impulse across the heart (1). At the same time that 
sodium channels open, outward K+ current diminishes as potassium channels 
close. This results in the membrane potential moving away from EK and closer 
toward the equilibrium potential for Na+ (ENa), which is +52mV (if the same 
conditions are used as in the previously described Nernst equation) (17). 
 
Phase 1 of the ventricular AP represents an initial repolarisation that is a result 
of the fast depolarisation activated, 4-AP (aminopyridine)-sensitive, Ca2+ 
independent transient outward K+ current (Ito). However, due to the transient 
nature of Ito and also a simultaneous large increase in slow inward Ca2+, 
repolarisation is delayed, described as phase 2. This inward calcium ICaL is via 
L-type calcium channels that open when the membrane depolarises to around -
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40mV. This plateau phase prolongs the AP duration (APD) and distinguishes 
the cardiac non-pacemaker APs from nerve and skeletal muscle APs. There are 
an additional two functionally distinct K+ current in the myocardium, rapidly and 
slowly delayed rectifier potassium currents (IKr and IKs respectively), so named 
due to their voltage-dependent kinetics of recovery (25). The repolarisation of 
phase 3 occurs when potassium conductance increases and leads to the 
activation of IKr and IKs alongside the inactivation of Ca2+ channels (26, 27). 
 
Figure 1.3. Ventricular action potential. 
The numbers refer to the phase of the AP. The respective membrane potential 
is shown to the left of the AP. Figure adapted from (28). 
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1.2.7.#Human#atrial#action#potential#
As previously stated, atrial APs differ from ventricular APs, aside of the 
difference in RMP (phase 4). The human atrial AP characteristically exhibits a 
more triangular morphology compared to that of the ventricular AP, which has a 
spike-and-dome shape with the prominent plateau phase (Figure 1.4). The 
characteristic difference in morphology of the human atrial AP compared to the 
ventricular AP is observed in most mammalian species, except for rats and 
mice, where both atrial and ventricular cardiomyocytes display short, triangular 
APs (29, 30).  
 
Maximum upstroke velocities (Vmax) of human atrial APs have been reported to 
be between 150-300V/s (19, 31, 32), notably less than the 300-400V/s reported 
for ventricular APs (33, 34). Vmax has long been established as a measure of INa 
in cardiac myocytes (19, 31). The lower Vmax of the atrium is possibly 
associated with the more depolarised RMP compared to that of the ventricles, 
as it would be expected that a more positive RMP would lead to reduced INa. 
   
Additionally, as detailed previously, the atrial RMP is more depolarised due to a 
smaller IK1, but this smaller density of IK1 is also partly accountable for the 
slower late phase of repolarisation in the atria. Human atrial cardiomyocytes 
exhibit a 2-fold greater density of the IKr current (generated predominantly by 
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the Kv4.3 channel) compared to that of the ventricles, which is responsible for 
the initial phase 1 repolarisation phase in the atria (Figure 1.4). Additionally, the 
slow component of the transient outward current IKs, generated from the Kv1.4 
channel, is completely absent in the atria, but exists in the ventricles (Figure 
1.4) (24). However, the atria do express three functional delayed rectifier K+ 
currents that contribute to AP repolarisation. The ultra-rapid delayed rectifier K+ 
current IKur (generated by the Kv1.5 channel) is exclusive to the atria and is 
active during the plateau phase of the AP (Figure 1.4). Its atrial specific nature 
has resulted in the IKur being an attractive target of antiarrhythmic drugs (AADs) 
for AF treatment (35). 
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Figure 1.4. Morphology and ionic currents of human atrial and ventricular 
action potentials. 
The AP morphology is shown by the top left and right hand side figures for the 
respective chamber. The numbers refer to the phase of the AP. For each 
current profile the thin horizontal line represents zero current. The blue inward 
currents fall below the line and red outward currents are above it. Figure 
adapted from (28). 
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1.2.8.#Effective#refractory#period#
After phase 0 and during phases 1,2 and part of 3 of the AP, another AP cannot 
be initiated as the voltage-gated sodium channels (VGSCs) are in the non-
conducting closed state and must recover back to the closed resting state 
before they can reopen. This period is known as the effective refractory period 
(ERP). Consequently, the length of the ERP restricts the frequency of APs (and 
thus contractions) that the cardiac tissue can generate. Therefore, the ERP is 
protective as it inhibits multiple, compounded AP’s from arising, that would 
render the heart unable to adequately fill with and eject blood (23). 
 
1.2.9.#Cardiac#excitationJcontraction#coupling#
The electrical activation of a cardiomyocyte triggers contraction followed by 
relaxation, known as excitation-contraction coupling (ECC). ECC includes the 
initial membrane depolarisation via the AP and activation of the Ca2+ transient, 
including the myofilament contractile response to the Ca2+ transient (Figure 
1.5)(36). 
 
In a ventricular cardiomyocyte an AP moves along the cell sarcolemma and 
down into the T-tubule system depolarising the cell membrane. Voltage-
sensitive L-type calcium channels open and Ca2+ enters into the cell during 
phase 2 of the AP (Figure 1.4). The resulting ICaL triggers a subsequent release 
of large amounts of Ca2+ from the sarcoplasmic reticulum (SR), via SR calcium 
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release channels called ryanodine receptors (RyR2s), causing intracellular Ca2+ 
([Ca2+]i) to rise. As previously described, atrial cardiomyocytes have fewer T-
tubules than ventricular cardiomyocytes, and the cells making up the SA node, 
AV node and Purkinje fibers have almost none. In the regions that lack T-
tubules, ICaL initiates SR Ca2+ release only at the surface membrane junctions 
(37).  
 
The released free Ca2+ binds to troponin-C (TN-C), part of the regulatory 
complex attached to the thin filaments. This stimulates a conformational change 
in the regulatory complex that causes troponin-I (TN-I) to expose a site on the 
actin molecules, which can then bind to the myosin ATPase located on the 
myosin head. This binding instigates ATP hydrolysis, providing energy for a 
conformational change to transpire in the actin-myosin complex. The overall 
consequence of the conformational changes is the action of the actin and 
myosin filaments sliding past each other (a ratchet motion) shortening the 
length of the sarcomere. This ratchet motion cycle ensues when the cytosolic 
Ca2+ remains elevated (38). 
 
Therefore, it is essential for the [Ca2+]i to decline for cardiac relaxation and 
ventricular filling to occur. ICaL slows at the end of phase 2 of the AP and the SR 
sequesters Ca2+ by an ATP-dependent Ca2+ pump, sarco-endoplasmic 
reticulum calcium-ATPase (SERCA). Additionally, Ca2+ is also transported out 
of the cell by the sodium-calcium exchanger (NCX) pump (39). The resultant 
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reduction of cytosolic Ca2+ concentration triggers removal of Ca2+ from TN-C. 
The unbinding of Ca2+ from TN-C causes a conformational change in the 
troponin complex, leading to the return of TN-I inhibition of the actin-binding 
site. A new ATP binds to the myosin head, displacing the ADP and the 
sarcomere length is restored, with subsequent muscle relaxation (38, 40). See 
Figure 1.5 for a schematic summarising this. 
Figure 1.5. A ventricular Ca2+ transport schematic. 
The different cardiomyocyte forms of Ca2+ transportation. A rabbit ventricular 
cardiomyocyte time AP, Ca2+ transient and contraction is shown inset. Figure 
extracted from (40). 
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1.3.#Sodium#handling#pathways#
In the heart [Na+]i is involved in numerous vital cell functions, such as 
excitability as a key modulator of AP waveform, ECC, pH regulation, energy 
metabolism and cardiac development and growth. Na+ homeostasis is complex, 
regulated in cardiac myocytes by a balance of Na+ influx and efflux pathways. In 
a healthy cardiomyocyte there is a steady state electrochemical gradient 
favouring Na+ influx. This potential energy is utilised by Na+ specific channels 
and transporters that couple Na+ influx to the co- or counter-transport of other 
ions and solutes (2). 
 
Under typical conditions sodium channels and Na+/Ca2+ exchange are the 
primary Na+ influx pathways. However, additional transport mechanisms, such 
as Na+/H+ exchange, can become greatly activated and potentially increasingly 
important during altered conditions, including acidosis (41). The Na+ extrusion 
from cardiomyocytes occurs principally via the Na+/K+-ATPase pump. 
Na+/Ca2+ antiporter and Na+/H+ exchange are also present in the mitochondria 
and are critical to mitochondrial function (42, 43). The paired fluxes of Na+ with 
Ca2+ and H+ make the detailed understanding of [Na+]i regulation crucial to the 
understanding of cardiac ECC and pH regulation.  
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1.3.1.#VoltageJgated#sodium#channel#
 VGSC’s are a class of intrinsic transmembrane proteins that are responsible for 
the initiation and propagation of the AP in electrically excitable cells, activated 
by fluctuations in cardiomyocyte membrane potential. Mammalian VGSCs are 
formed of a pore-forming α-subunit (260kDa) that is associated with one or two 
β-subunits (30-40kDa) (44). 
 
1.3.1.1.#Sodium#channel#αJsubunit#and#gating#
The α-subunit (pore-forming subunit) is capable of forming a fully functional 
channel and can generate electrical impulses independent of the auxiliary β-
subunits. The mammalian species express nine functional VGSC α-subunit 
isoforms, Nav1.1-1.9.!The primary α-subunit isoform expressed in the heart is 
Nav1.5, encoded by the SCN5A gene located on chromosome 3p21, forming 
the principal electrophysiological and pharmacological properties of the INa 
within the myocardium (45, 46). However, Nav1.5 expression has also been 
detected in other tissues, including the brain and gastrointestinal smooth 
muscle (47). Similarly, expression of the Nav1.1 (44, 48-50), Nav1.2 (49), Nav1.3 
(50, 51), Nav1.4 (52), Nav1.6 (50, 51) and Nav1.8 (49) isoforms have also been 
determined in the heart but contribute to a very small proportion of the total 
cardiac sodium current compared to Nav1.5. 
 
All eukaryotic VGSCs have shown to have similar overall folding patterns. The 
α-subunits are large, single-chain polypetides that consist of approximately 
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2000 amino acid residues organised into four homologous transmembrane 
domains (DI-DIV), covalently or non-covalently linked to one or two β-subunits 
via the N and C termini (53). Figure 1.7 illustrates a schematic representation of 
a VGSC. 
 
There are three distinct primary states for VGSCs (Figure 1.6): a closed resting 
state, an open conducting state, and a non-conducting inactivated state. The 
rapid depolarisations of the cardiomyocyte and conduction of the electrical 
impulse depend on Nav1.5 availability and if channels are in a closed or open 
state (54). Each DI-DIV domain of the VGSC is composed of two sub-domains: 
a cytoplasmic sub-domain and a transmembrane sub-domain. The domains are 
linked by intracellular loops and each domain is comprised of six 
transmembrane segments (S1–S6). Segment S1-S4 from each domain form 
the structural component with the function of regulating the channel opening 
upon depolarisation of the membrane, known as the voltage-sensing domain 
(VSD) (Figure 1.7). 
 
At RMP (-80 to -90mV in LV and -60 to -80mV in LA), Nav1.5 is in the closed 
resting state and in this configuration the activation gate is closed and 
inactivation-gate is open. There are conformational changes of the channel 
gates in response to changes in voltage. The S4 segment is positively charged 
and involved in the voltage-dependent activation of the channel. The VSD is 
linked to the pore domain (PD) by an intracellular loop between the S4 and S5 
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segments. The PD physically conducts Na+ into the cardiomyocyte and is lined 
by S6 segments, forming the intracellular cavity known as the activation-gate 
(55, 56). When the membrane depolarises the positively charged S4 segment 
moves towards the extracellular surface and this motion transfers to the PD via 
intracellular linkers, resulting in a conformational change, causing opening of 
the activation gate and so also the channel pore. This means that the channel is 
in the open conducting state and Na+ enters the cardiomyocyte, driven by the 
electrochemical gradient (54). As described, this inward current causes the 
initiation and propagation of action potentials throughout the myocardium, 
subsequently playing a central role in the excitability of myocardial cells and 
accurate conduction of the electrical impulse throughout the heart (1). 
 
The channel inactivation-gate is formed and stabilised by the C-terminal domain 
and the intracellular loop between DIII on S6 and DIV on S1 (57, 58). During 
membrane depolarisation this loop (inactivation-gate) acts as a hinged lid and 
folds toward the intracellular opening of the α-subunit pore, inactivating the 
channel. This conformational change renders the channel to be in the non-
conducting inactivated state, as Na+ can no longer enter the cardiomyocyte. 
When the membrane repolarises the VGSC recovers from inactivation and the 
S4 segments return to the closed resting state, available for a subsequent 
depolarisation and the inactivation-gate unfolds out of the α-subunit pore. 
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Figure 1.6. A schematic representation of VGSC gating. 
A representation of the three distinct primary gating states of a VGSC. Figure 
extracted from (59). 
 
Figure 1.7. A schematic representation of VGSC structure. 
The four (I-IV) domains are labelled above the respective S1-S6 segments. The 
PD and VSD are labelled above the respective segments. The positively 
charged S4 segments are shown in green. The β-subunit isoform has not been 
specified. Figure adapted from (60). 
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1.3.1.2.#Sodium#channel#βJsubunit#
Most VGSCs isolated from mammalian cells contain associated β-subunits and 
as detailed previously, VGSCs are composed of one α-subunit and one or two 
β-subunits. The VGSC β-subunits are type 1 intrinsic membrane proteins, 
members of the immunoglobulin (Ig) domain family of cell-adhesion molecules. 
The V-type Ig domain is connected to a single α-helical transmembrane domain 
and a carboxy-terminal intracellular region (Figure 1.7). There are 4 identified β-
subunits of sodium channels, β1 and β3 that are non-covalently linked with the 
α-subunit (61, 62) and β2 and β4 that are inter-subunit disulfide-linked to the α-
subunit (63, 64). 
 
Studies in heterologous expression systems and in native cells have revealed 
that VGSC β-subunits regulate properties of the α-subunits, including level of 
plasma membrane expression, subcellular localisation, channel gating kinetics 
and voltage dependence (53, 65). Although there are some discrepancies in 
observations, it is generally agreed that co-expression of β1 with Nav1.5 in vitro 
promotes Nav1.5 trafficking to the plasma membrane, resulting in increased 
peak INa (53, 66). However, it has been shown that the co-expression of β2 and 
β4 subunits with Nav1.5 has little to no effect on INa density but experiments 
were conducted using hyperpolarised holding potentials, so may not be 
representative of INa effects in vivo (4, 67). Furthermore, studies of mutated β3 
have shown reduced INa density, supporting the notion that β3 co-expression 
with Nav1.5 increases INa density (68-70).  
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The β-subunits have also been shown to affect the gating kinetics of VGSCs. 
The expression of β1 with Nav1.5 has shown to result in a negative shift in 
steady-state inactivation of the channel (71). However, others have shown 
opposing results, observing a positive shift in steady-state inactivation (72). 
Similarly, the effect of β1 co-expression on the activation of Nav1.5 has been 
inconclusive, with some reporting no effect (44), others reporting a negative 
shift (73) and others reporting positive shifts (72). Additionally, β1 co-expression 
was shown to reduce the persistent current, known as the late Na+ current 
(INaL), (74). 
 
Co-expression of β2 and β4 with Nav1.5 shifted the steady-state inactivation 
kinetics positively and caused faster recovery of the channel (4). Others found a 
negative shift in activation with β4 (64) but this is conflicting with no difference in 
activation voltage when Nav1.5 is expressed with both the β2 and β4 subunits 
compared to Nav1.5 expression alone (4). Additionally, silencing of the β2 
subunit in ventricular cardiomyocytes has resulted in an increase in INaL (75). 
Co-expression of β3 with Nav1.5 studies have also shown contradictory results, 
negative shifts (70) and positive shifts (69) in the steady-state inactivation of the 
channel. 
 
 
 
30 
1.3.1.3.#Late#sodium#current#
After opening briefly in phase 0 of the AP, Nav1.5 ordinarily inactivates and 
remains in the non-conducting inactivated state until complete repolarisation. 
However, VGSCs that remain open after initial depolarisation create a small 
persistent current known as INaL, lasting throughout phase 2 of the AP. Although 
INaL peak is very small compared to the peak INa (approximately <1%) (76), it 
occurs throughout the low conductance phase of the AP and has proven to 
contribute to AP morphology, plateau potential and AP duration (APD) in human 
ventricular cardiomyocytes. As membrane resistance is great during the AP 
plateau, even a slight increase of inward current can cause APD prolongation 
(77). Although the magnitude of INaL is small, due to its persistence throughout 
the AP, the resultant Na+ loaded into the cardiomyocytes is actually comparable 
to that of the INa (76). 
 
1.3.2.#SodiumJcalcium#exchanger#
NCX is the dominant Ca2+ efflux mechanism in cardiomyocytes and is therefore 
an essential modulator of cardiomyocyte Ca2+ regulation, Ca2+ cycling and 
contractile function (2). There are three mammalian NCX isoforms that are 
expressed in a tissue-specific manner, NCX1-3 (78). NCX1 is the primary 
isoform expressed in the mammalian heart (79). NCX1 is a plasma membrane 
protein, consisting of 10 transmembrane segments with a molecular weight of 
110kDa and appears to assemble as dimers. Studies have shown that NCX1 is 
distributed throughout the cardiomyocyte surface membrane, with some studies 
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suggesting there is a higher density within the t-tubules (80, 81). However, 
NCX1 localisation remains controversial (82). 
 
NCX1 binds and transports one Ca2+ ion in exchange for three Na+ ions across 
the cardiomyocyte plasma membrane, resulting in electrogenic transport that 
can be measured as an ionic current (83). On a beat-to-beat basis, NCX has 
the main function of extruding Ca2+ from cardiomyocytes during relaxation and 
diastole, balancing Ca2+ entry via L-type Ca2+ channels during cardiac excitation 
(84, 85). Therefore, small changes in NCX activity can significantly alter Ca2+ 
homeostasis. However, as NCX is driven by the trans-membrane Na+ gradient, 
aside from extrusion of Ca2+ in exchange for Na+, the “forward mode”, the NCX 
can also act inversely in “reverse mode”, facilitating Ca2+ influx and Na+ efflux. 
The direction of the NCX mode of activity is determined upon the physiological 
conditions of membrane potential and intracellular concentrations of Ca2+ and 
Na+ (86). 
 
Therefore, an increase in [Na+]i can result in a decrease in NCX “forward 
mode”, subsequently leading to increased [Ca2+]i and an increase in force of 
contraction. Equally, high [Na+]i can lead to “reverse-mode” NCX activation and 
trigger Ca2+ overload. A significant rise in [Ca2+]i controls the activity of a 
number of sarcolemmal ion channels and affects release of [Ca2+]i from the SR, 
causing a subsequent arrhythmogenic increase (87). With a sufficiently large 
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Ca2+ release from the SR, the NCX can generate a depolarising current and 
even prematurely activate Nav1.5 (3). 
 
1.3.3.#SodiumJpotassium#ATPase#pump#
The sodium-potassium ATPase (NKA) pump is an electrogenic transmembrane 
ATPase pump that utilises energy from ATP hydrolysis to extrude three Na+ 
ions in exchange for two K+ ions in, leading to net movement of charge. It 
consists of an α-subunit of approximately 110kDa and a β-subunit of 55kDa. 
Four isoforms of the α-subunit, α1-4 and three β-isoforms, β1-3 have been 
detected in mammalian cells (88). 
 
The NKA α-subunit contains the binding sites for ATP, Na+, K+ and cardiac 
glycosides. It transports 3 Na+ out in exchange for 2 K+ in for each ATP 
hydrolyzed. The principal isoform responsible for bulk Na+/K+ regulation in the 
cardiomyocytes is α1. However, α2 is accountable for Na+/K2+ regulation in the 
t-tubules and consequently maintaining contractility (89). Association with the β-
subunit is essential to stabilise the α-subunit in the endoplasmic reticulum and 
in directing the αβ-complex to the plasma membrane (90). The β1 and β2 
isoforms are the primary isoforms expressed in the human heart (91, 92). 
 
Phospholemman (PLM) is a small transmembrane protein that associates with 
and inhibits NKA, principally by reducing its affinity for internal Na+ (93). The 
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inhibition is relieved upon phosphorylation of PLM by protein kinase A (PKA) at 
site Serine68 or protein kinase C (PKC) at both sites Serine68 and Serine63 
(94). 
 
1.3.4.#SodiumJhydrogen#exchanger#
The sodium-hydrogen exchanger (NHE) is a ubiquitously expressed integral 
membrane protein that regulates intracellular pH, volume and [Na+]i, by 
extrusion of one H+ in exchange for one extracellular Na+. There are nine 
known isoforms of mammalian NHE’s, categorised NHE1-9. The first 
discovered isoform, NHE1, is the best characterised and is the primary 
cardiomyocyte isoform (95). The efflux of Na+ via the NKA pump provides a 
constant driving force for H+ extrusion and Na+ influx via the NHE. 
 
NHE1 is a protein of 815 amino acid residues with a molecular mass of 85kDa. 
It consists of two domains: an N-terminal membrane domain that transports ions 
and a C-terminal cytoplasmic regulatory domain that controls activity and 
facilitates cytoskeletal interactions (96). NHE1 is constitutively phosphorylated 
and further phosphorylation increases its activity and although it does not use 
ATP directly, AT depletion decreases its activity significantly (97). 
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1.4.#Cardiac#arrhythmias#
As described previously, ionic currents in cardiomyocytes generate a 
propagating wave of electrical potential, triggering a co-ordinated and directed 
contraction in order to pump blood around the body effectively. This sequence 
of processes is known as Normal Sinus Rhythm (NSR). Cardiac arrhythmia is a 
disturbance of NSR resulting from abnormalities in the electrophysical 
properties of the heart and it is a widespread and growing problem. Several 
pathological conditions can cause electrophysiological disturbances that are 
proarrhythmic, including acute ischemia, structural and/or biochemical 
abnormalities such as heart failure, cardiac fibrosis, cardiac hypertrophy, or 
genetically determined arrhythmia syndromes, electrolyte or hormonal 
imbalances and medication usage that alter ion fluxes and/or the effects of the 
autonomic nervous system of the heart (98). 
 
Electrical disturbances can lead to arrhythmia in the upper and lower chambers 
of the heart. Atrial fibrillation (AF) is the most common sustained cardiac 
arrhythmia in clinical practice and is recognised as an increasing health-care 
burden (99). 
 
1.4.1.#Atrial#fibrillation##
AF affects around 2% of the UK population and is becoming progressively more 
prevalent (99). Over the last few decades, hospital admissions for AF have 
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increased by two thirds, likely owed to an aging population, more frequent 
diagnosis as a result of improved monitoring, a rising prevalence of chronic 
heart disease and improved survival from disorders such as acute myocardial 
infarction (100). 
 
AF is characterised by a loss of the ordinarily close synchrony of the excitation 
and resting phases between atrial cardiomyocytes, triggering cells in different 
regions of the atria to depolarise, repolarise and become excited again in an 
uncoordinated fashion (101, 102) (Figure 1.8). The irregular pattern of excitation 
renders the affected atria incapable of coordinated contraction (103). 
Additionally, in AF the ventricular rate is often irregular as impulses enter the AV 
node from the atria at irregular times (104). However, as atrial contraction 
typically plays a minor role in ventricular filling, most individuals can tolerate AF 
if ventricular rate is adequate to maintain cardiac output, so AF is not 
immediately life threatening (105).  
 
Nonetheless, AF is a major cause of morbidity and mortality, as a result of 
stroke and thromboembolism, congestive heart failure, sudden death and 
impaired quality of life (106, 107). Due to increase in AF incidence it is 
anticipated that cardiovascular morbidity and economic costs will rise 
substantially (108). Evidenced by AF prevalence, the atria appear more 
susceptible to arrhythmia generation than the ventricles but the reason for this 
is yet to be clearly identified. 
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AF is characterised by progression over time and classified into three forms, 
paroxysmal, persistent and permanent. Paroxysmal AF is defined as short, self-
terminating episodes that convert to NSR within 7 days. Persistent AF is defined 
as recurrent episodes requiring intervention for restoration of sinus rhythm. 
Permanent AF is defined when AF is accepted and no attempts are made to 
restore sinus rhythm. It is thought that AF evolves from paroxysmal to persistent 
and then permanent as a result of atrial remodelling due to AF, although there 
are exceptions to this rule (109). This auto-reinforcing property has been 
replicated in animals models and termed as “AF begetting AF” (110). 
Paroxysmal, persistent and permanent forms of AF necessitate personalised 
approaches to management (111), calling for a more individualised 
understanding of the drivers of AF (112). Though AF has been acknowledged 
and studied greatly since the early twentieth century, and despite the progress 
made in stroke prevention by anticoagulation, management is inadequate and a 
greater understanding of AF mechanisms is crucial to understands the atria’s 
susceptibility and improve therapy. 
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Figure 1.8. Diagram comparing movement of electrical impulse between 
NSR and AF. 
In the NSR heart the impulse is initiated by the SA node in the RA and travels to 
the AV node via the intermodal pathways and to the LA via the Bachmann’s 
bundle pathway. Via the AV node the impulse travels to the Bundle of His and is 
divided between the RV and LV bundle branches. The impulse reaches the 
Purkinje fibres and spreads throughout the ventricular myocardium. In the atrial 
fibrillation heart the typical electrical impulse pathways are not follower and the 
impulse is spread in a disordered abnormal manner. This image was created by 
the author of this thesis. 
 
1.4.2.#AF#mechanisms##
The mechanism that sustains AF is referred to as the “driver”. The irregularity of 
atrial electrical impulses in AF can be due to an irregular response to a rapid 
regularly discharging driver as a result of random ectopic firing, a localised re-
entry circuit or multiple re-entry circuits that vary in time and space (111). 
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1.4.2.1.#AF#mechanisms#underlying#ectopic#firing#
Normal cardiomyocyte APs remain at resting potential after repolarisation, 
maintained by the high K+ permeability and resulting inward IK1. However, atrial 
cardiomyocytes also have a pacemaker current (If) that is much smaller than IK1. 
When there is a change in the balance with decreased IK1 and/or increased If, 
enhanced automaticity can occur. This results in diastolic membrane 
depolarisation that enables abnormal AP initiation and therefore AF generation 
(113). 
 
Early afterdepolarisations (EADs) comprise of irregular secondary membrane 
depolarisation during AP phase 3 repolarisation. The primary causing factor of 
EADs is APD prolongation, enabling L-type Ca2+ channels to recover with 
resulting inward ICaL depolarising the membrane triggering an irregular AP 
(114). Additionally, abnormal diastolic release of Ca2+ from the SR causes 
delayed afterdepolarisations (DADs) (115). As previously described, the SR 
Ca2+ stores are regulated by a balance between Ca2+ release from the SR into 
the cytosol via RyRs channels and Ca2+ uptake into the SR via SERCA (39). 
Although this system is adaptive to increase of acute stress-related conditions, 
sustained Ca2+ loading or functionally defective RyRs can cause abnormal 
diastolic RyRs Ca2+ release. The released Ca2+ is extruded via the NCX, with a 
net depolarising inward positive Na+ current underlying DADs during phase 4 of 
the AP and abnormal AP generation (115). 
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1.4.2.2.#Basic#mechanisms#underlying#reJentry#
Re-entry sustains AF by generating a rapidly firing driver with fibrillatory 
propagation or by producing multiple irregular re-entry circuits. The basic 
concept of re-entry was described over 100 years ago in experimental models 
(102). Re-entry is modelled as either the leading-circle or spiral-wave model. In 
both models the preservation of continuous activity relies on atrial properties, 
with a balance between a shortened ERP and slowed excitability of the 
cardiomyocytes (116). 
 
In the leading-circle model (Figure 1.9), re-entry circuits are established 
spontaneously in a ‘circuit’ length (the wavelength [WL]), quantified by the 
distance the impulse travels in 1 ERP. This can be calculated by the following 
equation: WL= ERP x CV (conduction velocity) (117). It has been shown that 
the shorter the WL the greater number of simultaneous re-entry circuits the atria 
can sustain. Likewise, the longer the WL, the fewer re-entry circuits can be 
housed by the atria. Consequently, reduction in ERP and/or CV can promote re-
entrant AF and increasing either (i.e. with drugs) can supress AF (118). 
 
The main difference between the leading-circle and spiral-wave models is the 
predicted responses to VGSC blockade. The leading circle model supports the 
understanding of the promotion of AF with CV reduction that is observed with 
Na+ channel mutations (119). However, the efficacy of Na+ channel blockers for 
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AF treatment contradicts the leading-circle, as you would expect the resulting 
reduction in CV would in fact promote AF (116, 120). 
 
Although scientists have shown appreciation for the leading-circle model, the 
spiral-wave theory has been more recently developed with modern theoretical 
analysis (Figure 1.9) (121). The spiral-wave model is related to the leading-
circle but is somewhat different. The activity induced by a spiral-wave follows 
the inside to outside of the excitable medium, keeping its shape and rotating 
around a core of constant size, shape and velocity. For a convex spiral-wave, 
electrical impulses radiate outward and each cardiomyocyte on the wavefront 
activates more than one cardiomyocyte downstream, reducing CV as the ratio 
of excited cells to resting is less. For a concave spiral-wave electrical impulse 
radiates inwards, each cardiomyocyte on the wave front activates less than one 
cardiomyocyte, increasing CV, as the ratio of excited cells to resting cells is 
greater (116). 
 
Therefore, the excited to resting cell ratio mismatch, limits the current that 
depolarises each cell ahead of the wave front. Decreasing current results in 
slower rate of voltage rise ahead of the wave front and a longer period before 
VGSCs are activated. This results in slowing the propagation of abnormal APs, 
by decreasing the stimulating power of the activation front. Theoretically, 
reduced ERP can also promote spiral-wave re-entry by increasing and 
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stabilising spiral-wave rotors. Therefore, both models explain AF occurrence 
with APD shortening (116). 
Figure 1.9. Mechanistic concepts of re-entrant arrhythmia. 
A) A depiction of the leading circle concept based on re-entrant excitation 
travelling around an unexcitable core. The circuit size is determined by 
wavelength (distance travelled by the electrical impulse in one ERP). B) A 
depiction of the spiral wave concept based on re-entry occurring around an 
excitable but continuously unexcited core. Re-entry relies on the balance of 
current-source/tissue excitability (favouring propagation) and current-sink 
(impairing propagation). Figure extracted from (122). 
 
1.4.2.3.#Electrical#determinants#of#AF#
The movement of ions via membrane channels and transporters controls the 
electrical properties of a cardiomyocyte and can be a determinant of AF 
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generation and/or maintenance. Increase in inward Ca2+ and Na+ prolong APD 
and escalate the likelihood of EAD generation. Conversely, a decrease in 
inward Ca2+ shortens APD, as does an increase in outward K+, due to resultant 
repolarisation of the cardiomyocyte. As previously described with the leading-
circle model, APD shortening promotes re-entrant AF as the circuit ERP is 
reduced and repolarisation is accelerated (123). 
 
Changes seen in Na+ handling have proven to be a factor in AF generation and 
maintenance (124). AP initiation and spread depends on inward INa during 
phase 0, making it a determinant of CV. Therefore, loss of function mutations of 
SCN5A with reduced INa have shown to slow conduction and in turn promote 
AF. Additionally, gain of function mutations of SCN5A have shown to induce AF 
due to increased APD and excitability leading to EADs (54, 125). Likewise, it 
has been demonstrated that INaL is upregulated in some pathophysiological 
settings, potentially disrupting the repolarisation (phase 3) of the AP with APD 
prolongation, also leading to development of EADs (126, 127). 
 
1.4.3.#AF#rate#and#rhythm#control#therapies#
The typical aims of AF treatment in order of importance are: prevention of 
thromboemboli, control of ventricular response, restoration of NSR, and 
maintenance of NSR by preventing recurrence. For AF treatment patients age, 
degree of symptoms and presence of underlying heart disease are considered 
(128). In order to reduce the risk of thromboembolic events anticoagulants are 
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used, as AF can result in blood stasis in the atria (129, 130). Current treatment 
therapies for AF involve the use of rate and rhythm control approaches as well 
as surgical interventions. There are also upstream therapies, targeting 
pathophysiological processes underlying the structural changes associated with 
AF, aiming to prevent occurrence or recurrence by slowing the progression of 
remodelling (131). 
 
Rate control strategies regulate ventricular rate by targeting the AV node as it 
transmits electrical signals from the atria, in order to minimise the common AF 
symptom of excessive ventricular rate and in turn prevent tachycardia-
associated cardiomyopathy (132). Rate control therapies include the use of 
negatively chronotropic drugs (such as β-blockers or digoxin) or 
electrophysiological/surgical intervention (133). However, with rate control the 
atria continue to fibrillate so additional medication is required to reduce the risk 
of thromboembolic events (133). Additionally, there are risks associated with 
rate control drugs, the ventricular rate can be slowed too much and result in 
complications, such as sinus bradycardia and heart block. Therefore, patients 
prone to these symptoms, notably the elderly, may need AV node ablation and 
permanent pacemaker implantation (133). 
 
Commonly, patients with AF have substantial symptoms despite rate control 
and require restoration of NSR. Non-invasive rhythm control strategies convert 
the heart to NSR with AADs, directly altering electrical currents (134). Rhythm 
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control treatment is decided based upon patient symptoms, the classification of 
AF (paroxysmal, persistent or permanent), comorbidities, health and 
anticoagulation status. Rhythm control is considered most beneficial in patients 
<65 years old, with recent AF onset and limited underlying heart disease (7). 
 
AADs that have been used for AF rhythm control are sodium and potassium 
channel blockers (135). The most common sodium channel blockers used 
clinically inhibit the VGSC, including propafenone and flecainide (136). They 
cannot be used in patients with structural heart disease, as they have shown to 
increase risk of ventricular arrhythmias and atrial flutter in patients with severe 
heart failure (134, 137). Other antiarrhythmic drugs inhibit various potassium 
channels (7), including sotalol, ibutilide, dofetilide and amiodarone (136). 
Although they can be used more freely, particulary amiodarone, they have extra 
cardiac side effects and have some proarrhythmic risk to ventricular arrhythmias 
with greater toxicity (128, 134, 135).  
 
AADs work by blocking K+, Ca2+ and Na+ channels and/or adrenergic receptors 
(138). However, the mechanisms of drugs differ greatly based on the ion 
channels targeted. Class IC work largely by blocking the VGSC in order to 
reduce the Vmax, in turn reducing the excitation of cardiac tissue. On the other 
hand, IIIC drugs largely work by blocking K+ channels and therefore prolonging 
the ADP and refractoriness, delaying conduction (7). Nonetheless, despite 
these AAD categorisations, it has been shown that many rhythm control drugs 
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impact AF by targeting ion channels and adrenergic receptors outside of the 
defined class specifications (7, 135). 
 
One of the newest areas of study is the development of atrial selective drugs; 
that work by targeting ion channels only within the atria. Atrial selective drugs 
could limit toxicity and reduce the increased risk of ventricular pro-arrhythmia 
associated with AADs (138). Drugs targeting K+ channels primarily expressed in 
the atria are in the early stages of development (139, 140) and atrial selective 
VGSC blockade has also been suggested as a possibility (4, 141, 142).  
 
Overall, clinical trials have revealed that when comparing rate and rhythm 
control therapies there is no difference in mortality (143-146). However, findings 
were limited as age of the patient populations was restricted (60-80 years), 
patients with excessive stroke risk were taken off anticoagulant therapy and 
AADs with proven high toxicity were included (7, 136). A large on-going clinical 
trial (EAST – AFNET 4) currently examines whether an early rhythm control 
therapy with antiarrhythmic drugs or AF ablation can improve outcomes in 
patients with AF (107). Furthermore, if atrial selective drugs were established, 
the mortality risks associated with rhythm control would be greatly neutralised 
and the potential over rate control for safer AF treatment could be immense. 
However, in order to determine VGSC blocking atrial selective drugs, a greater 
understanding of atrial sodium handling is required. 
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1.4.3.1.#Flecainide#pharmacology#
Class I AADs work by binding to and blocking VGSCs (7). Blocking VGSCs 
decreases the slope of phase 0, leading to a decrease in AP amplitude. The 
primary effect of reducing the rate and magnitude of depolarisation is to 
decrease conduction velocity to depress abnormal conduction. Different sodium 
channel blockers inhibit the fast upstroke of the AP, driven by the opening of 
VSGCs, to different extents, explaining their differential effects on cardiac 
conduction (147). Drug induced VGSC block accumulates with tachyarrhythmia 
increased firing frequencies, slowing the rate of AP generation in 
cardiomyocytes and reducing cardiac excitability (148, 149). This can explain 
why flecainide is effective in terminating AF (150). 
 
Sodium channel blockers may also alter APD and ERP. Effects on ERP are not 
directly related to sodium channel blockade but also the related drug actions on 
potassium channels involved in repolarisation. Altering the ERP can either 
increase or decrease arrhythmogenesis, depending on the cause of the 
arrhythmia. For example, re-entry tachycardia can be interrupted by increasing 
ERP, as tissue is unexcitable for longer so is less likely to be re-excited by re-
entrant currents. However, increasing APD can also result in the generation of 
EADs (as discribed earlier).  
 
Flecainide acetate was first synthesised in 1972 (151). The clinical efficacy of 
flecainide as a potent inhibitor of the VGSC (Nav1.5) in humans was confirmed 
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by several clinical trials and was first approved for oral use in 1984 (152-154). 
Flecainide has proven to convert AF into NSR in both animal and human trials, 
with a high affinity for open-state Nav1.5 channels with slow unbinding kinetics 
from the channel during diastole. Therefore, flecainide slows recovery of Nav1.5 
during diastole, prolonging ERP, in a rate dependent manner (155). 
Additionally, due to increased atrial activation, AF causes increased [Na+]i via 
VGSCs and in turn promotes Ca2+ entry via NCX as excessive Na+ is being 
extruded. The resulting accumulation of [Ca2+]i promotes ischemia and cellular 
dysfunction (156). However, flecainide attenuates [Ca2+]i accumulation by 
blocking the VGSCs, reducing the oxidative stress processes and further atrial 
remodelling that would otherwise occur as a result of increased [Ca2+]i (157). 
 
However, it has been demonstrated that flecainide use was associated with 
increased proarrhythmic evens in patients with severe cardiac disease (158). 
Following the publication of the 1989 Cardiac Arrhythmia Suppression Trial 
(CAST) there was a major revision of the role of AADs. The trial was designed 
to investigate the efficacy of Class I AADs in patients post myocardial infarction 
with reduced ejection fraction and recurrent ventricular ectopic beats. Flecainide 
was shown to suppress ventricular ectopy but also had a threefold increase in 
arrhythmic death compared to the placebo (159). Nevertheless, due to its 
efficacy at blocking Nav1.5, flecainide became recommended as a first line 
therapy for patients with AF, as long as there was no evidence of structural 
heart disease (160). Furthermore, recent data has reinforced the safety of using 
flecainide in patients without structural heart disease (161). 
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Flecainide was also shown to inhibit the opening of K+ channels in atrial and 
ventricular cardiomyocytes, particularly effecting IKr, resulting in prolonged APD 
(162). However, Kvam et al., demonstrated that flecainide shortens APD in the 
Purkinje fibers, due to VGSC blockade (163). Additionally, recent studies have 
found that flecainide reduces SR Ca2+ release by blocking RyR2s, potentially 
preventing DADs and triggered activity (164). Flecainide has also demonstrated 
the proarrhythmic effect of converting AF into atrial flutter and potentially 
resulting in rapid tachycardia. However, the reported rate of this proarrhythmic 
effect is only 3-5% and has been associated with high adrenergic conditions 
(165). Therefore, drugs such as β-blockers, diltiazem and verapamil, that have 
AV blockade properties, can be administered concomitantly with flecainide to 
reduce risk (156). Additionally, flecainide exerts a negative inotropic effect and 
can significantly reduce stroke volume index and LV ejection fraction and 
increase RA and pulmonary capillary wedge pressures, in patients with 
coronary artery disease, congestive heart failure and already reduced ejection 
fraction. These outcomes are related to the reduction of inward Na+ and Ca2+ 
into cardiomyocytes (156). 
 
The efficacy of oral and intravenous flecainide in hindering recent onset AF has 
been compared to other AADs in several clinical trials. One trial found that 
intravenous flecainide was shown to cause earlier reversion of recent onset AF 
to NSR compared to intravenous amiodarone (166). Additionally, another trial 
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showed that a higher proportion of patients reverted to NSR when treated with 
intravenous flecainide compared to intravenous amiodarone and propafenone 
(167). Conversely, a different study found that oral flecainide had a similar 
conversion rate to NSR as oral propafenone (168). However, it should be 
recognised that the findings from the different clinical trials are affected by 
distinctions in the study design characteristics, methodological limitations and 
the time intervals from drug initiation to assessment of reversion to NSR. 
 
The long-term efficacy and safety of flecainide treatment for AF prevention 
compared to other AADs or placebo has been extensively studied. In the 
prevention of AF recurrence, it has been established that oral flecainide is 
superior to placebo (169) but similar to propafenone  (170, 171), quinidine (172) 
and sotalol (169). Flecainide has shown to be better tolerated than quinidine 
and had a lower rate of adverse events compared to propafenone (170, 171). 
Overall, a meta-analysis of 60 trials concluded that 2/3 of patients responded to 
short-term flecainide treatments and 1/2 to long-term treatment (173).  
 
When selecting the right AAD for AF treatment many considerations need to be 
made in order for treatment to be tailored to each patient. Flecainide has been 
used for AF treatment extensively for over 30 years and its ability to reduce AF 
symptoms and provide long-term restoration of NSR has been well established 
(174). In younger patients without co-existing structural heart disease, the 
breadth of knowledge accumulated over the last few decades supports 
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flecainide as a safe and effective option to achieve and maintain NSR (156). 
However, an increased understanding of VGSC blockade properties of 
flecainide in the atria compared to ventricles would give a greater insight into its 
true value as an AF medication. 
 
1.5.#Study#Hypotheses#
As it has been described previously, β-subunits regulate the biophysical 
properties of the Nav1.5 α-subunit, with alterations in the gating of VGSCs 
dependent on co-expression of β1-4 subunits (4, 64, 69-74). Furthermore, atrial 
and ventricular differences in expression of β2 and β4 were shown by Chen et 
al., in human and rat myocardium (4). Therefore, it is hypothesised in this thesis 
that there will also be distinctive expression of the β2 and β4 subunits between 
the atria and ventricles in the mouse model and these distinctions will lead to 
differences in the sodium channel gating kinetics between the chambers. 
Differences in VGSC gating kinetics may also lead to chamber distinctions in 
inhibition with a sodium channel blocking AAD. 
 
Additionally, loss-of-function mutations in desmosomal proteins (desmoplakin, 
plakophilin or plakoglobin) were shown to cause changes in morphological 
structure and be a primary cause of an inherited cardiomyopathy (175-177). 
Knockdown of the gene that encodes plakophilin 2 in mice has proven to 
decrease INa density and alter channel gating kinetics in rat ventricular 
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cardiomyocytes, with a significant arrhythmogenic decrease in CV (178). As 
heart samples from ARVC patients with reduced plakoglobin expression 
revealed reduction in ventricular Nav1.5 at the intercalated disks (179, 180) it is 
postulated in this thesis that INa density and channel gating kinetics may also be 
altered in plakoglobin deficient mice. 
 
High quality cardiomyocytes are essential for experimental investigation of 
VGSC kinetics. The simple Langendorff-free isolation technique we developed 
is able to provide high yields of healthy cardiomyocytes to enable 
electrophysiological data to be collected more efficiently. 
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2.#Materials#and#Methods#
2.1.#Ethical#statement#and#study#approval#
All animal surgical procedures/experiments were conducted according to the 
rules and regulations of the Animals (Scientific Procedures) Act, 1986, 
approved by the Home Office (PFDAAF77F), the institutional review board at 
the University of Birmingham and the local authorities. 
 
Prof. Giueseppe Faggian at the University of Verona provided all human tissue 
samples. Human surgical procedures/sample donations were conducted under 
the consent of the donors and according to the rules and regulations of the 
Human Tissue Act 2006. 
 
2.2.#Animal#models#
Experiments were conducted on male and female adult mice (12-20 weeks old), 
bred on the 129/sv background. Some experiments in the Langendorff-free 
technique for mouse cardiomyocyte isolation chapter were conducted on 
C57/BL6J male and female (8-12 weeks old) mice, this is specified with the 
relevant data. Mice were housed in individually ventilated cages, with sex-
matched littermates (2-7 mice/cage), under standard conditions (12 hour 
light/dark cycle, 22°C and 55% humidity). Food and water were available ad 
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libitum. The visible health status of all mice (body weight, grooming, bearing) 
was monitored daily. 
 
Experiments were performed on wild type and heterozygous Plakoglobin 
deficient mice (Plako+/-) (181). 
 
2.3.#Western#blotting#methods#
2.3.1.#Western#blot#statistical#analysis#
Data were expressed as mean ± standard error, unless otherwise stated. 
Statistical analysis was performed using one way Analysis of Variance 
(ANOVA) with Tukey’s’s post hoc analysis where appropriate, when comparing 
three or more groups. Unpaired Student t-tests were used when comparing 
tissue from two different chambers. Significance was taken as P<0.05 
(GraphPad Prism 7.0b). 
 
2.3.2.#Mouse#heart#excision#
Mice were weighed. For heart excision under deep terminal anaesthesia, each 
mouse was placed inside the anaesthesia chamber with 4% isoflurane in O2, 
1.5L/min with active scavenging of surplus gas, using the Fluovac system for 
mice with table-top anaesthesia system and small induction box (Harvard 
Apparatus U.K. #726425), until breathing rate significantly slowed and the 
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righting reflex was absent. The mouse was removed from the induction box and 
the pedal reflex was checked (by a firm toe pinch) as a measure of deep pain 
recognition, to ensure that the mouse was under deep anaesthesia before any 
incisions were made. Mice were placed in a supine position on a polystyrene 
block with the limbs taped down and sacrificed through death by 
exsanguination. Thoracotomy was performed using scissors, to expose the 
heart under continuing deep terminal isoflurane anaesthesia via a face mask 
with active scavenging of surplus gas (4% isoflurane in O2, 1.5L/min). The heart 
was extracted using curved scissors to excise vessels (avoiding laceration of 
the aorta). 
 
Hearts were then placed in polystyrene standard weighing boats with 40ml of 
ice cold Krebs buffer (0.118 mol/L NaCl, 0.02488 mol/L NaHCO3, 0.00118 mol/L 
KH2PO4, 0.011 mol/L Glucose, 0.00083 mol/L MgSO4.7H2O, 0.00352 mol/L KCl, 
0.0018 mol/L CaCl2 adjusted to pH 7.3) with 50uL of heparin (LEO Laboratories, 
Ltd, UK) to reduce risk of thrombus formation. Krebs buffer was ice cold to 
encourage cardioplegia (temporary cessation of cardiac activity) to aid 
cannulation. 
 
The heart was transferred to a 50ml glass petri dish, containing 40ml of ice cold 
Krebs buffer on a stand that housed a 2ml syringe with attached cannula of 
outer diameter 1mm, as seen in Figure 2.1. The aorta was cannulated and 
secured with a suture in less than 3 minutes in the 50ml glass petri dish to limit 
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any tissue damage, as shown in Figure 2.1. The syringe attached to the 
cannula was used to flush the heart with 2ml of Krebs via retrograde perfusion. 
Pressure from retrograde perfusion caused the aortic valve to close, forcing the 
buffer flowing in via the cannula into the coronary circulation. It was essential to 
ensure the cannula and syringe were free of air bubbles to avoid the 
introduction of air into the isolated heart. 
 
The chambers and septum of the heart were separated, placed into 1.5mL 
Eppendorf tubes (Thermo Scientific; #3451) and snap frozen in liquid nitrogen. 
Samples were stored at -80oC in until required for Western blotting experiments. 
 
Figure 2.1. Cannulation of ascending aorta. 
Photograph of a mouse heart cannulated via the aorta submerged in cold Krebs 
buffer solution in 50ml petri dish. The dish was held into place using blue tack 
on a custom stand that also holds the buffer filled syringe with attached 
cannula. The cannula is secured by fine suture, which is seen as the black 
string above the cannula across the image. The cannula is attached to a 2ml 
1cm 
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syringe and secured with black silicone. When the heart was flushed with buffer 
from the syringe the blood was expelled, as seen by the red clouded regions in 
the image (182). 
 
2.3.3.#Mouse#sample#preparation#
Weights of the heart chambers were recorded. Atria were put into 0.5mL 
homogenisng CK14 Precellys tubes (KTO3961-1-203.0.5) and ventricles into 
2mL homogenising CK14 Precellys tubes (KT03961-1-003.2). Samples were 
homogenised in homogenisation buffer (Tris adjusted to pH 7.3, 1 protease 
cocktail inhibitor tablet (Roche Diagnostics; complete ULTRA Tablets, Mini, 
EASYpack; 05892970001) diluted in 10mL buffer, with phosphatase cocktail 
inhibitor 2 (Sigma; #p5726) and 3 (Sigma; #P0044)) added (both 1:100 
concentration). The homogenisation buffer was added to the tubes containing 
the tissue in a ratio of 1mg of tissue: 10uL of buffer. The tubes were loaded 
onto the Precellys24 Homogeniser set to 5000rpm for 2x 15seconds. 
Homogenates were transferred into 2.0mL Eppendorf tubes (Thermo Scientific; 
#3434) and diluted 2 times in SDS sample buffer (i.e. 1mg of tissue: 20uL of 
buffer) (100mM Tris, 20% w/v glycerol, 5% w/v β-mercaptoethanol, 4% w/v SDS 
and 0.2% bromophenol blue, pH 6.8). This resulted in samples with a protein 
concentration of ≈1.5ug of protein/1ul of sample solution, tested using Qubit 
protein assay kit (Life Technologies; #Q33211). 
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2.3.4.#SDSJPolyacrylamide#Gel#(SDSJPAGE)#for#mouse#samples#
Samples were centrifuged using the Hettick® MIKRO 220R centrifuge for 10 
minutes 14000RPM at 2°C so that sediment was separated and could be 
avoided during loading. Then 10uL of sample (≈15ug of protein) was loaded 
onto, 4-15% gradient Mini-PROTEAN® TGXTM gels (Bio-Rad; #4561084) 
immersed in running buffer (0.025M Tris base, 0.19M glycine and 0.1% w/v 
sodium dodecyl sulphate). 8uL Precision PlusTM Protein Dual-Colour Standard 
(Bio-Rad; #1610374) was ran alongside samples for molecular weight 
estimation. 90-140V was applied to the gels using a PowerPac™ Basic power 
supply (Bio-Rad; #1645050) until the visible sample buffer line reached the 
bottom of the gels. 
 
2.3.5.#SemiJdry#electrophoretic#transfer#
Proteins were transferred from Mini-PROTEAN® TGXTM gels onto methanol 
(VWR chemicals; 20847.307) activated TransBlot® TurboTM mini-size 
polyvinylidene difluoride membranes (Bio-Rad, #170-4156) using a Trans-Blot® 
TurboTM semi-dry electrophoretic transfer system (Bio-Rad; #170-4155). Single 
Trans-Blot® TurboTM Mini-size Transfer Stacks (Bio-Rad; #1703966) were 
placed in the semi-dry transfer sandwiching the membrane. Bio-Rad 1.3A, 25V 
and 30M transfer protocol was ran for 10 minutes. 
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2.3.6.#Human#tissue#collection#
Tissue samples were collected during heart transplant, left ventricular assist 
device (LVAD) fitting, aortic valve replacement, coronary artery bypass, mitral 
valve repair, subaortic membrane removal surgeries or from deceased organ 
donors. 
 
The operating surgeon separated the samples and they were snap frozen in 
liquid nitrogen, then stored at -80oC in 1.5mL Eppendorf tubes (Thermo 
Scientific; #3451) until required for Western blotting experiments. 
 
2.3.7.#Human#sample#preparation#
The excised frozen tissue was crushed with a cryogenic tissue pulveriser 
(Cellcrusher; Ballina) in a pestle and mortar manner. The pulveriser was cooled 
in liquid nitrogen and the frozen sample was placed in the chamber and was 
pulverised by hitting the pestle portion with a mallet. The pulverised samples 
were then removed from the chamber using an ice-cooled spatula and put in a 
1.5mL Eppendorf tubes (Thermo Scientific; #3451) and stored at -80oC. After 
each sample was removed from the pulveriser it was cleaned in warm water 
and then wiped down with ethanol then cooled again in liquid nitrogen. 
 
A portion of each of the pulverised tissue samples (approximately relative to the 
size of a mouse left ventricular sample) was put into 2.0mL Eppendorf tubes 
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(Thermo Scientific; #3434). Samples were homogenised in 150uL of 
homogenisation buffer (Tris adjusted to pH 7.3, 1 protease cocktail inhibitor 
tablet (Roche Diagnostics; complete ULTRA Tablets, Mini, EASYpack; 
05892970001) diluted in 10mL buffer, with phosphatase cocktail inhibitor 2 
(Sigma; #p5726) and 3 (Sigma; #P0044)) added (both 1:100 concentration). 
The homogenisation buffer was added to the tubes containing the tissue and 
the samples were homogenised using a mechanical handheld homogeniser on 
setting 6 (Power Gen 125, Fisher Scientific) over dry ice to keep the sample 
cool.  The handheld homogeniser was cleaned using distilled water between 
each sample homogenisation. Homogenates were centrifuged using the 
Hettick® MIKRO 220R centrifuge for 10 minutes 14000RPM at 2°C. A volume 
of the centrifuged samples was transferred into 2.0mL Eppendorf tubes 
(Thermo Scientific; #3434), without disturbing the visible lipid deposit on the 
surface and unhomogensied detritus at the bottom of the tube. 
 
The Qubit protein assay kit (Life Technologies; #Q33211) was used to quantify 
the amount of protein in each sample. Sample buffer was added each sample 
(100mM Tris, 20% w/v glycerol, 5% w/v β-mercaptoethanol, 4% w/v SDS and 
0.2% bromophenol blue, pH 6.8) with the volume calculated using the results of 
the protein assay in order to achieve a concentration of 1.5ug of protein/1ul of 
solution. For human samples it was essential that the final volume of the 
sample solution was ≥ 50% sample buffer (homogenisation buffer: sample 
buffer, 1:≥ 1) to ensure adequate volume of sample buffer for denaturing of 
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proteins and breakage of disulphide bonds. Samples were then vortexed for 
uniformity. 
 
2.3.8.#SDSJPolyacrylamide#Gel#(SDSJPAGE)#for#human#samples#
Samples were heated to 90°C for 8 minutes before loading when probing for 
Navβ2 and Navβ4 but left unheated when probing for Nav1.5. 12uL of sample 
(18ug of protein) was loaded onto, 4-15% gradient Mini-PROTEAN® TGXTM 
gels (Bio-Rad; #4561084) immersed in running buffer (0.025M Tris base, 0.19M 
glycine and 0.1% w/v sodium dodecyl sulphate). 8uL Precision PlusTM Protein 
Dual-Colour Standard (Bio-Rad; #1610374) was ran alongside samples for 
molecular weight estimation. 90-140V was applied to the gels using a 
PowerPac™ Basic power supply (Bio-Rad; #1645050) until the visible sample 
buffer line reached the bottom of the gels. 
 
2.3.9.#Isolated#cardiomyocyte#sample#preparation#
For Western blot experiments comparing protein expression in injection-isolated 
and Langendorff-isolate cardiomyocytes cells were pipetted onto laminin-coated 
coverslips (10mm diameter) in the absence of 1,2-butanedione monoxime 
(BDM) and kept in culture for media for 4 hours. Plates were then placed on ice, 
cells were washed with ice cold phosphate buffered saline (PBS), and lysed by 
addition of a ureabased lysis buffer (235 mmol/l Tris pH 6.8, 18.75% glycerol, 
5.6% sodium dodecyl sulfate, 6 mol/l urea, 1 mmol/l dithiothreitol), containing 
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Halt™ protease and phosphatase inhibitor cocktail (Thermo Scientific). Total 
cell lysates were prepared by scraping of wells and transfer to 1.5 ml tubes on 
ice, passage through a 27 G needle x 5, and incubation at 4°C for 30 min with 
nutation. SDS-page was carried out as described in mouse sample preparation 
above. 
 
2.3.10.#Membrane#probing#
Membranes were each submerged in 15mL of dissolved, non-fat, dried 
powdered milk (AppliChem; 04021011) diluted to 5% in PBS (Sigma-Aldrich; 
P4417-50TAB; 0.01mol/L phosphate buffer; 0.0027 mol/L KCl; 0.1037 mol/L 
NaCl; pH 7.3) with 0.1% TWEEN® 20 (PBS-T) (Sigma Aldrich; 9005-64-5) and 
incubated over night at 4oC. The membranes were incubated for 1 hour with 
primary IgG antibodies diluted in non-fat, dried powdered milk diluted to 1% in 
PBS-T at room temperature (see Table 1.1 and 1.3 for primary antibody 
details). 
 
Membranes were then washed for 1 hour with 6 changes (every 10 minutes) in 
PBS-T to remove unbound antibody. The membranes were then incubated for 1 
hour at room temperature with the appropriate horseradish peroxidase linked-
conjugated (HRP) secondary IgG antibodies diluted in non-fat, dried powdered 
milk diluted to 1% in PBS-T at room temperature (see Table 1.2 and 1.4 for 
secondary antibody details). The membranes were then washed for one hour 
with 6 changes in PBS-T to remove unbound antibody. 
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Table 1.1: Primary antibodies used for mouse Western blot experiments. 
Target of 
antibody 
Concentration 
used 
Animal Source Company and 
catalogue number 
Nav1.5 1:200 Rabbit, polyclonal Alomone, ASC-005 
Navβ2 1:400 Rabbit, polyclonal Alomone, ASC-007 
Navβ4 1:800 Rabbit, polyclonal Alomone, ASC-044 
NHE1 1:200 Mouse, monoclonal Santa Cruz 
Biotechnology, sc-
58635 
NCX 1:1000 Mouse, monoclonal Swant, R3F1 
NKA α1 1:1000 Mouse, monoclonal Santa Cruz 
Biotechnology, sc-
28800 
PLM pSer63 1:1000 Sheep, polyclonal Badrilla, A010-110 
GAPDH 1:4000 Mouse, monoclonal ThermoFisher 
Scientific, AM4300 
Total-ERK1/2 1:1000 Rabbit, polyclonal New England 
Biolabs, 9102 
Phospho- 1:1000 Rabbit, polyclonal New England 
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ERK1/2 Biolabs, 9101 
Total- PKC-α1 1:1000 Mouse, monoclonal Santa Cruz, sc-
8393 
Total PLM 1:500 Rabbit, polyclonal Abcam, ab75597 
Ser-63 PLM 1:2000 Sheep, polyclonal Badrilla, A010-110 
 
Table 1.2: Secondary antibodies used for mouse Western blot 
experiments. 
Target of 
antibody 
Concentration 
used 
Source animal Company and 
catalogue 
number 
Rabbit 1:7500 Donkey GE Healthcare, 
NA934V 
Rabbit 1:4000 Goat Merck, AP307P 
Mouse 1:4000 Sheep GE Healthcare, 
NA931V 
Sheep 1:1000 Donkey R&D Systems, 
HAF016 
 
Table 1.3: Primary antibodies used for human Western blot experiments. 
Target of Concentration Animal Source Company and 
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antibody used catalogue number 
Nav1.5 1:200 Rabbit, polyclonal Alomone, ASC-005 
Navβ2 1:200 Rabbit, polyclonal Alomone, ASC-007 
Navβ4 1:400 Rabbit, polyclonal Alomone, ASC-044 
GAPDH 1:4000 Mouse, monoclonal ThermoFisher 
Scientific, AM4300 
α-Actinin 1:2500 Mouse, monoclonal Sigma-Aldrich, 
A7811 
 
Table 1.4: Secondary antibodies used for human Western blot 
experiments. 
Target of 
antibody 
Concentration 
used 
Source animal Company and 
catalogue 
number 
Rabbit 1:4000 Goat Merck, AP307P 
Mouse 1:4000 Sheep GE Healthcare, 
NA931V 
 
2.3.11.#Visualisation#of#membranes#
The membranes were submerged in 5ml of detection reagent (GE Healthcare, 
ECL Western Blotting Detection Reagents, Amersham, RPN2106) and placed 
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between 2 sheets of transparency film. Densitometry was performed to quantify 
the levels of chemiluminescence using the Odessey Fc Imaging System. The 
optical density readings (OD) acquired from the densitometry recordings were 
taken to proportionally monitor the level of protein expression. 
 
2.3.12.#Membrane#stripping#and#reJprobing#
Calnexin or GAPDH was used as a loading control for Western Blots. The 
expression of calnexin/GAPDH was measured once the membranes had been 
stripped of primary and secondary antibody. Membranes were washed in PBS-
T for 10 minutes, submerged in stripping buffer (RestoreTM PLUS Western 
Blotting) for 15 minutes and re-washed in PBST for a further 10 minutes. The 
membranes were then blocked in 5% milk dissolved in PBS-T over night at 4OC. 
Membranes were then re-probed using the previously described antibody 
incubation methods. 
 
2.3.13.#Image#analysis#
The raw densitometry values obtained for the proteins were normalised by their 
corresponding densitometry value for calnexin or GAPDH to correct the data for 
possible variations in protein concentration between samples or loading errors 
of the samples onto the gels. In order to combine data (when severable blots 
were used to achieve larger sample sets) the calnexin/GAPDH normalised 
values were again normalised to the mean of LV values within each blot. 
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#
2.4.#WholeJcell#patch#clamp#electrophysiology#
2.4.1#LangendorffJbased#mouse#cardiomyocyte#Isolation#
Hearts of 129/sv background (15-20W) were isolated under isoflurane 
anaesthesia, as described previously (2.3.2 Mouse Heart Excision). 
 
Solutions were perfused at 4mL/min, 36-37°C in the Langendorff set up. The 
cannulated heart was transferred to the Langendorff apparatus and perfused 
with Krebs buffer (0.118 mol/L NaCl, 0.02488 mol/L NaHCO3, 0.00118 mol/L 
KH2PO4, 0.011 mol/L Glucose, 0, 0.00083 mol/L MgSO4.7H2O, 0.00352 mol/L 
KCl, 0.0018 mol/L CaCl2, pH 7.3) for 4-5 minutes. Krebs solution (minus CaCl2) 
was perfused through the Langendorff system for 5 minutes to clear out Ca2+ 
from the heart, causing the heart to consequently cease contracting. The heart 
was digested using the enzyme solution (0.118 mol/L NaCl, 0.02488 mol/L 
NaHCO3, 0.00118 mol/L KH2PO4, 0.011 mol/L Glucose, 0, 0.00083 mol/L 
MgSO4.7H2O, 0.00352 mol/L KCl, 0.02 mol/L Taurine, 0.03 CaCl2, Liberase TM 
Research Grade (Roche, Indianapolis, IN), 0.1% Bovine Serum Abumin, 20mM 
taurin and 3µmol CaCl2, pH 7.3), until the heart was judged to be sufficiently 
soft (digestion time judged on appearance of heart tissue). If the heart was 
being digested well it would enlarge and go pale (salmon pink) within 1-2 
minutes of the Liberase reaching the cannula. Enzyme digestion varied 
between different hearts but would generally fall between 15-25 minutes. 
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The heart and cannula were then removed from the Langendorff apparatus and 
placed into a petri 10ml dish filled with “STOP solution” ( 0.025 mol/L KCl, 0.01 
mol/L KH2PO4,  0.005 mol/L HEPES, 0.002 mol/L MgSO4.7H2O, 0.02 mol/L 
Glucose, 0.01 mol/L DL aspartic acid potassium salf, 0.1% Bovine Serum 
Albumin, 0.1 mol/L L-Glutamic acid potassium salt, 0.02 mol/L Taurine, 0.0005 
mol/L EGTA, 0.005 mol/L Creatine, pH 7.2). Then 5mL of the “STOP solution” 
was perfused through the heart using a 5mL syringe to inhibit the enzyme 
digestion activity any further. 
 
The LA and LV chambers were dissected from the digested heart and placed 
into separate small 10ml petri dishes containing 1mL/2ml respectively of the 
“STOP solution”. The chambers were then gently teased apart with forceps and 
triturated gently to release the cells using glass pipettes with increasing 
resistance (smallest diameter ≈ 0.3-0.5mm). The cells were then checked under 
the microscope to see if they were well triturated. Further 2mL/4ml respectively 
(LA/LV) of Krebs solution (no CaCl2) was added to each petri dish. The LA cell 
suspension was transferred into a 15mL falcon tube using a Pasteur pipette, 
without creating bubbles. The LV cell suspension was pipetted over 200um 
nylon gauze into a 50mL falcon tube. The LV cells were left to settle down to 
form a pellet for 15 minutes and 4mL of supernatant was then removed without 
disturbing the pellet. 
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All data within this Thesis that utilised isolated cardiomyocytes relied on this 
method of isolation, aside of the data specified as using the injection-based 
isolation method in the Langendorff-free technique for mouse cardiomyocyte 
isolation chapter. 
 
2.4.2#InjectionJbased#mouse#cardiomyocyte#Isolation#
Mice were initially weighed before any surgical procedure. Each mouse was 
placed inside the anaesthesia chamber with 4% isoflurane in O2, 1.5L/min with 
active scavenging of surplus gas, using the Fluovac system for mice with table-
top anaesthesia system and small induction box (Harvard Apparatus U.K. 
#726425), until breathing rate significantly slowed and the righting reflex was 
absent. The mouse was removed from the induction box and the pedal reflex 
was checked (by a firm toe pinch) as a measure of deep pain recognition, to 
ensure that the mouse was under deep anaesthesia before any incisions were 
made. Mice were placed in a supine position on a polystyrene block with the 
limbs taped down. Thoracotomy was performed using scissors, to expose the 
heart under continuing deep terminal isoflurane anaesthesia via a face mask 
with active scavenging of surplus gas (4% isoflurane in O2, 1.5L/min). 
 
With round-end forceps the left lung was moved aside to expose the 
descending aorta and inferior vena cava. Both were cut using scissors and the 
heart was gently held using curved forceps. Using 10ml sterile syringe with 
attached 27 G hypodermic needle (ensuring there are no bubbles inside) 7ml of 
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4°C EDTA buffer (0.13 mol/L NaCl, 0.005 mol/L KCl, 0.0005 mol/L NaH2PO4, 
0.01 mol/L HEPES, 0.01 mol/L Glucose, 0.01 mol/L BDM, 0.01 mol/L Taurine, 
0.005 mol/L EDTA, adjusted to pH 7.8 and sterilised using 0.2µm filter) was 
injected steadily over a 1 minute period into the base of the RV, with the needle 
penetrating no more that 2mm into the RV wall. This caused contractions to 
quickly cease and blood to be flushed out of the heart. 
 
The ascending aorta was then clamped with a curved-end haemostatic clamp, 
avoiding clamping the atrial appendages. The clamped heart was then removed 
by incision around the outside of the forceps and transferred into a 65ml glass 
petri dish, containing 40ml of 4°C EDTA buffer (0.13 mol/L NaCl, 0.005 mol/L 
KCl, 0.0005 mol/L NaH2PO4, 0.01 mol/L HEPES, 0.01 mol/L Glucose, 0.01 
mol/L BDM, 0.01 mol/L Taurine, 0.005 mol/L EDTA, adjusted to pH 7.8 and 
sterilised using 0.2µm filter), ensuring the heart was submerged. 
 
Using 10ml sterile syringe with attached 27 G hypodermic needle (ensuring 
there are no bubbles inside) 10ml of the same 4°C EDTA buffer was injected 
into the LV of the heart, 2-3mm above the apical point, with the needle 
penetrating no more that 2mm into the LV wall. During this injection very little 
pressure was used, with a flow rate of 1ml per 2-3 minutes in order to avoid 
perforation of the LA appendage. With this any remaining blood was cleared out 
of the coronary circulation and the heart became pale in colour. 
 
 
 
70 
After 6 minutes or injection of all 10ml of buffer (whatever was first) the needle 
was removed from the LV and the heart was transferred to another 50ml glass 
petri dish, containing 30ml of 4°C perfusion buffer (0.13 mol/L NaCl, 0.005 
mol/L KCl, 0.0005 mol/L NaH2PO4, 0.01 mol/L HEPES, 0.01 mol/L Glucose, 
0.01 mol/L BDM, 0.01 mol/L Taurine, 0.001 mol/L MgCl2, adjusted to pH 7.8 
and sterilised using 0.2µm filter). To clear remaining EDTA within the heart, 3ml 
of the same perfusion buffer was injected into the LV via the perforation made 
during the first injection, with the needle penetrating no more that 2mm into the 
LV wall. During this injection very little pressure was again used, with a flow rate 
of 1ml per 1-2 minutes. After 2 minutes or injection of all 3ml of buffer (whatever 
was first) the needle was removed from the LV and the heart was transferred to 
a 50ml petri dish, containing 10ml of 37°C (warmed in a water bath) 
collagenase buffer (0.13 mol/L NaCl, 0.005 mol/L KCl, 0.0005 mol/L NaH2PO4, 
0.01 mol/L HEPES, 0.01 mol/L Glucose, 0.01 mol/L BDM, 0.01 mol/L Taurine, 
0.001 mol/L MgCl2, with 0.5mg/ml of collagenase 2 and 0.5mg/ml of 
collagenase 4, adjusted to pH 7.8 and sterilised using 0.2µm filter). 
 
The same pre-heated to 37°C 10ml (4-7 syringes) collagenase buffer was 
injected into the LV via the perforation made during the first injection, with the 
needle penetrating no more that 2mm into the LV wall. The injection rate was 
sufficient to keep the heart inflated, typically 2ml/minute, but increased as the 
procedure progressed. Following injection of collagenase with each syringe 
10ml of buffer was removed from the petri dish with an empty syringe to prevent 
overflow. The volume, and therefore number of syringes, of collagenase puffer 
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required varied between hearts, depending on the age, size and health of the 
heart. Complete digestion was determined when there was reduction in 
resistance to injection pressure, when the heat lost its shape and rigidity, when 
holes began appearing and when it turned pale and fluffy at the surface. 
Additionally, ejection of cardiomyocytes into the effluent buffer was also visible 
to the naked eye.  
 
Once complete digestion was confirmed the clamp was removed from the aorta 
and the chambers and septum of the heart were separated and placed into 
separate small 10ml petri dishes containing 3ml respectively of the collagenase 
solution. The chambers were then gently teased apart with forceps and 
triturated gently to release the cells using glass pipettes with increasing 
resistance (smallest diameter ≈ 0.3-0.5mm). Then 5ml of “STOP solution” ( 
0.025 mol/L KCl, 0.01 mol/L KH2PO4,  0.005 mol/L HEPES, 0.002 mol/L 
MgSO4.7H2O, 0.02 mol/L Glucose, 0.01 mol/L DL aspartic acid potassium salf, 
0.1% Bovine Serum Albumin, 0.1 mol/L L-Glutamic acid potassium salt, 0.02 
mol/L Taurine, 0.0005 mol/L EGTA, 0.005 mol/L Creatine, pH 7.2) was added to 
each petri dish and each suspension was gently pipetted for a further 2 
minutes. 
 
The cells were then checked under the microscope to see if they were well 
triturated. The LA cell suspension was then transferred into a 15mL falcon tube 
using a Pasteur pipette, without creating bubbles. The LV cell suspension was 
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pipetted over 200um nylon gauze into a 50mL falcon tube. The LV cells were 
left to settle down to form a pellet for 20 minutes and 4mL of supernatant was 
then removed without disturbing the pellet. Supernatant was removed so that 
atrial cells were suspended in 3ml and ventricular cells were suspended in 6ml 
of buffer. 
 
2.4.3.#Calcium#reintroduction#
KB Buffer with Ca2+ ( 0.025 mol/L KCl, 0.01 mol/L KH2PO4,  0.005 mol/L 
HEPES, 0.002 mol/L MgSO4.7H2O, 0.02 mol/L Glucose, 0.01 mol/L DL aspartic 
acid potassium salf, 0.1% Bovine Serum Albumin, 0.1 mol/L L-Glutamic acid 
potassium salt, 0.02 mol/L Taurine, 0.0005 mol/L EGTA, 0.005 mol/L Creatine, 
0.018 mol/L CaCl2) was added to the suspension of cells in the flacon tube to a 
final Ca2+ concentration of 1.8mM over a 1.5 hour period. The KB buffer was 
added to the LA/LV cell suspensions in the following increments:  firstly 
100/200ul, 15 minutes later 100/200ul, 15 minutes later 400/800ul, 30 minutes 
later 600/1200ul then finally another 600/1200ul 30 minutes later (respectively 
LA/LV as LV suspension was x2 the volume of LA suspension at beginning of 
calcium reintroduction). Cells were then left in this suspension for at least 20 
minutes at room temperature before use. Experiments were performed within 5 
hours of isolation. 
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2.5.#WholeJcell#patch#clamp#electrophysiology#
2.5.1.#INa#recordings#
150uL of dissociated LA and LV cells were pipetted onto laminin-coated 
coverslips (10mm diameter) and allowed to adhere for 15-20 minutes. The 
coverslips were then transferred to a dry bath recording chamber under a 
microscope (Axiovert 25, Zeiss). The silver electrode wire used was chlorinated 
in a solution of 20mM NaCl. Cells were perfused with extracellular patch clamp 
solution (0.01 mol/L NaCl, 0.13 mol/L C5H14ClNO, 0.01 mol/L HEPES, 0.0012 
mol/L MgCl2, 0.0018 mol/L CaCl2, 0.01 mol/L Glucose, 0.002 mol/L NiCl, 0.0045 
mol/L KCl) adjusted to pH 7.4 with CsOH, at a rate of 2mL/minute.  
 
Whole cell patch clamp recordings were obtained in voltage clamp mode using 
pipettes were pulled from borosilicate glass capillaries (Model P-97, Intracel) 
using a microprocessor-controlled puller (30-0057, Harvard Apparatus). They 
were automatically heat polished and had an input resistance of 2.2-3 MΩ. The 
glass pipette microelectrodes were filled using a 2mL syringe with attached 
micro-loader tip with internal solution (0.15 mol/L CsCl, 0.01 mol/L HEPES, 0.01 
mol/L EGTA, 0.005 mol/L MgATP, 0.0005 mol/L MgCL2, 0.02 mol/L TEA) 
adjusted to pH 7.2 with CsOH. The microelectrode was then placed into the 
pipette holder and positive pressure was applied using a 5ml syringe, displacing 
about 0.5mL of air through the pressure control system and pressure held in the 
pipette by closing the three-way valve. Experiments were performed at 22± 
0.5°C. 
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The microelectrode was homed into the bath that held the cell suspension 
coverslip using a micromanipulator (Scientifica) and the amplifier (AXOPATCH-
1D, Axon Instruments, CA) was set to voltage-clamp mode. The pipette offset 
was corrected, so the currents measured at that point were considered as 0 pA. 
The seal test protocol was applied through the electrode (see Table 1.5). The 
cell of interest was then approached by the microelectrode (avoiding nuclei), 
until the tip touched the cell (enough to create a very small dimple in the cell) 
and the positive pressure was released in order to form a seal between the 
microelectrode and the cell and the voltage clamp was changed to -80mv. Once 
a minimum of a 1GΩ seal occurred (maybe requiring some suction by mouth) 
the cell was broken into using continuous light suction until the membrane 
broke and if a 1GΩ minimum access resistance was achieved the test protocols 
were run immediately (see Table 1.5). As the membrane of the cells acts as a 
capacitor, when the microelectrode breaks into the intracellular space, the 
current response to the seal tests should show exponential decay. 
For current comparison of +/- sodium channel blocker, the baseline recordings 
were performed followed by recordings with flecainide 1µmol/L in the 
extracellular patch clamp solution after it had been ran through the system for 5 
minutes, to ensure the flecainide free solution had been cleared from the bath 
recording chamber. All experiments were performed at room temperature. 
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Figure 2.2. Diagram of whole cell patch clamp general set up and 
principle. 
Shown are cells adhered to coverslips and submerged in bath solution, glass 
pipette containing the internal electrolyte solution, with positive pressure, 
causes a visible dimple on the surface of the cardiomyocyte when near to the 
cell. The glass pipette is sealed to membrane of the cell by removing positive 
air pressure. The electrode inside the glass pipette is connected to a highly 
sensitive amplifier, recording currents flowing through the channels in the cell 
membrane. This image was created by the author of this thesis. 
 
2.5.2.#Patch#clamp#statistical#analysis#
All experiments were performed and analysed in blinded fashion to genotype in 
littermate pairs (control vs. heterozygous Plakoglobin deficient mice (Plako+/-) 
(181). However, blinding was not possible when performing experiments 
comparing cardiomyocytes from different chambers as atrial and ventricular 
cardiomyocytes have different morphologies so could be identified. Data were 
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expressed as mean ± standard error, unless otherwise stated. Statistical 
analysis was performed using unpaired Student t-tests when comparing 
cardiomyocytes from different chambers/hearts and paired parametric Student 
t-tests were used when comparing the same cardiomyocytes under two different 
conditions (i.e. measurements before and after perfusion of flecainide). two-way 
ANOVA with Tukey’s post-hoc analysis was used when two variables were 
being tested. Significance was taken as P<0.05 (GraphPad Prism 7.0b). 
 
Data was analysed using Signal 6.0 (Axon Instruments). I/V curves were fitted 
using the modified Boltzmann equation:  
Na = Gmax(Vm – Vrev)/(1+Exp[(V0.5-Vm)/k]) (equation 1). 
Where INa is current density at a given test potential (Vm), Gmax is the peak 
conductance, Vrev is the reverse potential, V0.5 is the membrane potential at 
50% current activation and k is the slope constant that describes the steepness 
of the current activation.  
 
INa inactivation curves were fitted using the equation: 
Normalised INa= 1-(1/(1+Exp[(V0.5-Vm)/k])) (equation 2). 
Where Vm is the pre-pulse potential, V0.5 is the pre-pulse potential at which INa is 
half maximally inactivated and k is the slope constant that describes the 
steepness of the inactivation curve (183). 
 
 
77 
Table 1. 5: Voltage patch clamp protocols. 
 
Seal Test 
Protocol 
A 10mV test pulse at 10ms. The oscilloscope shows the square 
current response to the seal test. The amplitude of the response 
is relative to the resistance of the pipette (larger the amplitude: 
greater the resistance). 
 
 
 
I/V 
Relationship 
Protocol 
Sodium currents were evoked by voltage steps from a holding 
potential of -100 to +10mV in 5mV increments from a holding 
potential of -100mV. 
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Steady 
State-
Inactivation 
Protocol 
Currents were activated by stepping the voltage to the potential at 
which the peak current is achieved (-100 to -30mV) but are 
preceded by stepping pre-pulse potentials at which the 
membrane is maintained for 100ms from -120 to -40mV in 5mV 
increments. The current amplitudes after the pre-pulse potential 
are normalised to the peak current recorded (pre-pulse current). 
 
Na+ Channel 
Recovery 
Protocol 
Currents were activated by stepping the voltage to the potential at 
which the peak current is achieved (-100 to -30mV) and again 
after different time intervals. The current amplitudes at each time 
interval after the pre-pulse are normalised to the largest current 
(the current with the greatest time lapse from the pre-pulse). Time 
intervals after initial current: 1ms, 5ms, 7ms, 10ms, 20ms, 30ms, 
50ms, 100ms, 300ms and 900ms 
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2.6.$Calcium,$cell$and$sarcomere$length$measurements$
2.6.1.$Plating$of$isolated$cardiomyocytes$
Tissue culture surfaces were coated with 5 µg/ml laminin in PBS for 1 hour at 
37°C or 4°C overnight. Laminin solution was drawn off and well surface was 
washed 1x with PBS before isolated cardiomyocytes were plated. 
 
2.6.2.$Calcium$handling$and$sarcomere$length$measurements$
Measurement of intracellular Ca2+ and sarcomere length was performed in 
freshly isolated left ventricular cardiomyocytes using an integrated 
contractility/photometry system (IonOptix Corporation, US). Isolated 
cardiomyocytes were loaded with 1 µmol/L of Fura-2-AM (Invitrogen, US) for 30 
min, allowed to de-esterify for 20 min and then perfused with standard Tyrode’s 
solution: NaCl 130 mmol/L, KCl 5.4 mmol/L, HEPES 10 mmol/L, MgCl2 0.5 
mmol/L, CaCl2 1.8 mmol/L, and glucose 10 mmol/L (pH 7.4) in an open-
perfusion chamber mounted on the stage of an upright microscope (Olympus). 
 
Myocytes were stimulated (1-3"Hz) using an external stimulator (Grass 
Technologies, US). Dual excitation (at 360 and 380 nm; F1 and F0) was 
delivered using OptoLED light sources (Cairn Research, UK) and emission light 
was collected at 510 nm (sampling rate 1 kHz). Simultaneous changes in 
calcium transients and sarcomere length were recorded using IonOptix 
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software. Parameters measured include calcium amplitude, diastolic and 
systolic (peak) calcium levels, calcium transient decay (t) and % sarcomere 
length (SL) shortening. All measurements were performed at room temperature 
(183). 
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3.$Sodium$handling$in$the$atria$and$ventricles$
3.1.$Chapter$introduction$and$overview$
[Na+]i  is an essential modulator of a range of physiological functions within the 
heart. INa governs the initiation and propagation of the AP, thus controlling 
cardiac excitability and CV of electrical stimuli across the heart (1). Blocking 
sodium channels decreases the rate of depolarisation, also leading to decrease 
in AP amplitude and CV (98). Therefore, inhibiting sodium channels with AADs 
can assist in maintaining NSR by supressing arrhythmias, which are a result of 
abnormal conduction (184). Subsequently, a variety of sodium channel 
modulating drugs are used as treatment of AF.  
 
Pharmacological rhythm control therapy is often associated with modification of 
otherwise normal and therefore healthy ventricular electrophysiology, possibly 
resulting in the adverse effect of developing lethal ventricular arrhythmias (147).  
This lead to an emphasis on the development of atrial-selective medications, in 
order to avoid altering ventricular electrophysiology of AF patients and improve 
efficacy and safety of AADs. This has stemmed increasing interest in comparing 
potential differences in the way sodium channels function between ventricles 
and atria, as chamber distinctions may provide targets for atrial-selective 
sodium channel blockade. Greater knowledge of sodium channel properties in 
the atria, compared to the ventricles, may enable understanding of the 
mechanisms that lead to drug selectivity of atrial sodium channels (4, 5, 184) 
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and potentially lead to development of novel atrial selective AADs. 
 
Although it has been shown that several mammalian species display different 
biophysical properties between LA and LV sodium channels (4, 5, 142, 185, 
186), these studies have not yet been conducted in mice. Furthermore, the 
molecular causes explaining differences in INa between chambers have not 
been fully established. A considerable amount of cardiac research and drug 
development relies on the use of mouse whole tissue and isolated 
cardiomyocytes, partly due to the wide availability of genetically modified 
murine models. Hence we characterised sodium channel function in mouse 
atrial and ventricular cardiomyocytes. Additionally, it is also imperative to 
explore the physiological relevance of the differences observed in sodium 
channel properties in the LA and LV, in order to develop a better understanding 
of what distinctions may exist between the chambers under the biological 
conditions expected in vivo. Physiologically relevant information may enhance 
understanding of what differences exist in sodium channel function in the upper 
and lower chambers of the heart. These mechanistic insights may potentially 
lead to improvements in treatment options and development of new AP 
therapeutics.  
 
It has been shown previously that β-subunits regulate the biophysical properties 
of the Nav1.5 α-subunit (53, 65). As detailed in the introduction of this thesis, 
studies have shown negative and/or positive shifts in steady-state inactivation 
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of the channel when Nav1.5 is co-expressed with β1-4 subunits (4, 69-72). 
Similarly, experiments co-expressing the β1 subunit found negative and positive 
shifts in activation of the sodium channel (72, 73). Co-expression of the β4 
subunit has displayed a negative shift in activation (64) but experiments co-
expressing both β2 and β4 together showed no difference in activation kinetics. 
Furthermore, co-expression of β2 and β4 with Nav1.5 has also shown to cause 
faster recovery of the channel. Therefore, we investigated the concentration of 
β-subunits in LA and LV. 
 
Chen et al., found that human and rat myocardium expressed less β2 and β4 in 
the LA compared to the LV (4). They consequently suggested that distinctive 
expression of the β2 and β4 subunits between the atria and ventricles leads to 
differences in the sodium channel gating kinetics between the chambers. In 
their experiments, using isolated rat atrial and ventricular cardiomyocytes, they 
showed that atrial cardiomyocytes displayed distinct sodium channel 
inactivation and recovery properties compared to the sodium channels of 
ventricular cardiomyocytes. Independent experiments conducted in HEK 293 
cells expressing Nav1.5 demonstrated that inactivation and recovery of sodium 
channels is altered following co-expression of β2 and β4 subunits. Chen et al., 
therefore proposed that the differences in biophysical properties between the 
atrial and ventricular rat cardiomyocytes are driven by alterations in expression 
of β2 and β4 subunits (4). However, whether the same differences in β2 and β4 
expression exist between mouse LA and LV is not known. 
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Investigation of β-subunit expression in healthy and diseased human LA and LV 
chambers could help to establish whether β-subunit expression is linked to 
cardiac disease susceptibility and/or progression. Furthermore, examination of 
how sodium is handled in the upper and lower chambers of the heart could offer 
insight into the mechanisms driving sodium handling in different chambers of 
the heart in health and disease (2). 
 
The aims of this investigation are summarised below: 
• To assess sodium channel biophysical properties in isolated mouse LA 
and LV cardiomyocytes and interpret the significance of potential 
chamber distinctions under physiological circumstances. 
 
• To examine the effects of flecainide on the sodium channels in isolated 
mouse LA and LV cardiomyocytes. 
 
• To examine the differences in expression of sodium channels between 
LA and LV chambers. 
 
• To examine β-subunit expression in diseased human myocardium 
samples.   
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3.2.$Electrophysiology$results$
3.2.1.$ Mouse$ LA$ sodium$ channels$ activate$ at$ more$ negative$ holding$
potentials$than$LV$sodium$channels$
Experiments were performed on isolated WT mouse LA and LV cardiomyocytes 
to compare the sodium channel I/V relationship, using the relevant I/V patch 
clamp protocol described in the materials and methods (Table 1.5). This 
protocol enabled assessment of the voltage/current relationship and sodium 
channel activation. 
 
Figure 3.1A shows raw representative traces of the INa from LA and LV 
cardiomyocytes, with greater peak INa in LV cardiomyocytes before normalising 
to cell capacitance. Individual ventricular cardiomyocytes have a larger 
membrane surface area than atrial cardiomyocytes, shown by the difference in 
capacitance values (Figure 3.1B), as capacitance is relative to membrane 
surface area (187). Therefore, individual LV cells will have more sodium 
channels across the greater membrane surface (188). It is essential for INa to be 
normalised against cell size (capacitance), in order to understand the 
physiology of the individual sodium channels and sodium channels over a set 
comparative area in both LA and LV cardiomyocytes. The patch clamp protocol 
is also shown in Figure 3.1A. The current-voltage relationship of the sodium 
channels (Figure 3.1C) shows that from a holding potential of -100mV, LA 
(n=42/13 cells/mice) and LV (n=28/13 cells/mice) sodium channels have a peak 
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current potential of -30mV, at which INa amplitude was comparable in both 
chambers (Figure 3.1D). 
 
The I/V curve data was fitted to a Boltzmann function to obtain the voltage 
dependence of the conductance activation of sodium channels using the initial 
downward slope of the curve (as described in the material and methods). This 
allows comparison of the voltage potential at which half of the sodium channels 
were activated (V50) in the LA and LV. It is evident that atrial sodium channels 
activated at significantly more negative potentials than ventricular sodium 
channels (Figure 3.1E). 
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Figure 3.1. LA and LV INa I/V relationship and sodium channel activation. 
INa I/V curve and channel activation in LA and LV cardiomyocytes from WT 
mouse hearts. A) LA and LV representative raw INa traces with patch clamp 
protocol on the right. B) LA and LV cell capacitance (LA=43.98 ± 2.412pF; 
n=42/13 cells/mice; LV=141.4 ± 9.592pF; n=28/13 cells/mice) ****p<0.0001. C) 
Current-voltage relationship of INa density in LA (n=42/13 cells/mice) and LV 
(n=28/13 cells/mice). D) INa peak density at a step from -100mV to -30mV in LA 
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(-26.84 ± 1.651pA/pF; n=42/13 cells/mice) and LV (-26.84 ± 1.037pA/pF; 
n=28/13 cells/mice). E) V50 of activation fitted to the Boltzmann distribution in 
LA (-42.71 ± 0.8017mV; n=42/13 cells/mice) and LV (-38.63 ± 0.9488mV; 
n=28/13 cells/mice) **P<0.01. Error bars indicate ± S.E.M. significance taken as 
*P<0.05 with unpaired Student t-test. 
 
3.2.2.$LA$peak$INa$is$smaller$than$LV$INa$at$physiologically$relevant$holding$
potentials$
Experiments were performed on isolated WT mouse LA and LV cardiomyocytes 
to measure the peak INa at varying holding potentials using the steady state 
inactivation patch clamp protocol described in the material and methods chapter 
(Table 1.5). The protocol enables the evaluation of the relationship between the 
holding potential (pre-pulse potential) of the cell and the current amplitude upon 
stimulation, and in turn how many sodium channels are available for activation 
at the different holding potentials. Data was analysed from the -120 to -75mV 
holding potential range of the pre-pulse, as current amplitudes were negligible 
at the more positive holding potentials, so could not be measured/compared. 
 
INa amplitude against holding potential relationship differs between the LA and 
LV. INa is greater in LA cardiomyocytes at more negative holding potentials of -
120 to -105mV compared to LV INa current density. At the -100mV holding 
potential, INa is comparable in both LA and LV cardiomyocytes and at holding 
potentials more positive than -100mV, INa current density is greater in LV 
cardiomyocytes (LA=40/13 and LV=28/13 cells/mice). The red box highlights 
the hyperpolarised holding potential commonly used in patch clamp protocols to 
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measure sodium current properties. The green box highlights the physiological 
holding potential range of cardiomyocytes (Figure 3.2A).  In Figure 3.2B INa is 
greater in LA than LV at -120mV holding potential. Conversely, the reverse is 
seen in Figure 3.2C, at the -75mV holding potential, where INa is significantly 
smaller in LA than LV. 
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Figure 3.2. INa density at varying holding potentials. 
INa in LA and LV cardiomyocytes from WT mouse hearts at varying holding 
potentials. A) INa mean density/holding potential relationship from with protocol 
shown inset, LA (n=40/13 cells/mice) and LV (n=28/13 cells/mice), denote 
holding potentials of interest. B) INa density at -120mV holding potential in LA (-
35.72 ± 1.718pA/pF; n=40/13 cells/mice) and in LV (-30.89 ± 1.322pA/pF; 
n=28/13 cells/mice) *p<0.05. C) INa density at -75mV holding potential in LA (-
6.569 ± 0.8474pA/pF; n=40/13 cells/mice) and LV (-9.735 ± 1.075pA/pF; 
-120 -115 -110 -105 -100 -95 -90 -85 -80 -75
-40
-30
-20
-10
0
Pre-pulse holding potential (mV)
I N
a d
en
si
ty
 p
A
/p
F
LV
LA
Hyperpolarised holding potential commonly
 used in published protocol
Physiological holding potential range
100ms 
- 1200mV 
- 40mV 
- 100mV 
- 30mV 
LA LV
-40
-30
-20
-10
0
I N
a d
en
si
ty
pA
/p
F
-120mV
holding potential
*
LA LV
-40
-35
-30
-25
-20
-15
-10
-5
0
I N
a d
en
si
ty
pA
/p
F
-75mV
holding potential
*
A
B C
 
 
91 
n=28/13 cells/mice) *p<0.05. Error bars indicate ± S.E.M. significance taken as 
*P<0.05 with unpaired Student t-test. 
 
3.2.3.$Mouse$ LA$ sodium$ channels$ inactivate$ at$ more$ negative$ holding$
potentials$than$LV$sodium$channels$
Experiments were performed on isolated WT mouse LA and LV cardiomyocytes 
to compare the potential at which the sodium channels inactivate (are no longer 
available), using the relevant steady-state inactivation patch clamp protocol 
described in the materials and methods chapter (Table 1.5). The voltage 
dependence of steady-state inactivation (channel availability, I/Imax) was 
determined from this protocol, as shown in Figure 3.3A and fitted to the 
Boltzmann function. 
 
The LA sodium channel inactivation potential is negatively shifted compared to 
the LV sodium channel inactivation potential (LA=41/13 and LV=27/13, 
cells/mice) (Figure 3.3A). This is confirmed in Figure 3.3B V50 for inactivation. 
The percentage of channel inactivation increases at more positive holding pre 
pulse potentials and Figure 3.3C uses the data from Figure 3.3A to illustrate the 
percentage of channel inactivation at varying pre pulse holding potentials. At -
120mV (the holding potential commonly used in other patch clamp studies of 
the sodium channel) there is no difference in inactivation, however at -100mV, 
inactivation is greater in LA sodium channels. Additionally, at -75mV (within the 
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physiologically holding potential range of LA membranes), inactivation is greater 
in LA sodium channels. 
 
 
 
 
 
 
 
 
 
 
Figure 3.3. LA and LV sodium channel inactivation. 
Channel steady-state inactivation in LA and LV cardiomyocytes from WT mouse 
hearts. A) Curve of normalised INa inactivation (I/Imax) fitted to the Boltzmann 
function in LA (n=41/13 cells/mice) and LV (27/13 cells/mice). B) V50 of 
inactivation fitted to the Boltzmann distribution in LA (-88.48 ± 1.08mV; n=41/13 
cells/mice) and LV (-81.95 ± 0.923mV; n=27/13 cells/mice) ***P<0.0001. C) 
Percentage of channel inactivation at different holding potentials; -120mV 
(LA=0.296± 0.147%; n=41/13 cells/mice; LV=0.2143± 0.923%; n=27/13 
cells/mice), -100mV (LA=20.644± 2.172%; n=41/13 cells/mice; LV=5.256± 
0.59%; n=27/13 cells/mice) ****P<0.0001, -75mV (LA=82± 2.172%; n=41/13 
cells/mice; LV=71.78± 2.795%; n=27/13 cells/mice) **P<0.01. Error bars 
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indicate ± S.E.M. significance taken as *P<0.05 with unpaired Student t-test 
between LA and LV in all data sets (N.B. in C only LA and LV data within each 
holding potential group were compared against each other, not between 
different holding potentials). 
 
3.2.4.$Mouse$LA$sodium$channels$have$slower$time$dependent$recovery$
than$LV$sodium$channels$
Experiments were performed on isolated WT mouse LA and LV cardiomyocytes 
to study the time dependent kinetics of recovery after inactivation, using the 
relevant channel recovery protocol described in the materials and methods 
(Table 1.5). Normalised peak current amplitudes were plotted and fitted to a 
one-phase association exponential function and the time when half of the 
channels were recovered and available for re-activation (P50) was determined 
in the LA and LV cardiomyocytes. 
 
The LA sodium channel recovery time is shifted to the right, slower compared to 
the LV sodium channel recovery (LA=38/13 and LV=28/13 cells/mice) (Figure 
3.4A), demonstrated clearly by the P50 for recovery. 
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Figure 3.4. LA and LV time dependent sodium channel recovery. 
Channel recovery in LA and LV cardiomyocytes from WT mouse hearts. A) 
Curve of normalised sodium channel recovery (I/Imax) fitted to one-phase 
association with protocol shown inset in LA (n=38/13 cells/mice) and LV (28/13 
cells/mice). B) P50 of recovery in LA (22.62 ± 1.703ms; n=38/13 cells/mice) and 
LV (15.49 ± 1.456ms; n=28/13 cells/mice) **P<0.01. Error bars indicate ± 
S.E.M. significance taken as *P<0.05 with unpaired Student t-test. 
 
3.2.5.$Flecainide$alters$I/V$curve$morphology$and$activation$potential$of$
LA$and$LV$sodium$channels$
Experiments were performed on isolated WT mouse LA and LV cardiomyocytes 
in the absence or presence of 1µmol flecainide, to compare peak INa inhibition 
between the chambers, using the I/V patch clamp protocol described in the 
materials and methods chapter (Table 1.5). This protocol enabled assessment 
of the effect of flecainide addition on voltage/current relationship and sodium 
channel activation. Sodium channel inhibition was measured by calculating the 
difference between the control currents and the currents after flecainide 
exposure as a percentage. 
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The raw LA and LV sodium currents +/-1µmol flecainide are shown in Figure 
3.5A, with the patch clamp protocol shown on the right. The flecainide currents 
are visibly smaller than the control currents recorded in the absence of 
flecainide. The current-voltage relationships of the sodiµmol channels in control 
LA against LA +1µmol flecainide are shown in Figure 3.5B (LA control n=11/6 
cells/mice; LA plus flecainide n=11/6 cells/mice) and in control LV against LV 
+1µmol flecainide in Figure 3.5C (LV control n=14/4 cells/mice; LV plus 
flecainide n=14/4 cells/mice). The addition of flecainide clearly alters the curve 
morphology in both LA and LV. The peak of both curves is significantly reduced 
with the addition of flecainide compared to the control curves, shown in figure 
3.5D and 3.5E, with peak current data from the -100mV to -30mV step. 
However, the inhibition of peak INa amplitudes is significantly greater in the LA 
than in LV (Figure 3.5F). 
 
The I/V curve data was fitted to a Boltzmann function to obtain the voltage 
dependence of the conductance activation of sodium channels using the initial 
downward slope of the curve. This allows comparison of the voltage potential at 
which half of the sodium channels were activated (V50) between LA control and 
LA +1µmol flecainide (Figure 3.5G) and between LV control and LV +1µmol 
flecainide (Figure 3.5H). The addition of flecainide results in sodium channel 
activation at significantly more negative potentials in both LA and LV 
cardiomyocytes (Figure 3.6G and Figure 3.5H). The negative shift effect on the 
activation potential of the sodium channels with flecainide addition appears to 
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be greater in LA than LV sodium channels (Figure 3.5I), but this is not 
significant. 
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Figure 3.5. LA and LV INa I/V and sodium channel activation with the 
addition of flecainide. 
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INa I/V curve and channel activation +/- flecainide in LA and LV cardiomyocytes 
from WT mouse hearts. A) LA and LV representative raw INa traces +/- 1µmol 
flecainide, with patch clamp protocol on the right. B) Current-voltage 
relationship of INa density in LA (n=11/6 cells/mice) C) Current-voltage 
relationship of INa density in LV (n=14/4 cells/mice). D) LA INa peak density at a 
step from -100mV to -30mV (LA control=-29.27 ± 3.291pA/pF; n=11/6 
cells/mice; LA plus flecainide=-15.09 ± 1.923pA/pF; n=11/6 cells/mice) 
****p<0.0001 E) LV INa peak density at a step from -100mV to -30mV (LV 
control=-29.89 ± 1.851pA/pF; n=14/4 cells/mice; LV plus flecainide=-20.15 ± 
1.797pA/pF; n=14/4 cells/mice) ****p<0.0001. F) Peak INa percentage inhibition 
(LA=47.64% ± 4.029; n=11/6 cells/mice; LV=33.77% ± 2.824; n=14/4 cells/mice 
**p<0.01). G) LA V50 of activation fitted to the Boltzmann distribution (LA 
control=-43.29 ± 2.063mV; n=11/6 cells/mice; LA plus flecainide=-46.52 ± 
1.589mV; n=11/6 cells/mice) *p<0.05 H) LV V50 of activation fitted to the 
Boltzmann distribution (LV control=-39.4 ± 0.621mV; n=14/4 cells/mice; LV plus 
flecainide=-40.75 ± 0.983mV; n=14/4 cells/mice) **p<0.01. I) Shift in V50 
activation after the addition of flecainide (LA =-3.232 ± 1.302mV; n=11/6 
cells/mice; LV=-1.352 ± 0.397mV; n=14/4 cells/mice). Error bars indicate ± 
S.E.M. Significance taken as *P<0.05 with paired Student t-test for C-F and 
unpaired Student t-test for G. 
 
3.2.6.$ Flecainide$ sodium$ channel$ inhibition$ increases$ at$ more$ positive$
holding$potentials$with$a$greater$effect$in$the$LA$
To compare the effect of different holding potentials on INa inhibition between 
the chambers the currents were measured using the steady state inactivation 
patch clamp protocol described in the material and methods chapter (Table 
1.5). The protocol enables the evaluation of the relationship between the 
holding potential (pre-pulse potential) of the cell and the current amplitude upon 
stimulation, and in turn can be representative of the magnitude of sodium 
channels inhibited by 1µmol flecainide at the different holding potentials. Data 
was analysed from the -120 to -75mV holding potential range of the pre-pulse, 
as current amplitudes reached 0pA/pF at the more positive holding potentials, 
so they could not be measured/compared. 
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Figure 3.6A shows there is a positive correlation between percentage inhibition 
of INa and holding potential in both LA (n=12/6 cells/mice) and LV (n=14/4 
cells/mice). At more positive holding potentials flecainide is more effective at 
inhibiting sodium channels. This is confirmed, as at the most negative holding 
potential, of -120mV, sodium currents were inhibited less than at the most 
positive holding potential analysed, in LA cardiomyocytes and in LV 
cardiomyocytes (Figure 3.6B and 3.6C). 
 
Moreover, Figure 3.6A shows that percentage inhibition of INa in the presence of 
1µmol flecainide is greater in LA than in LV at all of the holding potentials 
recorded from. At -120mV and at the -70mV holding potential inhibition of INa 
was significantly greater in LA than in LV (Figure 3.6D and Figure 3.6E). 
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Figure 3.6. Sodium channel flecainide inhibition in LA and LV at different 
holding potentials. 
Percentage of INa inhibition in LA and LV cardiomyocytes. A) INa percentage 
inhibition at varying holding potentials in LA (n=12/6 cells/mice) and LV 
cardiomyocytes (12/6 cells/mice). B) LA INa percentage inhibition at -120 and -
-120 -115 -110 -105 -100 -95 -90 -85 -80 -75 -70
0
10
20
30
40
50
60
70
80
90
100
Holding test potential (mV)
LV
LA
I N
a %
 in
hi
bi
tio
n
**
*** *** ** **
*
**
**
*
**
100ms 
- 1200mV 
- 40mV 
- 100mV 
- 30mV 
-120mV -70mV
0
10
20
30
40
50
60
70
80
90
100
LV
 I N
a %
 In
hi
bi
tio
n
**
-120mV -70mV
0
10
20
30
40
50
60
70
80
90
100
LA
 I N
a %
 In
hi
bi
tio
n
***
A
B C
LA LV
0
10
20
30
40
50
60
70
80
90
100
I N
a %
 In
hi
bi
tio
n
at
 -7
0m
V 
ho
ld
in
g 
po
te
nt
ia
l
***
LA LV
0
10
20
30
40
50
60
70
80
90
100
I N
a %
 In
hi
bi
tio
n
at
 -1
20
m
V 
ho
ld
in
g 
po
te
nt
ia
l *
D E
 
 
101 
70mV (-120mV=47.41% ± 4.642; n=12/6 cells/mice; -70mV=75.89% ± 6.801; 
n=12/6 cells/mice) ***p<0.001. C) LV INa percentage inhibition at -120 and -
70mV (-120mV=33.61% ± 2.58; n=14/4 cells/mice; -70mV=44.43% ± 4.508; 
n=14/4 cells/mice) **p<0.01. D) LA and LV INa percentage inhibition at -120 
(LA=47.41% ± 4.642; n=12/6 cells/mice; LV=33.61% ± 2.580; n=14/4 
cells/mice) *p<0.05. E) LA and LV INa percentage inhibition at -70 (LA=75.89% ± 
6.801; n=12/6 cells/mice; LV=44.43% ± 4.508; n=14/4 cells/mice) ***p<0.001. 
Error bars indicate ± S.E.M. significance taken as *P<0.05; paired Student t-test 
in B and C and unpaired Student t-test in D and E. 
 
3.2.7.$Flecainide$alters$LA$and$LV$sodium$channel$inactivation$$
Experiments were performed on isolated WT mouse LA and LV cardiomyocytes 
to compare the potential at which the sodium channels inactivate (are no longer 
available) in the presence and absence of flecainide, using the relevant steady-
state inactivation patch clamp protocol described in the materials and methods 
(Table 1.5). The voltage dependence of inactivation (channel availability, I/Imax) 
was determined form this protocol, as shown inset in Figure 3.7A and 3.7C and 
fitted to the Boltzmann function. 
 
There is a shift in the inactivation potential of the sodium channels between the 
control and +1µmol flecainide in both the LA (n=12/6 cells/mice) and LV (n=14/4 
cells/mice), demonstrated by the V50 for inactivation (Figure 3.7B and Figure 
3.7D). Nevertheless, the shift in the inactivation potential of the sodium 
channels between the control LA and +1µmol flecainide LA is greater than the 
shift seen in the LV, demonstrated by the V50 voltage shifts (Figure 3.7E) but 
this is not significant, likely due to a larger standard deviation of the LA dataset. 
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Figure 3.7. LA and LV INa inactivation with the addition of flecainide. 
Channel inactivation +/- flecainide in LA and LV cardiomyocytes from WT 
mouse hearts. A) LA curve of normalised INa inactivation (I/Imax) fitted to the 
Boltzmann function (n=12/6 cells/mice). B) LA V50 of inactivation fitted to the 
Boltzmann distribution (LA control=-86.82 ± 1.821mV; n=12/6 cells/mice; LA 
plus flecainide=-89.4 ± 2.156mV; n=12/6 cells/mice) *p<0.05. C) LV curve of 
normalised INa inactivation (I/Imax) fitted to the Boltzmann function (n=14/4 
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cells/mice). D) LV V50 of inactivation fitted to the Boltzmann distribution (LV 
control=-83.06 ± 0.8622mV; n=14/4 cells/mice; LV plus flecainide=-84.7 ± 
1.016mV; n=14/4 cells/mice) ****p<0.0001 E) V50 inactivation shift with 
flecainide (LA=-2.78 ± 1.139mV; n=12/6 cells/mice; LV=-1.639 ± 0.2927mV; 
n=14/4 cells/mice). 
 
3.2.8.$Flecainide$slows$sodium$channel$recovery$in$the$LA$
Experiments were performed on isolated WT mouse LA and LV cardiomyocytes 
to study the time dependent kinetics of recovery after inactivation in the 
presence and absence of flecainide, using the relevant channel recovery 
protocol described in the materials and methods (Table 1.5). Normalised peak 
current amplitudes were plotted and fitted to a one-phase association 
exponential function and the time when half of the channels were recovered 
(P50) was determined in the LA and LV cardiomyocytes. 
 
In the LA (n=12/6 cells/mice) there was a clear right shift in the sodium channel 
recovery time in the presence of 1µmol flecainide (Figure 3.8), demonstrating 
that channel recovery was significantly slower after flecainide was added, 
confirmed by the P50 in Figure 3.8B. However, in the LV (n=14/4 cells/mice) the 
sodium channel recovery time was not altered by the addition of flecainide 
(Figure 3.8C), confirmed by the sodium channel P50 for recovery (Figure 3.8D). 
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Figure 3.8. Flecainide effect on LA and LV time dependent sodium channel 
recovery. 
Channel recovery in control/flecainide LA and LV cardiomyocytes from WT 
mouse hearts. A) LA curve of normalised sodium channel recovery (I/Imax) 
fitted to one-phase association with protocol shown inset (n=12/6 cells/mice). B) 
LA P50 of recovery (LA control=20.16 ± 2.589ms; n=12/6 cells/mice; LA plus 
flecainide=29.29 ± 4.709ms; n=12/6 cells/mice) *p<0.05. C) LV curve of 
normalised sodium channel recovery (I/Imax) fitted to one-phase association 
with protocol shown inset (n=14/4 cells/mice). D) LV P50 of recovery (LV 
control=15.53 ± 1.441ms; n=14/4 cells/mice; LV plus flecainide=16.88 ± 
2.408ms; n=14/4 cells/mice). Error bars indicate ± S.E.M. significance taken as 
*P<0.05 with paired Student t-test. 
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3.3.$Protein$expression$
3.3.1.$Nav1.5$expression$in$WT$mouse$LA$and$LV$
Western blot experiments were performed on WT mouse LA and LV tissue 
homogenates, in order to assess whether the protein expression of Nav1.5 (the 
major cardiac sodium channel isoform) varies between the atrial and ventricular 
chambers. The only antibody that worked (Alomone, ASC-005) consistently 
displayed multiple bands on the blots; the expected 250kDa and 75kDa bands 
(shown on the data sheet attached to the antibody) and an additional band of 
25kDa. Lower molecular weight bands can arise from degradation of the 
sample during processing steps. However, samples were immediately snap 
frozen after collection, stored at -80°C and always kept on ice during the 
homogenisation process so degradation was avoided. Additionally, protease 
inhibitors were also included in the homogenisation buffer to prevent protease 
activity and protein splicing during sample preparation. 
 
In order to determine whether the additional bands are due to the Nav1.5 
protein or were due to technical artifacts, several optimisation steps were used. 
To determine whether multiple bands seen on the blot were a result of non-
specific binding of the secondary antibody, separate experiments were 
conducted in the absence of the primary antibody. This resulted in a blank 
image (data not shown), as expected, and verified that the additional bands 
were not due to non-specific binding of the secondary antibody. Although the 
Nav1.5 protein was expected to be abundant in the samples non-specific 
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binding to proteins of greater abundance may have been likely. To avoid this 
type of non-specific binding an increase in the duration of washes was done, 
doubling washing time, with no effect on the additional bands appearance. 
Experiments were also done with the primary antibody pre-incubated with the 
blocking peptide provided with the antibody and all three bands were no longer 
present, proving that the bands observed are indeed Nav1.5. Lower 
concentrations of primary and secondary antibody were also tested, but this 
resulted in blank blots (data not shown). 
 
Therefore, the data for the Nav1.5 protein expression in mouse LA and LV 
samples has been analysed and presented using the densities of the individual 
molecular weight bands alone as well as averaging the densities of all three 
bands. Other groups that have used this antibody have either only analysed 
data using the largest band (189) or not stated what the molecular weight of the 
analysed band was (190, 191). 
 
Figure 4.1A is a copy of the rat brain tissue Western blot example provided, on 
the Alomone data sheet for the Nav1.5 antibody, clearly showing two expected 
bands at around 250kDa and 75kDa. Figure 4.1B is an example of a whole 
Western blot generated in this study, showing three distinct bands with the 
Nav1.5 antibody at 250kDa, 75kDa and 25kDa. Figure 4.1B also shows a 
representative GAPDH Western blot band at 37kDa molecular weight, used for 
normalisation. 
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Figure 4.1C shows Nav1.5 protein expression using only the largest 250kDa 
band. Using the 250kDa band, expression of the Nav1.5 protein is shown to be 
greater in the LA than LV (LA n=13; LV n=13). Figure 4.1D shows data from the 
250kDa and 75kDa bands combined (Figure 4.1A). When 250kDa and 75kDa 
band are combined, expression of the Nav1.5 protein is greater in the LV than 
LA (LA n=13; LV n=13). Figure 4.1E is a combination of all three bands that 
were visible on the Western blot (seen in Figure 4.1B) and also shows greater 
expression of the Nav1.5 protein in the LV than LA (LA n=13; LV n=13). Table 
2.1 shows data obtained from all of the bands individually. The difference in the 
expression on Nav1.5 between LA and LV varies, dependent on which Western 
blot bands were analysed. 
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Figure 4.1. Nav1.5 expression in mouse LA and LV. 
Expression of Nav1.5 protein in LA and LV tissue from WT mouse hearts. A) 
The Western blot example provided on the Alomone data sheet for the Nav1.5 
antibody (192). B) Top: image of the whole Nav1.5 Western blot obtained, 
showing three distinct bands with the Nav1.5 antibody at 250kDa, 75kDa and 
25kDa, bottom: representative GAPDH Western blot band. C) Analysis of the 
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250kDa band alone (LA=3.182 ± 0.3977AU; n=13; LV=1.00 ± 0.1598AU; n=13) 
****p<0.0001. D) Analysis of the 250kDa and 75kDa band combination 
(LA=0.7381 ± 0.08387AU; n=13; LV=1.00 ± 0.005585AU; n=13) *p<0.05. E) 
Analysis of the 250kDa, 75kDa and 25kDa band combination (LA=0.6392 ± 
0.06412AU; n=13; LV=1.00 ± 0.05798AU; n=13) ***p<0.001. Error bars indicate 
± S.E.M. significance taken as *P<0.05 with unpaired Student t-test. 
 
Table 2.1: Individual molecular weight band data for Nav1.5 expression in 
mouse WT LA and LV. 
Molecular weight 
of Nav1.5 
antibody band 
Normalised protein 
expression in LA 
(AU) 
Normalised protein 
expression in LA (AU) 
Unpaired Student 
t-test significance 
250kDa 3.182 ± 0.3977 1.00 ± 0.1598 ****p<0.0001 
75kDa 0.3818 ± 0.04430 1.00 ± 0.04894 ****p<0.0001 
25kDa 0.4835 ± 0.05624 1.00 ± 0.07739 ****p<0.0001 
 
 
3.3.2.$Nav1.5$βRsubunit$expression$in$WT$mouse$LA$and$LV$
A lower expression of Navβ2 and Navβ4 was observed in LA rat myocardial 
tissue compared to the LV rat myocardial tissue (4). The same study also found 
that currents of Nav1.5 co-expressed with Navβ2 and Navβ4 subunits in HEK 
293 cells had a more positive activation potential, more positive inactivation and 
faster recovery of the sodium channels, compared to HEK 293 cells expressing 
Nav1.5 alone (4). Therefore, the INa in the HEK 293 cell expressing Nav1.5 with 
Navβ2 and Navβ4 subunits could be likened to the INa in LV cardiomyocytes and 
likewise the INa in HEK 293 cell expressing Nav1.5 alone could be compared to 
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LA cardiomyocyte INa. In this study we investigated whether the described 
differences in expression of the β-subunits was conserved in mouse and human 
tissue. 
 
Western blot experiments were performed on WT mouse LA and LV tissue 
homogenates, in order to assess whether the protein expression of the Navβ2 
and Navβ4 subunits varies between the atrial and ventricular chambers. Figure 
4.2A shows the Western blot for Navβ2 with a 15kDa band and GAPDH that 
was used for normalisation with a 37kDa molecular weight. The expression of 
the β2 is lower in the LA than in the LV (LA n=6; LV n=6). Figure 4.2B shows 
the Western blot for Navβ4 with a 25kDa band and a 37kDa GAPDH that was 
used for normalisation. The expression of the β4 is lower in the LA than in the 
LV (LA n=6; LV n=6). 
Figure 4.2. Navβ2 and Navβ4 expression in mouse LA and LV. 
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Expression of Navβ2 and Navβ4 protein in LA and LV tissue from WT mouse 
hearts. A) Raw example blot of GAPDH and Navβ2 Western blots. Analysis of 
the Navβ2 protein band normalised with GAPDH (LA=0.2237 ± 0.02926AU; 
n=6; LV=0.4131 ± 0.05483AU; n=6) *p<0.05. B) Raw example blot of GAPDH 
and Navβ4 Western blots. Analysis of the Navβ4 protein band normalised with 
GAPDH (LA=0.0881 ± 0.003234AU; n=6; LV=0.21 ± 0.008832AU; n=6) 
*****p<0.0001. Error bars indicate ± S.E.M. significance taken as *P<0.05 with 
unpaired Student t-test. 
 
3.3.3.$Nav1.5$βRsubunit$expression$in$human$LA$and$LV$
Western blot experiments were performed on diseased and healthy human LA 
and LV tissue homogenates, in order to assess the protein expression of the 
Navβ2 and Navβ4 subunits. As Navβ2 and Navβ4 subunits are greater in mouse 
LA than LV, it is interesting to examine whether the same difference is seen 
between diseased human LA and LV. Hearts are classified as diseased due to 
a reduced ejection fraction below 50%. 
 
Figure 4.3A shows the Western blot for Navβ2, with a 50kDa band and 
associated GAPDH that was used for normalisation with a 37kDa molecular 
weight. The expression of the β2 is higher in the LA than in the LV (LA n=6; LV 
n=6), contrary to the findings in healthy mouse tissue (Figure 4.2A). Figure 4.3B 
shows the Western blot for Navβ4 with a 25kDa band and associated GAPDH 
that was used for normalisation with a 37kDa molecular weight. There is a 
pattern of much lower expression of the β4 in the LA compared to the LV, 
matching findings in the healthy mouse tissue (see Figure 4.2B), but likely due 
to the small n numbers and data variability this is not significant (LA n=6; LV 
n=6). 
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Figure 4.3. Navβ2 and Navβ4 expression in diseased human LA and LV. 
Expression of Navβ2 and Navβ4 protein in LA and LV tissue from diseased 
human hearts. A) Raw example blot of GAPDH and Navβ2 Western blots. 
Analysis of the Navβ2 protein band normalised with GAPDH (LA=0.3041 ± 
0.009002AU; n=6; LV=0.2562 ± 0.01155AU; n=6) **p<0.01. B) Raw example 
blot of GAPDH and Navβ4 Western blots. Analysis of the Navβ4 protein band 
normalised with GAPDH (LA=0.0546 ± 0.03751AU; n=6; LV=0.15 ± 0.04394AU; 
n=6). Error bars indicate ± S.E.M. significance taken as *P<0.05 with unpaired 
Student t-test. 
 
Western blot experiments were performed on human healthy LA and diseased 
LA tissue homogenates, in order to assess whether the protein expression of 
Navβ2 varies. Healthy tissue was collected from donor hearts that were not 
used for transplantation.  
 
Figure 4.4A shows the Western blot for Navβ2 with a 50kDa band and 
associated GAPDH that was used for normalisation with a 37kDa molecular 
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weight. The expression of the β2 is higher in the diseased LA than in the 
healthy LA (LA n=4; LV n=4). 
 
 
 
 
 
 
 
 
Figure 4.4. Navβ2 expression in diseased and healthy human LA. 
Expression of Navβ2 protein in LA and LV tissue from diseased human hearts. 
Raw example blot of GAPDH and Navβ2 Western blots. Analysis of the Navβ2 
protein band normalised with GAPDH (LA=0.3934 ± 0.02893AU n=4; 
LV=0.2209 ± 0.0257AU n=4) **p<0.01. Error bars indicate ± S.E.M. significance 
taken as *P<0.05 with unpaired Student t-test. 
 
3.3.4.$$Expression$of$the$genes$that$encode$SCN5A,$SCN2B$and$SCN4B$in$
healthy$human$LA$and$LV$
This work was performed by Dr Nathan Tucker. 
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RNA-sequencing was done on paired LA and LV samples from 4 donor hearts 
and the mRNA expression of SCN5A (the gene that encodes Nav1.5), SCN2B 
and SCN4B (the genes that encode the Navβ2 and Navβ4 respectively). 
 
There is no difference in SCN5A mRNA between the human LA and LV (LA 
n=4; LV n=4). However, there is a trend of lower mRNA expression of SCN2B in 
the human LA compared to the LV but this is not significant, likely due to 
variability and small data set (LA n=4; LV n=4). SCN4B is significantly lower in 
the human LA than LV (LA n=4; LV n=4) (Figure 4.5). 
 
 
 
 
 
 
 
 
Figure 4.5. Expression of the mRNAs that encode Nav1.5 and the Navβ-
subunits in healthy human LA and LV. 
The mRNA of SCN5A, SCN1B, SCN2B, SCN3B and SCN4B in healthy human 
LA and LA. Expression of SCN5A (LA=57.83 ± 4.857 RPKM n=4; LV=42.61 ± 
6.780 RPKM; n=4). The mRNA expression of SCN2B (LA=2.435 ± 0.789 RPKM 
n=4; LV=3.925 ± 0.2191 RPKM; n=4). The mRNA expression of SCN4B 
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(LA=3.52 ± 0.5294 RPKM n=4; LV=5.233 ± 0.3568 RPKM; n=4) *p<0.05. Error 
bars indicate ± S.E.M. significance taken as *P<0.05 with unpaired Student t-
test. 
 
3.4.$Chapter$synopsis$and$discussion$
3.4.1.$Overview$of$main$findings$
The key findings of the chapter are described as follows: 
• Mouse LA INa density is smaller than LV INa density at physiological RMP 
(-75mV). Density of LA INa is only greater than LV INa when the holding 
potential of the cells is hyperpolarised in comparison to normal 
physiological RMP. 
 
• The biophysical properties of mouse LA and LV sodium channels differ. 
LA sodium channels activate and inactivate at more negative potentials 
and have slower time dependent recovery than LV sodium channels. 
 
• Flecainide displays a more potent inhibition of LA sodium channels than 
LV sodium channels across the full range of holding potentials tested (-
120 to -70mV). 
 
• Expression of Nav1.5 protein is greater in mouse LA than LV (when 
analysed using the standard 250kDa band) but the expression of Navβ2 
and Navβ4 protein is reduced in mouse LA compared to LV. Conversely, 
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expression of Navβ2 protein is greater in human diseased LA than 
diseased LV. 
 
3.4.2.$Physiological$INa$density$comparison$between$LA$and$LV$
There have been several studies comparing the biophysical properties of 
mammalian atrial and ventricular sodium channels, that have resulted in 
multiple publications stating chamber distinctions in the sodium channel 
physiology. Different activation, inactivation and recovery kinetics of VGSCs in 
LA and LV cardiomyocytes of guinea pig, canine, rat and rabbit (4, 5, 142, 185, 
186) have been shown. One of the conclusions from these studies is that the 
LA cardiomyocytes display greater peak INa than LV cardiomyocytes (4, 5, 142, 
185, 186).  
 
However, this does not correlate with what is understood about the physiology 
of the heart. Maximum rate of rise of the AP upstroke (Vmax), has long been 
established as a measure of INa in cardiomyocytes (19, 31) and the Vmax of 
atrial APs has been experimentally described as being between ≅150-300 V/s 
(31, 32), compared to higher values of 300-400 V/s for human ventricular cells 
(33, 34), with similar differences also shown in smaller mammals (193, 194). 
This contrasts with the published exclamation of atrial INa density being greater 
than ventricular, as in fact the opposite would be expected, considering that the 
atrial Vmax is smaller than ventricular Vmax. 
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However, there is no difference seen in mouse peak LA and LV INa in Figure 
3.1D, with the -100mV holding potential that currents were initiated from, in 
order to obtain I/V data. No difference in INa density, at a -100mV holding 
potential, conflicts with what has been shown in other mammals in the 
previously stated publications. Consequently, further analysis was required into 
the effect of the holding potential on peak INa, as this was the only clear 
difference between this study and published data, which used a -120mV (or 
more negative) holding potential when obtaining I/V data (4, 5, 142, 185, 186). 
 
In the data published in guinea pig, canine, rat and rabbit, that showed atrial 
peak INa was greater than ventricular peak INa (4, 5, 142, 185, 186), the -120mV 
holding potential used in these studies is much more negative than normal RMP 
of mammalian atrial and ventricular cardiomyocytes (19, 20). Protocols use 
hyperpolarised holding potential to ensure that all sodium channels are 
available for activation, so that currents recorded are representative of all of the 
sodium channels within the cells. This is demonstrated in Figure 3.3A, where 
minimal inactivation occurs (and therefore greatest current density) when 
sodium currents are initiated from at -120mV holding potential. 
 
However, physiologically, in an in vivo setting, not all sodium channels would be 
available at normal mammalian RMP. This is evident in Figure 3.2; INa density is 
clearly much greater in both LA and LV chambers when currents are initiated 
from more negative potentials (-120mV Figure 3.2B), compared to when 
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currents are initiated from more physiological potentials (Figure 3.2C). 
Consequently, previously published data demonstrating greater LA INa 
compared to LV INa, is not physiologically relevant, due to protocols relying on 
the hyperpolarised holding potentials and not accounting for the effect of 
holding potential on current density between the chambers. 
 
In order to gain understanding of physiologically relevant INa differences 
between chambers, it would be beneficial for cardiomyocytes to be examined 
under more physiological conditions. Therefore, patch clamp experiments could 
be performed at holding potentials of -65 to -80mV (20) for LA cardiomyocytes 
and -80 to -90mV (19) for LV cardiomyocytes. Figure 3.2A shows that INa 
density in LA at the holding potential of -75mV is -6.459pA/pF and LV INa at the 
-85mV holding potential is -19.479pA/pF. Hence, in vivo LA INa would be 
approximately a third that of LV INa, fitting more with what is understood about 
atrial and ventricular Vmax (31-34, 193, 194). In Figure 3.2A, there is no 
difference between LA and LV INa density at -100mV holding potential. This 
clarifies why no difference is seen in peak INa in Figure 3.1D, as the -100mV 
holding potential was used to collect peak current data. 
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3.4.3.$Voltage$dependence$of$inactivation$and$the$effect$on$peak$LA$and$
LV$INa$
Sodium channel inactivation positively correlates with depolarisation of holding 
potential voltage in both the LA and LV (Figure 3.3A). The difference in sodium 
channel inactivation kinetics between the atrial and ventricular sodium channels 
results in a greater impact of change in holding potential on LA INa density. 
Figure 3.3A shows a negative shift in LA sodium channel inactivation compared 
to LV sodium channel inactivation. This is supported by the significant V50 data 
in Figure 3.3B, 50% of the LA sodium channels are inactivated at -88.481mV, 
compared to the more positive -81.952mV for LV sodium channels. 
 
Nav1.5 sodium channels adopt one of three structurally distinct states: open, 
closed and inactivated. As described in the introduction of this thesis, sodium 
channels activate (open) when the membrane potential depolarises and 
reaches the threshold for the activation gate to open, followed by a rapid influx 
of Na+. This state is brief due to the rapid closure of the inactivation gate; this is 
referred to as the inactivated (closed) state (195, 196). Therefore, negative 
regulation of sodium channel conductance occurs via this inactivation as influx 
of Na+ is halted. Recovery from this inactivation occurs upon further 
repolarisation, the channel recovers from the inactivated (closed) state 
(inactivation gate opens) and deactivates to the original closed available state 
(activation gate is closed), this is known as the deactivated (closed) state. The 
functional difference between the inactivated (closed) and deactivated (closed) 
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state is that channels inactivate when the cell depolarises, rendering it 
unavailable to open and conduct Na+, whereas the deactivated state occurs 
during hyperpolarisation and channels are available to open when the cell 
depolarises. Consequently, in order for channels to be available for activation 
they must return to the deactivated (closed) state. The period of the inactivated 
(closed) state is important, as the influx of Na+ and therefore the upstroke of the 
AP rely on the sodium channels being available to open (197). 
 
Therefore, the negative shift in LA sodium channel inactivation results in a 
greater proportion of channels remaining in the inactivated (closed) state than 
the LV sodium channels at holding potentials more positive than -120mV 
(Figure 3.3A), so fewer are available for activation. To measure whether 
reduction in peak INa is a result of the negative shift in voltage dependence of 
inactivation, peak INa can be compared to currents initiated from more positive 
holding potentials. When initiated from a holding potential of -120mV, the LA INa 
density is -35.721pA/pF (Figure 3.2A). When this current density is reduced by 
the percentage of channel inactivation at -100mV (20.644%) (Figure 3.3C), the 
value is -28.347pA/pF, which is comparable to the LA INa density observed 
when the current is initiated from -100mV holding potential, of -26.84pA/pF 
(Figure 3.2A). The same is seen when this calculation is also done with the LV 
INa data. When initiated from a holding potential of -120mV, the INa density is -
30.89pA/pF in the LV (Figure 3.2A). When this current density is reduced by the 
percentage of channel inhibition at -100mV (5.256%) (Figure 3.3C), the value is 
-29.27, which is comparable to the LV INa density when the current is initiated 
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from a -100mV holding potential, of -27.08pA/pF (Figure3.2A). Therefore, taking 
into account channel inactivation percentage at the different holding potentials 
and reducing the maximal current achieved (the current initiated from -120mV) 
by that percentage equates to the INa density value at the different holding 
potentials.  
 
As previously described, sodium channel inactivation is negatively shifted in the 
LA compared to the LV (Figure 3.3A), with a resulting reduction in LA INa at 
physiological holding potentials. The sodium channel inactivation gate is usually 
described as open during the RMP phase of the AP (198), this clearly is not 
always accurate. At the RMP expected in vivo (-65 to -90mV), larger proportions 
of LA sodium channels remain in an inactivated closed state. Sodium channels 
do not need to open before they inactivate (199) and the hyperpolarised 
membrane potentials required for the sodium channels to enter the deactivated 
closed state would not occur naturally in vivo. Therefore, some sodium 
channels, more in the LA than LV because of the more negative inactivation 
and the more positive membrane potential in vivo, are in a perpetual inactivated 
closed state and can be rendered dormant physiologically. 
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3.4.4$ Pathophysiological$ considerations$ due$ to$ differences$ in$ INa$
inactivation$between$LA$and$LV$
As demonstrated in Figure 3.3A, the negative shift in inactivation of LA sodium 
channels means that in vivo, LA INa density is less than LV INa density. This is 
important as smaller INa would lead to reduced CV, which as previously 
described can be proarrhythmic and may suggest a possible cause of the atria’s 
susceptibility to arrhythmia (1). Therefore, sodium channel blocking drugs, such 
as flecainide, could further contribute to arrhythmia generation, as conduction 
slows (200). 
 
In large mammals, such as dogs and humans, the INa,late has been shown to 
modulate APD by providing a sustained influx of Na+, disrupting the balance of 
inward Ca2+ and outward K+ during the AP plateau (201). APD prolongation, as 
a result of more positive sodium channel inactivation and more positive sodium 
channel activation and subsequent INa,late, is linked to arrhythmogenesis. 
Enhanced INa,late can instigate repolarisation failure and result in EAD’s, causing 
a regenerative L-type Ca2+ channel re-activation or providing sufficient time for 
sodium channels to recover and reactivate (127). Additionally, DAD’s can follow 
full repolarisation via Ca2+ overload in sodium-calcium overload conditions 
(202). As described in the data here, LA sodium channels may be less likely to 
reactivate prematurely as hyperpolarisation is required for sodium channels to 
convert from the inactivated state and be available for activation. Therefore, 
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atria may display negligible or smaller INa,late compared to the ventricles and this 
may be considered as cardioprotective. 
 
Conversely, LA sodium channels may remain open during the plateau phase of 
the AP due to the shift in inactivation potential and could in fact have a greater 
INa,late compared to the ventricles. Luo et al., demonstrated this by showing 
greater INa,late density in rabbit atrial cardiomyocytes compared to ventricular 
cardiomyocytes (203). This is also supported by additional studies that have 
demonstrated ranolazine, an INa,late blocker, as an effective AF treatment (204-
207). However, ranolazine inhibition of potassium channels also needs to be 
considered, as Kr block has the antiarrhythmic effect of prolonging APD (208, 
209).  
 
However, direct voltage clamp measurements comparing INa,late from rabbit atrial 
and ventricular cardiomyocytes found no difference in INa,late density when 
currents were measured from a -80mV holding potential (210). Nevertheless, it 
must be considered that these experiments utilised additional agents to prolong 
the sodium channel open time and facilitate reopening to increase INa,late, in 
order for it to be possible to measure such small currents. Therefore, the normal 
gating kinetics of the sodium channels in these studies may have been altered, 
and perhaps not be representative of what would occur in vivo. Furthermore, 
other studies have shown that accurate direct voltage clamp measurements 
comparing INa,late from healthy WT atrial and ventricular cardiomyocytes under 
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physiological conditions is extremely difficult, as the currents are so small or 
appear non-existent (211). 
 
Depolarisation of the RMP can occur as a result of medication, ischemia or 
hypoxia. For example, acute myocardial ischemia causes a series of complex 
biochemical alterations in the myocardium, including acidosis with a rapid rise in 
local extracellular K+. As predicted in the Nernst equation, increases in 
extracellular K+ results in depolarisation (17). A rise in extracellular K + occurs 
due to a fall in ATP in the absence of blood flow, which results in the opening of 
ATP-modulated K+ channels, that are normally inhibited with physiological 
levels of intracellular ATP and inhibition of the ATP-dependent NKA pump. As 
the RMP depolarises there is expected to be an increase in sodium channel 
inactivation and therefore INa amplitude decrease, resulting in slower CV (212). 
Given the accepted determinants of re-entry, slower conduction decreases the 
size of the re-entrant circuit and increases the number of circuits, increasing the 
likelihood of AF occurrence (213).  Therefore, the negatively shifted inactivation 
of LA sodium channels suggests that the LA are likely to experience greater 
slowing in conduction, under conditions that may depolarise the RMP, 
potentially leading to arrhythmia generation. This is a feasible mechanism for 
the atria’s increased susceptibility to arrhythmia compared to the ventricles if 
the RMP becomes depolarised. 
 
 
 
125 
Acidosis can result in depolarisation of the RMP (214). The arrhythmic effect of 
a shift in inactivation with acidosis has been shown in patients with the R1512W 
mutation in SCN5A, that was identified as the first cause of Chinese sudden 
unexplained nocturnal death syndrome (SUNDS) (215) but showed no obvious 
loss of function of the cardiac sodium channel in vitro (216). Patch clamp 
experiments measuring INa on Xenopus oocytes expressing sodium channels 
with the R1512W mutation have revealed a 4-5mV negative shift in the steady-
state inactivation curves compared to their WT counterparts (216), this shift is 
comparable to the differences observed between LA and LV sodium channel 
inactivation (Fig 3.3A). It was shown that slight acidosis conditions resulted in 
significant loss of function of the mutant sodium channel in cells with the 
R1512W mutation, compared to cells expressing WT Nav1.5 (216). This 
suggested that nocturnal sleep disorders-associated with slight acidosis could 
trigger the lethal arrhythmia underlying the sudden death of people with this 
genetic defect. This again endorses that the more negative inactivation of LA 
sodium channels could result in a greater susceptibility to arrhythmia compared 
to the LV, under conditions that shift RMP positively, such as acidosis. 
 
Antiarrhythmic drugs, Class I: fast sodium channel blockers, Class II: beta 
blockers and Class IV: calcium channel blockers, can have the adverse effect of 
decreasing CV and so can be proarrhythmic (165). Therefore, factors that affect 
the RMP, such as electrolyte abnormalities, fibrosis, ischemia and inflammation 
are important to consider when treating AF. The sensitivity of atrial sodium 
channel inactivation to depolarisation of the RMP could result in conduction 
 
 
126 
slowing, with antiarrhythmic drugs contributing to this. Indeed, proarrhythmic 
risk of flecainide treatment in patients with structural heart disease is well 
documented, as they would likely have fibrosis and/or inflammation and/or 
ischemia (159). Consequently, in patients with conditions that result in 
depolarised RMP, the development of atrial specific drugs that shift the 
inactivation of sodium channels to more positive potentials or repolarise the 
RMP could be protective against AF. 
 
3.4.5.$Sodium$channel$activation$differences$between$LA$and$LV$
Activation of sodium channels depends upon voltage sensing, whereby 
alterations in membrane potential promote change to the channel conformation. 
The sodium channels are closed under resting conditions and those that are in 
the deactivated (closed) state are available for activation (opening), when the 
membrane potential depolarises and reaches the threshold for the channel 
activation gate to open, followed by a rapid influx of Na+.  The influx of Na+ into 
the cardiomyocyte results in a positive feedback loop, with more sodium 
channels activating in response to the depolarising membrane potential, driving 
the AP upstroke until there is inactivation (closure) of the channels (217, 218). 
 
The LA -4.08mV shift in the V50 activation potential detected in this study 
reveals that the voltage at which half of the sodium channels are available for 
activation is more negative compared to that of the LV sodium channels (Fig 
3.1E). This difference in V50 activation potential is also supported by previously 
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published findings in rabbit LA and LV cardiomyocytes (5). It would be 
expected, that a negative shift of the voltage dependence of LA sodium channel 
activation would decrease the voltage difference between the RMP and the 
activation threshold, leading to increased INa. However, this is counteracted by 
the greater negative shift in the voltage dependence of LA sodium channel 
inactivation (Fig 3.3A), resulting in a decrease in channel availability, leading to 
a decreased LA INa compared to LV INa, when initiated from physiological 
holding potentials (Fig 3.2C). 
 
This negative shift in V50 activation potential of the LA sodium channels 
suggests an enhancement of excitability of LA cardiomyocytes compared to LV 
cardiomyocytes. Negative shifts in the voltage dependence of sodium channel 
activation permits channel activation with smaller depolarisations. This can 
result in premature initiation of the sodium channels with minor depolarisation 
and therefore could instigate DAD generation via Ca2+ oscillations in sodium-
calcium overload conditions. Although it has been shown here that there are a 
smaller proportion of LA sodium channels available for activation at 
physiologically relevant holding potentials, those that are available are more 
sensitive to an untimely depolarisation of membrane potential and may be more 
susceptible to premature activation, offering a foundation to the atria’s greater 
susceptibility to arrhythmia. Consequently, identifying the molecular 
determinants driving enhanced atrial sodium channel activation at 
hyperpolarised potentials may reveal novel drug targets for treatment of AF in 
patients. 
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The R1512W mutation in SCN5A, that was identified as the first cause of 
Chinese SUNDS described above, has also shown to cause a -5.1mV negative 
shift in activation in Xenopus oocytes (216), comparable with the shift observed 
between LA and LV sodium channels (Figure 3.1E). Rook et al., also suggest 
that this shift in activation to more negative potentials could lead to enhanced 
excitability of cardiomyocytes and also be a mechanism for the 
arrhythmogenesis observed in patients that have the R1512W mutation (216). 
 
However, as previously discussed, the greater difference in V50 inactivation of 
the sodium channels at physiological potentials in both the LA and LV, 
overrides the activation differences at physiologically relevant potentials, as 
shown by the fact that the LA peak INa is smaller than the LV INa (Fig 3.2C). 
Altering the activation kinetics of the LA sodium channel in order to inhibit AF 
may not only supress premature activation but would also result in a reduction 
in INa, which in itself may be proarrhythmic due to reductions in CV. Additionally, 
inactivation derives much of its voltage dependence from coupling to activation, 
so the rate of inactivation increases as a result of conformational changes in the 
sodium channel activation domain (219, 220). Therefore, altering the activation 
region/kinetics could also alter inactivation kinetics and lead to undetermined 
and potentially unsafe further modifications in INa. 
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3.4.6.$Sodium$channel$recovery$differences$between$LA$and$LV$
After sodium channels activate and open, inactivation closes the sodium 
channel, preventing it from reopening until there is adequate time for recovery. 
Subsequently channels undergo deactivation, after which re-excitation is 
permitted. The extent of sodium channel inactivation and time dependence of 
recovery from inactivation controls the ERP, where AP initiation cannot occur 
(221). The recovery process occurs on a millisecond timescale, with exponential 
kinetics that are accelerated with hyperpolarisation (222). 
 
Studies on sodium channels with the I1768V mutation on SCN5A, underlying 
LQT-3 syndrome, results in channel reopening during repolarisation due to 
faster recovery by 28.9ms compared to WT counterparts. This causes 
increased INa,late, due to channel reopening, producing severe prolongation of 
the AP plateau, with the resultant arrhythmic triggers described previously 
because of this late current (223, 224). Therefore, the faster recovery of the LV 
sodium channels could be considered to be proarrhythmic. However, the LA 
sodium channel P50 for recovery time is only 6.83ms slower than LV sodium 
channel recovery (Figure 3.4B), a substantially smaller difference than what is 
described between the I1768V mutation on SCN5A and the WT. 
 
Unlike the LQT-3 syndrome mutations that are linked with faster recovery of the 
sodium channels, the p.I848fs SCN5A mutation, associated with Brugada 
syndrome, has been shown to slow recovery time of the sodium channels (224). 
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The slowing in recovery results in a decrease in INa as channels do not recover 
quickly enough to be available for reactivation when another AP is generated, 
leading to decrease in AP amplitude and CV (98). As described previously, a 
reduction in CV is associated with arrhythmia generation, so a slower recovery 
time of the sodium channels may also be considered proarrhythmic. As 
recovery is accelerated with hyperpolarisation (222) and in vivo LV have more 
negative RMP than the LA, differences in recovery could be amplified.  
 
Overall, it is difficult to determine the effect of a slower recovery of sodium 
channels in the atria compared to ventricles, or whether the time difference in 
recovery is substantial enough to make one chamber more susceptible to 
conduction disturbances than the other. Further studies, examining the effects 
of these biophysical characteristics under physiological (increased heart rate) 
and pathophysiological stressors (ischemia, fibrosis) are required to gain a 
greater understanding of the impact of modulation of recovery kinetics on heart 
function and arrhythmia predisposition in the different chambers of the heart. 
 
3.4.7.$Flecainide$sodium$channel$inhibition$in$the$LA$and$LV$
The LA sodium channels are clearly distinctive to the LV sodium channels, with 
more negative V50 inactivation, more negative V50 activation, slower recovery 
and smaller peak INa at physiological holding potentials. It is clear that the 
negative shift in V50 for inactivation is responsible for reduced LA INa at 
physiological potentials, but whether or not the differences in kinetics are 
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responsible for the atria’s susceptibility to arrhythmias requires further 
examination. 
 
The difference in LA and LV sodium channel kinetics can alter the susceptibility 
to sodium channel blocking drugs and therefore drug efficacy in different 
chambers of the heart. If AADs block LA sodium channels more effectively due 
to these kinetic distinctions, there may be potential atrial specific AF drugs that 
work without altering electrophysiology of otherwise normally functioning 
ventricles. Existing studies with several AADs suggest that sodium channels in 
atrial cardiomyocytes/tissue are more sensitive to their blockade than 
ventricular sodium channels; ranolazine in canines (142), amiodarone in 
canines (185), dronedarone in rats (4) and ranolazine in rabbits (5). The greater 
sensitivity of LA sodium channels to these drugs may be as a result of the 
differences in channel gating kinetics. 
 
As previously described, flecainide is a Class IC AAD and its efficacy has been 
confirmed by several clinical trials (152, 153). Flecainide has a high affinity for 
open-state sodium channels with slow unbinding kinetics from the channels 
during diastole, owing to a slowing of recovery during diastole and prolongation 
of refractoriness (225). Flecainide also inhibits the opening of potassium 
channels, prolonging APD in the ventricles and atria (163). However, it has 
been demonstrated that flecainide use was associated with increased 
proarrhythmic events in patients with severe cardiac disease, as described 
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previously (158). Nevertheless, flecainide is still recommended as one of the 
first line therapies for pharmacological conversion and maintenance of NSR in 
patients with AF (226). 
 
Open and inactivated channels are more susceptible to block from Class I 
AADs than resting deactivated closed state channels (7). As shown in Figure 
3.3, a larger proportion of LA sodium channels, compared to LV sodium 
channels, are inactivated at physiological membrane potentials and they 
activate (open) at more negative potentials (Figure 3.1), with slower recovery to 
the deactivated closed state (Figure 3.4). This suggests that Class I drugs can 
target the LA sodium channels more than the LV sodium channels at 
physiological membrane potentials, as a greater proportion of the LA sodium 
channels will be in the open and inactivated states (227). Figure 3.5A clearly 
shows that flecainide inhibits both LA and LV INa, as currents are visibly smaller 
with the addition of 1µmol flecainide and the peak of both I/V curves are 
significantly reduced (Figure 3.5D and 3.5E). However, the percentage 
inhibition of peak INa is considerably greater in the LA than the LV, by 18.87% 
(Figure 3.5F). This is likely due to the LA channels being more available for 
inhibition because of the differences in channel gating kinetics (227). Therefore, 
this provides evidence that flecainide is more selective to atrial sodium 
channels. 
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Furthermore, as demonstrated in Figure 3.6 and previously described by others 
(228), there is a positive correlation between percentage inhibition of INa and 
holding potential in both LA and LV cardiomyocytes. As holding potential 
depolarises, the inhibition of sodium channels with 1µmol flecainide increases. 
However, percentage inhibition with flecainide is significantly greater in LA 
sodium channels than in LV sodium channels at all of the holding potentials 
recorded. This is particularly important, as the RMP of the atria is more positive 
than that of the ventricles in vivo, so the two mechanisms contributing to its 
greater effectiveness are: 1. greater inhibition due to the difference in RMP, and 
2. greater inhibition of LA INa regardless of holding potential. Therefore, in order 
to get a true representation of flecainide inhibition between the chambers, the 
percentage inhibition can be compared from the data at each of the chambers 
respective to approximate RMP in vivo. Using Figure 3.6A, at -75mV LA INa 
inhibition is 70.71% and at -85mV LV INa inhibition is 41.78%, suggesting that 
flecainide would be approximately 28.93% more effective at inhibiting atrial 
sodium channels at physiological holding potentials in vivo. 
 
There is also a significant negative shift in the inactivation potential of the 
sodium channels in both the LA and LV post flecainide addition (Figure 3.7). 
The LA shift in the inactivation potential of the sodium channels is -1.141mV 
greater than the shift observed in the LV (Figure 3.7E), but this is not significant, 
possibly due to the spread of data and small data set. However, the trend of 
greater shift in LA sodium channel inactivation is probably partly accountable for 
the greater inhibition of LA sodium channels with flecainide. More sodium 
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channels would therefore be inhibited at the physiological RMP of the atria so 
would not be available for activation and INa density would be reduced. 
 
LV sodium channel recovery was not affected by the addition of flecainide but 
LA sodium channel recovery time was increased when flecainide was added to 
the cells (Figure 3.7B). The increase in recovery time would reduce INa,late, 
safeguarding from prolongation of the AP plateau and the resultant arrhythmic 
triggers described previously because of this late current (223, 224). 
Additionally, with increase in channel recovery time the LA ERP would increase 
(221) and this could be protective against re-entrant AF (118). 
 
Similarly, in canines and rabbits ranolazine has proven to have greater 
inhibition of LA sodium channels than LV sodium channels. This is likely due to 
it being an inactivated-state sodium channel blocker, as a greater proportion of 
atrial sodium channels are in the inactivated state (5, 142). It is also claimed 
that ranolazine has no known proarrhythmic effects, unlike flecainide, so may 
be more suitable for patients with pre-existing heart conditions (229). Likewise, 
with similar ion channel block profile and kinetics to ranolazine, amiodarone has 
also proven to have greater affinity for the LA sodium channels. In canine tissue 
amiodarone has been shown to reduce Vmax of the atria significantly, but like 
flecainide does still have some effect on the LV, also reducing LV Vmax but to a 
lesser extent (185). Dronedarone inhibition of rat cardiomyocyte sodium 
channels has also proven to be greater in the LA than LV. Dronedarone 
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negatively shifts LA and LV sodium channel inactivation, with a greater shift in 
the LA and slows recovery in both chambers but with a greater effect in the LV 
(4). Dronedarone appears to act very similarly to flecainide but  predominantly 
blocks potassium channels to prolong repolarisation, not target sodium 
channels primarily. Additionally, dronedarone potency decreases as the heart 
rate increases, so is unlikely to be as useful in fast-firing, fibrillating atria, unlike 
flecainide (230). 
 
Therapeutic effectiveness of flecainide is mediated by reduction in INa, 
decreasing the rate and magnitude of depolarisation and subsequent decrease 
in CV, thereby depressing abnormal conduction in AF patients. From the data 
provided here it is evident that flecainide is more effective in the LA than LV. 
Greater percentage inhibition and also the effects on inactivation and recovery 
time that would reduce CV demonstrate this. Additionally, flecainide is a use-
dependent drug, meaning its inhibition increases as rate of contraction 
increases (231). Therefore in AF patients, flecainide is likely to have a greater 
effect on atrial sodium channels as atrial tissue would be firing at a faster rate 
than ventricular tissue.  
 
Overall, comparisons of atrial selectiveness of flecainide to the other AADs is 
difficult, as the other studies do not provide direct percentage inhibition data of 
the sodium channels at physiological holding potential ranges. Furthermore, the 
effects on the other ion channels, aside of the sodium channels, needs to be 
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considered when assessing the effectiveness for AF treatment. Also, none of 
the AADs previously tested by others have proven to specifically target only LA 
sodium channels, so electrophysiological effects on normally functioning 
ventricles may still occur. 
 
3.4.8.$Varying$Nav1.5$expression$in$WT$mouse$LA$and$LV$
As demonstrated in Figure 3.2A, at physiological holding potentials LA INa 
density is less than LV INa density. However, LA INa density is greater than that 
of the LV at the -120mV holding potential, when all sodium channels are 
available for activation. This is in agreement with previously published studies 
using hyperpolarised holding potentials to measure INa density (4, 5, 142, 185, 
186). Therefore, data presented here and by others (4, 5, 142, 185, 186) 
suggests that the LA have a greater density of sodium channels, even though 
many are dormant under physiological conditions. Nav1.5 protein expression 
data shown in Fig 4.1C analysing the band at the expected/standard molecular 
weight, shows greater expression in LA compared to LV. This explains greater 
INa in LA cardiomyocytes at the -120mV holding potential (Figure 3.2A). Nav1.5 
protein expression was also greater in rat LA compared to LV myocardium but 
this was not significant, as demonstrated by Chen et al., with n=4 (4). 
Nevertheless, considering that a greater proportion of the LA sodium channels 
are inactive at physiological RMPs, if Nav1.5 expression was greater in the LA it 
would not be evident when measuring currents in vivo. 
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Antibody specificity and selectivity are unclear and indeed several bands at 
varying molecular weights were observed. When the additional bands where 
analysed individually (Table 2.1), aside of the primary 250kDa band expected 
and analysed by others (4, 189), there was opposing results to those shown in 
Figure 4.1C, as shown in Figure 4.1D and Figure 4.1E. Analysis using a 
combination of the data from the other bands shows that expression of Nav1.5 
is greater in LV compared to LA, contradicting Figure 4.1C. This also opposes 
the findings of Chen et al. in rat atrial and ventricular cardiomyocytes that 
showed no difference in SCN5A gene expression. The mRNA data in Figure 4.4 
corresponds with the findings of Chen et al., in that no difference is observed in 
SCN5A expression between the healthy human LA and LV, though these are 
based on a limited number of samples (n=4). Clearly, more analysis in larger 
tissue sample sets is needed to be able to detect differences in SCN5A 
expression between chambers in the human heart, as illustrated by the large 
variability even in the controlled mouse setting here (Figure 4.1). 
 
Although the data of Chen et al., showed a trend for greater Nav1.5 protein 
expression in the mouse LA, there was no significant difference. However, that 
study used a 260kDa band for the protein expression analysis and provided no 
description on whether bands of any other molecular weight were visible on the 
Western blots (4). Also, Chen et al., provided no Nav1.5 expression data 
between the human LA and LV, which is unexpected, considering they 
measured the expression of all the Navβ-subunit proteins (4). This may be due 
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to poor reactivity of the antibody with human samples, as observed in this 
study. 
 
Therefore, no conclusive report can be provided on whether Nav1.5 expression 
is greater in the LA or LV as the data is varied depending on how it is analysed 
and there is contradiction with previously published data (4). Moreover, no other 
antibodies tried in this study were successful or demonstrated improved signals. 
Another limitation of the work presented here is that the Western blotting 
measured Nav1.5 protein expression within the whole tissue, and did not 
discriminate between sodium channels in cardiomyocytes alone, nor does it 
discriminate between the functional channels at the membrane surface and 
those in the secretome (188). 
 
3.4.9.$Navβ2$and$Navβ4$expression$is$lower$in$WT$mouse$LA$than$LV$
A reduction of Navβ2 and Navβ4 expression in mouse LA compared to LV 
myocardium is clearly demonstrated (Figure 4.2). This is comparable to protein 
expression findings reported in rat myocardial tissue and in healthy human 
tissue (4). Figure 4.4 also corresponds with this, as significantly less SCN4B 
(the gene that encodes Navβ4) is expressed in the healthy human LA compared 
to the LV. In Figure 4.4 there is also a trend for less SCN2B (the gene that 
encodes Navβ2) expression in the LA, although this is not significant likely due 
to the variability in data and small data set. 
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The lower expression of Navβ2 and Navβ4 subunits in atrial cardiomyocytes 
may be responsible for the negative shift in activation, negative shift in 
inactivation and slower recovery of the LA sodium channels. This is supported 
by voltage clamp experiments that measured INa in HEK 293 cells co-
expressing Nav1.5 with and without Navβ2 and Navβ4 subunits together. Chen 
et al., showed that kinetic properties of sodium channels co-expressing Nav1.5 
with Navβ2 and Navβ4 subunits were similar to those of the ventricular sodium 
channels, with more positive activation potential, more positive inactivation and 
faster recovery of the sodium channels.  Equally, kinetic properties of sodium 
channels expressing Nav1.5 alone were similar to those of the atrial sodium 
channels (4). However, it is difficult to determine whether it is the co-expression 
of Navβ2 or Navβ4 individually, or a combination of the two that causes the 
change in kinetic properties of the sodium channel, as experiments were only 
done on HEK 293 cells co-expressing both subunits together. 
 
These findings are supported by further published data that established the 
voltage dependence of activation and inactivation was positively shifted in HEK 
293 cells with the co-expression of Nav1.2 (232) and Nav1.8 (233) with Navβ2. 
Neuronal sodium currents measured in β2−/− mice also had a negative shift in 
inactivation and resultant decrease in INa density compared to their WT 
counterparts (234). 
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However, it has also been reported that Navβ2 co-expression with Nav1.3 in 
Chinese hamster ovary cells (235) and most relevant to this study Nav1.5 in 
HEK 293 cells (64), had no effect on the channel gating kinetics. Similarly 
opposing the above stated finding, Navβ4 co-expression has been shown to 
cause negative shifts in activation and negative shift in inactivation, or no effect 
on inactivation with Nav1.1, Nav1.2 and Nav1.4 in HEK 293 cells and had no 
effect on the channel gating kinetics when co-expressed with Nav1.5 (64, 236). 
Also, INa that was measured in mutant mice with genetically lower levels of 
Navβ4 showed a positively shifted activation compared to INa measured in mice 
with higher Navβ4 expression (237). 
 
Although it would be expected that the INa in cells with Navβ2 loss of function 
mutation would be more comparable to LA cells, as they have lower Navβ2 
expression, this was not the demonstrated in Chinese hamster ovary cells co-
expressing Nav1.5 with Navβ2 loss of function mutation. Current activation and 
inactivation was positively shifted compared to Nav1.5 co-expressed with WT 
Navβ2 (238). This opposes the suggestion that it is the lower Navβ2 expression 
in the LA that negatively shifts sodium channel activation and inactivation. 
 
The same group found that Navβ2 loss of function mutations reduced INa density 
when currents were initiated at hyperpolarised potentials (238). At first this 
seems confusing, as you would expect a positive shift in inactivation to cause 
increase INa. However, under the experimental conditions used it is 
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understandable, as the difference in inactivation compared to cells expressing 
WT Navβ2 is negligible at the hyperpolarised potentials that were used to 
measure peak INa. Conversely, the positive shift in activation in the cells co-
expressing the mutated Navβ2 means that more of the sodium channels would 
not have activated and opened, compared to those co-expressing the WT 
Navβ2. 
 
Nevertheless, the Navβ2 loss of function mutation was identified in patients with 
AF and associated with a distinctive ECG phenotype. This supports the notion 
that the lower expression of Navβ2 within the atria and the resulting effects on 
the sodium channel gating kinetics may be accountable for the atria’s 
susceptibility to arrhythmia (238). Watanabe et al., suggested that the AF 
susceptibility of those patients was due to the reduced INa resulting in slowed 
conduction and as previously described, this is a substrate for re-entrant 
arrhythmias (239).  
 
Overall, there is a lot of inconsistency in the published data on the effect of 
Navβ2 and Navβ4 expression, with opposing information on whether the 
subunits affect sodium channel gating kinetics and how. Also, it has been well 
documented that the co-expression of the other Nav β-subunits alongside Navβ2 
and Navβ4 can cause further changes in channel gating kinetics (236, 238, 240, 
241). Therefore, the effects of Navβ1 and Navβ3 expression on sodium channel 
function, and how all of the β-subunits interact with each other should be 
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considered. Nonetheless, Figure 4.2 clearly demonstrates lower expression of 
Navβ2 and Navβ4 and with the findings described by Chen et al., it is 
conceivable that the distinction in β-subunit expression is responsible for 
differences in the LA and LV sodium channel gating kinetics. 
 
3.4.10.$Navβ2$expression$is$greater$in$human$diseased$LA$than$in$healthy$
LA$
Chen et al., compared the expression of the Navβ2 and Navβ4 subunits 
between human LA and LV tissue. The human tissue they used was from donor 
hearts that had failed to be used in transplantation surgery (234) so it can be 
assumed that the tissue was from healthy hearts.  They found that the protein 
expression of both Navβ2 and Navβ4 was significantly less in the LA than in the 
LV, corresponding with their findings in rat tissue, findings in Figure 4.2 in 
mouse tissue and findings in Figure 4.4 healthy human tissue. Also, Figure 4.3B 
indicates that Navβ4 expression is much lower in the LA, comparable with the 
findings in rat tissue, healthy human tissue (4), mouse tissue in Figure 4.2 and 
findings in Figure 4.4 healthy human tissue. However, the difference in Navβ4 
expression between the chambers is not significant, likely because of the small 
data set as human tissue is limited and there was some variability. 
 
Conversely, Figure 4.3A reveals that the expression of Navβ2 is greater in the 
LA than the LV in the diseased human heart. This indicates that people most 
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susceptible to disease may already have different ratios of Navβ2 compared to 
what was seen in the healthy human tissue by Chen et al., where the LA had 
lower Navβ2. Conversely, it could be considered that disease progression 
affects the expression of the Navβ2, increasing it in the LA and/or reducing it in 
the LV. However, as the expression of Navβ2 is greater in the diseased LA 
compared to the healthy LA in Figure 4.4, it indicates that it is expression within 
the LA that is altered in diseased tissue, not expression in the LV. Although 
experiments measuring the expression of Navβ2 in diseased LV compared to 
healthy LV would be required, in order to determine whether changes in 
expression occur only in the LA or both chambers with disease. Therefore, the 
lack of LV healthy vs. disease data is a limitation within this study. 
 
According to the sodium channel gating data here and published by Chen et al., 
an increase in Navβ2 in the diseased atria could result in the diseased atrial INa 
presenting more like the ventricular INa. Therefore, in disease the atrial sodium 
channels may activate at more positive potentials. This could result in a 
reduction in the excitability of diseased LA cardiomyocytes and could be 
cardioprotective against premature initiation of sodium channels with minor 
depolarisation, inhibiting arrhythmia generation. Interestingly, of all the diseased 
samples, one pair of LA and LV tissue samples came from a patient that 
presented with AF. The samples from this patient showed almost identical 
expression of Navβ2 between the chambers and were the only pair that did not 
show greater expression of Navβ2 in the LA compared to its LV counterpart. 
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Therefore, this patient may have been more susceptible to AF because there 
was no/less upregulation of Navβ2 in the LA. 
 
However, a positive shift in activation could also lead to reduced INa as the 
threshold potential for activation is increased. This could lead to a reduction in 
CV, which as previously described can be proarrhythmic and may increase the 
atria’s susceptibility to arrhythmia in diseased hearts (1). Therefore, in diseased 
patients, sodium channel blocking drugs, such as flecainide, could exasperate 
arrhythmia generation, as conduction could be slowed too much. However, 
there may also be a positive shift in inactivation counteracting the effects of a 
positive shift in activation if the diseased LA present with a more LV phenotype. 
This could result in an increased INa density in vivo, increasing CV and reducing 
the likelihood of arrhythmia generation (1). Therefore, sodium channel blocking 
drugs, such as flecainide, that reduce CV may be safe to use, although this is 
not supported by previous findings on the efficacy of flecainide in patients with 
cardiac disease (147). 
 
Nevertheless, diseased atria may also display greater INa,late compared to 
healthy atria, as the sodium channels in the atria could be more likely to 
inactivate and then activate prematurely if increased Navβ2 expression does 
alter gating kinetics. This has been shown in the ventricles of a dog heart failure 
(HF) model, were increased INa,late was observed when compared with dogs 
without HF (242). Likewise, the ventricles of rat hearts post myocardial 
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infarction present with increased LV INa,late (243). However, studies measuring 
atrial INa,late in disease models are limited, most likely due to the difficulty of 
measuring such a small current. 
 
As described previously, an enhanced INa,late can instigate repolarisation failure 
and result in EAD’s causing a regenerative L-type Ca2+ channel re-activation or 
providing sufficient time for sodium channels to recover and reactivate (127). 
Additionally, DAD’s can follow full repolarisation via Ca2+ overload in sodium-
calcium overload conditions (202). Furthermore, in diseased atria if greater 
Navβ2 expression causes the LA to follow the LV phenotype, sodium channel 
recovery would be quicker, potentially amplifying INa,late. This could cause 
severe prolongation of the AP plateau, with the resultant arrhythmic triggers 
described previously (223, 224). Therefore, inhibition of INa,late that has been 
established as an effective arrhythmia treatment in the ventricles (77, 244, 245) 
may be more effective at treating AF in patients with severe cardiac disease 
than it is in patients without cardiac disease. This has been confirmed by the 
more potent suppression of AF by ranolazine, a drug that inhibits INa,late, in dogs 
with HF than in non-failing dog hearts (206).  
 
However, due to inconsistency in the published data, it has not been 
conclusively confirmed that increased Navβ2 expression does cause the 
described changes in sodium channel gating kinetics or whether the co-
expression of other Nav β-subunits in vivo can cause further changes (236, 238, 
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240, 241). Therefore, additional research is required to compare INa when 
Nav1.5 is expressed with/without all of the Nav β-subunits individually and in 
different combinations together under physiological conditions. Further research 
would be essential in order to better clarify effects on gating kinetics in the 
diseased LA and how electrophysiology is altered. 
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4.$Plakoglobin$deficiency$and$sodium$handling$ in$the$atria$and$
ventricles$
4.1.$Chapter$introduction$and$overview$
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is one of the most 
common inherited cardiomyopathies, characterised by fibrofatty replacement of 
cardiomyocytes. Prevalence of ARVC is approximately 1:2000-5000, with a 
greater proportion of men affected than women (246, 247). The primary clinical 
observations associated with ARVC are sudden death, ventricular arrhythmias, 
and heart failure (248, 249). The RV is predominantly affected (as specified in 
the name) and during the later stages of ARVC the RV dilates, reducing cardiac 
contractility and ejection fraction (250). Additionally, LV involvement may also 
occur with disease progression and can be the chamber of dominant disease 
presentation (251, 252). 
 
Pharmacological options for ARVC treatment include antiarrhythmic agents, β-
blockers and heart failure drug therapy (253). AAD treatment in ARCV patients 
aims to improve quality of life by inhibiting symptomatic ventricular arrhythmias. 
However, the efficacy of AAD therapy in ARVC patients has proven problematic 
to assess, as patients usually have multiple arrhythmic events over time and 
drugs are frequently changed (254). Therefore, due to a lack of ARVC case 
control studies, retrospective analyses and clinical registries, choice of a 
suitable AAD treatment is based on the experimental approach of clinicians, 
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resulting from personal experience, consensus, individual opinion and 
extrapolation from other diseases (253). 
 
In 30-50% of cases ARVC is familial, classically inherited in an autosomal 
dominant fashion but recessive forms are also known. Loss-of-function 
mutations in desmosomal proteins (desmoplakin, plakophilin or plakoglobin) 
were shown to cause changes in morphological structure and be a primary 
cause of ARVC (175-177). Furthermore, reduced plakoglobin concentrations 
have been observed in many patients with ARVC, whether the primary mutation 
was in the plakoglobin gene or in another gene (255). Therefore, ARVC is 
considered a disease of the desmosome (181). Desmosomes are intracellular 
junctions that attach intermediate filaments to cell surfaces and provide cell-to-
cell adhesion at the intercalated disks, as described previously (12). Mechanical 
stress weakens cell-to-cell adhesion and it has been established that 
environmental factors, such as endurance training, can exacerbate the ARVC 
phenotype in those with these desmosomal mutations. This explains ARVCs 
infamous association with the sudden death of young athletes (246). 
 
It has been confirmed that plakoglobin deficiency in mice provokes the ARVC 
phenotype and endurance training aggravates RV arrhythmias (181). 
Plakoglobin, also known as γ-catenin, is a ≈82kDa protein encoded by the JUP 
gene in humans. It is a key constituent of the desmosomes and responsible for 
adhesion between cardiomyocytes. Therefore, dysfunction of plakoglobin 
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diminishes mechanical adhesion of cardiomyocytes. This can result in RV 
dysfunction, as a result of the increased sensitivity to mechanical instability of 
the thinner RV wall (256, 257). 
 
It has been challenging for scientists to identify a direct link between 
desmosomal proteins and cardiac electrophysiology. Studies have described a 
molecular crosstalk between desmosomes and both VGSCs and gap junction 
proteins at the intercalated discs. Knockdown of the gene that encodes 
plakophilin 2 in mice has proven to decrease INa density, negatively shift 
inactivation and prolong channel recovery in rat ventricular cardiomyocytes, 
with a significant decrease in conduction velocity and propensity for arrhythmia 
generation (178). Furthermore, heart samples from ARVC patients with reduced 
plakoglobin expression, revealed reduction in ventricular Nav1.5 expression at 
the intercalated disks (179, 180). This could help develop an understanding of 
the mechanism underlying ARVC arrhythmogenesis in those with plakoglobin 
deficiency, if reduced Nav1.5 expression results in reduced INa, as with the 
reduced plakophilin 2 expression described above.  Alterations in Nav1.5 
function therefore may be partly accountable for the increased arrhythmia 
vulnerability in ARVC patients due to slowed conduction (180). However, 
whether desmosomal proteins and VGSCs interact directly, or via other 
molecular partners is yet to be established (180). Nevertheless, if INa is reduced 
in patients with desmosomal mutations it may provide a target for ARVC 
therapy. Conversely, AADs that further reduce INa may be proarrhythmic in 
ARVC patients due to additional conduction slowing. 
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Endurance training has been associated with increased AF risk (258). Further to 
the increase in ventricular arrhythmias, endurance training has also been 
associated with increased atrial arrhythmia generation with plakoglobin 
deficiency in mice in unpublished studies (259, 260). Therefore, functional 
experiments comparing Nav1.5 biophysical properties between control and 
plakoglobin deficient hearts would provide further insight into the 
electrophysiological effects of desmosomal dysfunction. Additionally, patients 
with plakoglobin deficiency experiencing atrial arrhythmia would require 
treatment that also targets AF. Comparison of the effect of a VGSC blocking 
AAD, such as flecainide, in plakoglobin deficient hearts compared to WT hearts 
may offer insight into whether INa block is suitable for AF treatment and whether 
flecainide could also be used to treat ventricular arrhythmias in ARVC patients. 
As described above, INa may be reduced as a result of plakoglobin deficiency 
and this must be established in order to uncover whether flecainide treatment 
may in fact be proarrhythmic. 
 
The aims of this investigation are summarised below: 
1. To assess sodium channel biophysical properties in isolated plakoglobin 
deficient mouse LA and LV cardiomyocytes 
2. To examine the effects of flecainide on the sodium channels in isolated 
plakoglobin deficient mouse LA and LV cardiomyocytes. 
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4.2.$Electrophysiology$results$
4.2.1.$ LA$sodium$channels$activate$at$more$negative$holding$potentials$
than$LV$sodium$channels$in$the$Plako+/R$mouse$
Experiments were performed on isolated Plako+/- and WT mouse LA and LV 
cardiomyocytes to compare the sodium channel I/V relationships, using the 
relevant I/V patch clamp protocol described in the materials and methods 
(Table 1.5). This protocol enabled assessment of the voltage/current 
relationship and voltage dependency of sodium channel activation. 
 
Figure 5.1A shows raw representative traces of the INa from Plako+/- LA and LV 
cardiomyocytes, with greater peak INa in LV cardiomyocytes before normalising 
to cell capacitance. This is comparable to the WT counterpart raw currents in 
Figure 3.1A. The current-voltage relationship of the Plako+/- LA and LV sodium 
channels (Figure 5.1B) shows that from a holding potential of -100mV, Plako+/- 
LA (n=24/7 cells/mice) and Plako+/- LV (n=41/10 cells/mice), sodium channels 
have a peak current potential at the -30mV step, comparable with WT. 
 
Additionally, as in the WT, INa amplitude was comparable between Plako+/- LA 
and LV (Figure 5.1E). No difference was observed in INa amplitude between the 
WT LV (n=28/13 cells/mice) and Plako+/- LV (n=41/10 cells/mice). Similarly, INa 
amplitude is comparable between the Plako+/- LA (n=24/7 cells/mice) and WT 
LA (n=42/13 cells/mice) (Figure 5.1E).  
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The I/V curve data was fitted to a Boltzmann function to obtain the voltage 
dependence of the conductance activation of sodium channels using the initial 
downward slope of the curve (as described in the material and methods). This 
allows comparison of the voltage potential at which half of the sodium channels 
were activated (V50) in WT and Plako+/- LA and LV (Figure 5.1F). As exhibited 
in Figure 3.1E in Chapter 3 of this thesis, WT LA sodium channels activated at 
significantly more negative potentials than WT LV sodium channels. However, 
there is no difference between Plako+/- LA and LV V50 activation (Figure 5.1F).  
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Figure 5.1. WT and Plako+/- LA and LV INa I/V relationship and sodium 
channel activation. 
INa I/V curve and channel activation in LA and LV cardiomyocytes from WT and 
Plako+/- mouse hearts. A) Plako+/- LA and LV representative raw INa traces in LA 
with patch clamp protocol on the right. B) Current-voltage relationship of INa 
density in Plako+/- LA (n=24/7 cells/mice) and Plako+/- LV (n=41/10 cells/mice). 
C) Current-voltage relationship of INa density in WT LA (n=42/13 cells/mice) and 
Plako+/- LA (n=24/7 cells/mice). D) Current-voltage relationship of INa density in 
WT LV (n=28/13 cells/mice) and Plako+/- LV (n=41/10 cells/mice). E) INa peak 
density at a step from -100mV to -30mV in WT LA (-26.84 ± 1.651pA/pF; 
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n=42/13 cells/mice), WT LV (-26.84 ± 1.037pA/pF; n=28/13 cells/mice), Plako+/- 
LA (-32.4 ± 1.858pA/pF; n=24/7 cells/mice) and Plako+/- LV (-31.82 ± 
1.511pA/pF; n=41/10 cells/mice). F) V50 of activation fitted to the Boltzmann 
distribution in WT LA (-42.71 ± 0.8017mV; n=42/13 cells/mice), WT LV (-38.63 
± 0.9488mV; n=28/13 cells/mice), Plako+/- LA (43.29 ± 0.8069mV; n=24/7 
cells/mice) and Plako+/- LV (-40.85 ± 0.7612mV; n=41/10 cells/mice). Error bars 
indicate ± S.E.M. significance taken as *P<0.05 with two-way ANOVA followed 
by post-hoc multiple comparisons (Tukey’s) test. 
 
4.2.2.$ No$ difference$ in$ peak$ INa$ between$ LA$ and$ LV$ at$ physiologically$
relevant$holding$potentials$in$the$Plako+/R$mouse$
Experiments were performed on isolated Plako+/- mouse LA and LV 
cardiomyocytes to measure the peak INa at varying holding potentials using the 
steady state inactivation patch clamp protocol described in the material and 
methods chapter (Table 1.5). The protocol enables the evaluation of the 
relationship between the holding potential (pre-pulse potential) of the cell and 
the current amplitude upon stimulation, and in turn how many sodium channels 
are available for activation at the different holding potentials. Data was analysed 
from the -120 to -75mV holding potential range of the pre-pulse, as current 
amplitudes were negligible at the more positive holding potentials, so could not 
be measured/compared. 
 
Although the INa amplitude against holding potential relationship appears to 
differ between the Plako+/- LA (n=24/7 cells/mice) and LV (n=38/10 cells/mice) 
(Figure 5.2A), similar to the WT counterparts (Figure 3.2A), differences between 
the Plako+/- chambers are smaller and not significant. Although there is a trend 
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of greater INa in the Plako+/- LA at the -120mV holding potential, the spread of 
data is pronounced and there is no significance (Figure 5.2B). Similarly, there is 
no difference in INa in the Plako+/- LA and LV at the -75mV holding potential 
(Figure 5.2C). 
Figure 5.2. INa density in Plako+/- LA and LV at varying holding potentials. 
INa in LA and LV cardiomyocytes from Plako+/- mouse hearts at varying holding 
potentials. A) INa mean density/holding potential relationship from with protocol 
shown inset, Plako+/- LA (n=24/7 cells/mice) and Plako+/- LV (n=38/10 
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cells/mice), denote holding potentials of interest. B) INa density at -120mV 
holding potential in WT LA (-35.72 ± 1.718pA/pF; n=40/13 cells/mice), WT LV (-
30.89 ± 1.322pA/pF; n=28/13 cells/mice), Plako+/- LA (37.37 ± 2.098pA/pF; 
n=24/7 cells/mice) and in Plako+/- LV (-33.16 ± 1.761pA/pF; n=38/10 cells/mice) 
C) INa density at -75mV holding potential in WT LA (-6.569 ± 0.8474pA/pF; 
n=40/13 cells/mice), WT LV (-9.735 ± 1.075pA/pF; n=28/13 cells/mice), Plako+/- 
LA (-7.728 ± 1.028pA/pF; n=24/7 cells/mice) and Plako+/- LV (-9,56 ± 
0.9292pA/pF; n=38/10 cells/mice). Error bars indicate ± S.E.M. significance 
taken as *P<0.05 with two-way ANOVA followed by post-hoc multiple 
comparisons (Tukey’s) test. 
 
 
4.2.3.$LA$sodium$channels$inactivate$at$more$negative$holding$potentials$
than$LV$sodium$channels$in$the$Plako+/R$mouse$
Experiments were performed on isolated WT and Plako+/- mouse LA and LV 
cardiomyocytes to compare the potential at which the sodium channels 
inactivate (are no longer available), using the relevant steady-state inactivation 
patch clamp protocol described in the materials and methods chapter (Table 
1.5). The voltage dependence of steady-state inactivation (channel availability, 
I/Imax) was determined from this protocol, as shown in Figure 5.3 A-C and fitted 
to the Boltzmann function. 
 
The Plako+/- LA (n=24/7 cells/mice) sodium channel inactivation potential is 
negatively shifted compared to the Plako+/- LV (n=43/10 cells/mice) sodium 
channel inactivation potential (Figure 5.3A), confirmed by the V50 for 
inactivation (Figure 5.3D). There is no difference in sodium channel inactivation 
between Plako+/- LA or LV and the respective WT counterparts (Figure 5.3B-C). 
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This is confirmed in Figure 5.3D V50 for inactivation (WT LA n=41/13 
cells/mice; WT LV n=27/13 cells/mice). 
Figure 5.3. Plako+/- LA and LV sodium channel inactivation. 
Channel steady-state inactivation LA and LV cardiomyocytes from WT and 
Plako+/- mouse hearts. A) Curve of normalised INa inactivation (I/Imax) fitted to 
the Boltzmann function in Plako+/- LA (n=24/7 cells/mice) and Plako+/- LV (43/10 
cells/mice). B) Curve of normalised INa inactivation (I/Imax) fitted to the 
Boltzmann function in WT LA (n=41/13 cells/mice) and Plako+/- LA (24/7 
cells/mice). C) Curve of normalised INa inactivation (I/Imax) fitted to the 
Boltzmann function in WT LV (27/13 cells/mice) and Plako+/- LV (43/10 
cells/mice). D) V50 of inactivation fitted to the Boltzmann distribution in WT LA 
(-88.48 ± 1.08mV; n=41/13 cells/mice), WT LV (-81.95 ± 0.923mV; n=27/13 
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cells/mice), Plako+/- LA (-86.29 ± 1.144mV; n=24/7 cells/mice) and Plako+/- LV (-
81.0 ± 0.7932mV; n=43/10cells/mice). Error bars indicate ± S.E.M. significance 
taken as *P<0.05 with two-way ANOVA followed by post-hoc multiple 
comparisons (Tukey’s) test. 
 
4.2.4.$ No$ difference$ in$ time$ dependent$ recovery$ between$ LA$ and$ LV$
sodium$channels$in$the$Plako+/R$mouse$
Experiments were performed on isolated WT and Plako+/- mouse LA and LV 
cardiomyocytes to study the time dependent kinetics of recovery after 
inactivation, using the relevant channel recovery protocol described in the 
materials and methods (Table 1.5). Normalised peak current amplitudes were 
plotted and fitted to a one-phase association exponential function and the time 
when half of the channels were recovered and available for re-activation (P50) 
was determined in the WT and Plako+/- LA and LV cardiomyocytes. 
 
Unlike with WT LA and LV, the Plako+/- LA and LV sodium channel recovery 
curves overlap (Figure 5.4A) (Plako+/- LA=23/7 and Plako+/- LV=44/10 
cells/mice) (Figure 5.4A). This is confirmed clearly by the P50 for recovery 
(Figure 5.4 D). This is due to the Plako+/- LA sodium channel recovery being 
faster than WT LA sodium channel recovery (WT LA=38/13 and Plako+/- 
LA=23/7 cells/mice) (Figure 5.4B), demonstrated by the P50 for recovery 
(Figure 5.4D), but not significant. However, there is no difference in recovery 
kinetics between WT LV and Plako+/- LV as sodium channel recovery curves 
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overlap (WT LV=28/13 and Plako+/- LV=44/10 cells/mice) (Figure 5.4C), 
demonstrated by the P50 for recovery (Figure 5.4D). 
 
Figure 5.4. WT and Plako+/- LA and LV time dependent sodium channel 
recovery. 
Channel recovery in LA and LV cardiomyocytes from WT and Plako+/- mouse 
hearts. A) Curve of normalised sodium channel recovery (I/Imax) fitted to one-
phase association with protocol shown in inset Plako+/- LA (n=23/7 cells/mice) 
and Plako+/- LV (44/10 cells/mice). B) Curve of normalised sodium channel 
recovery (I/Imax) fitted to one-phase association with protocol shown in inset 
WT LA (n=38/13 cells/mice) and Plako+/- LA (23/7 cells/mice). C) Curve of 
normalised sodium channel recovery (I/Imax) fitted to one-phase association 
with protocol shown in inset WT LV (n=28/13 cells/mice) and Plako+/- LV (44/10 
cells/mice). D) P50 of recovery in WT LA (22.62 ± 1.703ms; n=38/13 
cells/mice), WT LV (15.49 ± 1.456ms; n=28/13 cells/mice), Plako+/- LA (19.25 ± 
1.512ms; n=23/7 cells/mice) and Plako+/- LV (16.6 ± 1.303ms; n=44/10 
cells/mice). Error bars indicate ± S.E.M. significance taken as *P<0.05 with two-
way ANOVA followed by post-hoc multiple comparisons (Tukey’s) test. 
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4.2.5.$No$difference$ in$ flecainide$ inhibition$between$LA$and$LV$ sodium$
channels$in$the$Plako+/R$mouse$
Experiments were performed on isolated WT and Plako+/- mouse LA and LV 
cardiomyocytes in the absence or presence of 1µmol flecainide, to compare 
peak INa inhibition between the chambers, using the I/V patch clamp protocol 
described in the materials and methods chapter (Table 1.5). This protocol 
enabled assessment of the current relationship of ion channel activation and 
voltage-dependence of inactivation, to characterise the biophysical properties of 
the sodium channels with the addition of flecainide. Sodium channel inhibition 
was measured by calculating the difference between the control currents and 
the currents after flecainide exposure as a percentage. 
 
The raw Plako+/- LA and LV sodium currents +/-1µmol flecainide are shown in 
Figure 5.5A, with the patch clamp protocol shown on the right. The flecainide 
currents are visibly smaller than the control currents recorded in the absence of 
flecainide, confirming the occurrence of current inhibition. The current-voltage 
relationships of the sodium channels in control Plako+/- LA against Plako+/- LA 
+1µmol flecainide are shown in Figure 5.5B and in control Plako+/- LV against 
Plako+/- LV +1µmol flecainide in Figure 5.5C. 
 
The addition of flecainide alters the curve morphology in both Plako+/- LA  
(n=7/3 cells/mice) and LV (n=7/3 cells/mice). The peak of both curves is 
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significantly reduced with the addition of flecainide compared to the control 
curves, shown in Figure 5.5D-E. 
 
As demonstrated in Figure 3.5F in Chapter 3 and here, inhibition of peak INa 
amplitudes is greater in the WT LA than in WT LV (Figure 5.5F). However, 
inhibition of peak INa amplitudes is no different between the Plako+/- LA and LV 
(Figure 5.5F). This is due to sodium channel % inhibition being greater in the 
Plako+/- LV than in the WT LV, although this is not significant (Figure 5.5F). 
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Figure 5.5. Plako+/- LA and LV INa I/V with the addition of flecainide. 
INa I/V curve and channel activation +/- flecainide in LA and LV cardiomyocytes 
from Plako+/- mouse hearts. A) Plako+/- LA and LV representative raw INa traces 
+/- 1µmol flecainide, with patch clamp protocol on the right. B) Current-voltage 
relationship of INa density in Plako+/- LA (n=7/3 cells/mice) C) Current-voltage 
relationship of INa density in Plako+/- LV (n=8/4 cells/mice). D) Plako+/- LA INa 
peak density at a step from -100mV to -30mV (Plako+/- LA control=-28.22 ± 
3.213pA/pF; n=7/3 cells/mice; Plako+/- LA plus flecainide=-14.07 ± 1.622pA/pF; 
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n=7/3 cells/mice) **p<0001. E) Plako+/- LV INa peak density at a step from -
100mV to -30mV (Plako+/- LV control=-33.27 ± 2.190pA/pF; n=8/4 cells/mice; 
Plako+/- LV plus flecainide=-18.72 ± 1.645pA/pF; n=8/4 cells/mice) 
****p<0.0001.F) Peak INa percentage inhibition (WT LA=47.64% ± 4.029; n=11/6 
cells/mice; WT LV=33.77% ± 2.824; n=14/4 cells/mice, Plako+/- LA=48.9% ± 
5.528; n=7/3 cells/mice and Plako+/- LV=43.98% ± 3.306; n=8/4 cells/mice). 
Error bars indicate ± S.E.M. Significance taken as *P<0.05 with paired Student 
t-test for (D and E) and two-way ANOVA followed by post-hoc multiple 
comparisons (Tukey’s) test (F). 
 
The I/V curve data was fitted to a Boltzmann function to obtain the voltage 
dependence of the conductance activation of sodium channels using the initial 
downward slope of the curve. This allows comparison of the voltage potential at 
which half of the sodium channels were activated (V50) between Plako+/- LA 
control and Plako+/- LA +1µmol flecainide (Figure 5.6G) and between Plako+/- 
LV control and Plako+/- LV +1µmol flecainide (Figure 5.6H). The addition of 
flecainide results in sodium channel activation at significantly more negative 
potentials in the Plako+/- LA (n=7/3 cells/mice) (Figure 3.6G), but not in the 
Plako+/- LV (n=8/4 cells/mice) (Figure 5.6H). The negative shift effect is shown 
in Figure 5.6I. 
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Figure 5.6. Plako+/- LA and LV sodium channel activation with the addition 
of flecainide. 
Sodium channel activation +/- flecainide in LA and LV cardiomyocytes from 
Plako+/- mouse hearts. G) Plako+/- LA V50 of activation fitted to the Boltzmann 
distribution (Plako+/- LA control=-42.93 ± 1.858mV; n=7/3 cells/mice; Plako+/- LA 
plus flecainide=-45.43 ± 1.878mV; n=7/3 cells/mice) *p<0.05. H) Plako+/- LV 
V50 of activation fitted to the Boltzmann distribution (Plako+/- LV control=-43.08± 
1.128mV; n=8/4 cells/mice; Plako+/- LV plus flecainide=-42.96 ± 1.062mV; n=8/4 
cells/mice). I) Shift in V50 activation after the addition of flecainide (WT LA =-
3.232 ± 1.302mV; n=11/6 cells/mice; WT LV=-1.352 ± 0.397mV; n=14/4 
cells/mice, Plako+/- LA =-2.5 ± 0.7788mV; n=7/3 cells/mice and Plako+/- LV=0.12 
± 0.4808mV; n=8/4 cells/mice. Error bars indicate ± S.E.M. Significance taken 
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as *P<0.05 with paired Student t-test for (G and H) and two-way ANOVA 
followed by post-hoc multiple comparisons (Tukey’s) test (I). 
 
4.2.6.$ Flecainide$ alters$ LA$ and$ LV$ sodium$ channel$ inactivation$ in$ the$
Plako+/R$mouse$
Experiments were performed on isolated WT mouse LA and LV cardiomyocytes 
to compare the potential at which the sodium channels inactivate (are no longer 
available) in the presence and absence of flecainide, using the relevant steady-
state inactivation patch clamp protocol described in the materials and methods 
(Table 1.5). The voltage dependence of inactivation (channel availability, I/Imax) 
was determined from this protocol, as shown in inset Figure 5.7A and 5.7C and 
fitted to the Boltzmann function. 
 
There is a shift in the inactivation potential of the sodium channels between the 
control and 1µmol flecainide in both the Plako+/- LA (n=6/3 cells/mice) and LV 
(n=10/4 cells/mice). This is confirmed by the significant negative shift in the V50 
inactivation data (Figure 5.7B and 5.7D). 
 
As demonstrated in Figure 3.7E Chapter 3, the shift in the inactivation potential 
of the sodium channels between the control WT LA and 1µmol flecainide LA is 
greater than the shift seen in the WT LV. This is demonstrated by the V50 
voltage shifts but is not significant, likely due to a larger standard deviation of 
the LA dataset (LA n=12/6 cells/mice; LV n=14/4 cells/mice). Similarly, the shift 
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in the inactivation potential of the sodium channels between the control Plako+/- 
LA and 1µmol flecainide Plako+/- LA is greater than the shift seen in the Plako+/- 
LV, demonstrated by the V50 voltage shifts (Figure 5.7E) but this is not 
significant, again likely due to a larger standard deviation of the LA dataset. 
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Figure 5.7. Plako+/- LA and LV INa inactivation with the addition of 
flecainide. 
Channel inactivation +/- flecainide in LA and LV cardiomyocytes from Plako+/- 
mouse hearts. A) Plako+/- LA curve of normalised INa inactivation (I/Imax) fitted 
to the Boltzmann function (n=6/3 cells/mice). B) Plako+/- LA V50 of inactivation 
fitted to the Boltzmann distribution (Plako+/- LA control=-88.76 ± 2.65mV; n=6/3 
cells/mice; Plako+/- LA plus flecainide=-93.17 ± 2.465mV; n=6/3 cells/mice) 
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**p<0.01. C) Plako+/- LV curve of normalised INa inactivation (I/Imax) fitted to the 
Boltzmann function (n=10/4 cells/mice). D) Plako+/- LV V50 of inactivation fitted 
to the Boltzmann distribution (Plako+/- LV control=-83.52 ± 1.588mV; n=10/4 
cells/mice; Plako+/- LV plus flecainide=-86.16 ± 1.631mV; n=10/4 cells/mice) 
**p<0.01. E) V50 inactivation shift with flecainide (WT LA=-2.78 ± 1.139mV; 
n=12/6 cells/mice; WT LV=-1.639 ± 0.2927mV; n=14/4 cells/mice; Plako+/- LA=-
4.405 ± 1.07mV; n=6/3 cells/mice and Plako+/- LV=0.689 ± 1.106mV; n=10/4 
cells/mice). Error bars indicate ± S.E.M. Significance taken as *P<0.05 with 
paired Student t-test for (B and D) and two-way ANOVA followed by post-hoc 
multiple comparisons (Tukey’s) test (E). 
 
4.2.7.$Flecainide$has$no$effect$on$recovery$of$LA$or$LV$sodium$channels$
in$the$Plako+/R$mouse$
Experiments were performed on isolated WT and Plako+/- mouse LA and LV 
cardiomyocytes to study the time dependent kinetics of recovery after 
inactivation in the presence and absence of flecainide, using the relevant 
channel recovery protocol described in the materials and methods (Table 1.5). 
Normalised peak current amplitudes were plotted and fitted to a one-phase 
association exponential function and the time when half of the channels were 
recovered (P50) was determined in the Plako+/- LA and LV cardiomyocytes. 
 
In the Plako+/- LA (n=6/3 cells/mice) there was a clear right shift in the sodium 
channel recovery time in the presence of 1µmol flecainide (Figure 5.8A), 
suggesting that channel recovery was slower after flecainide was added. 
However, the P50 in Figure 5.8B shows that the difference in recovery time is 
not significant, likely due to the large standard deviations of the flecainide data 
set. In the Plako+/- LV (n=10/4 cells/mice) there was also a slight right shift in the 
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sodium channel recovery time in the presence of 1µmol flecainide (Figure 
5.8C), suggesting that channel recovery was slightly slower after flecainide was 
added. However, the P50 in Figure 5.8D shows that there is no difference in 
recovery time. Figure 5.8E shows that the shift in recovery between the LA and 
LV after flecainide is significantly greater in the WT. However, there is no 
significant difference in the shift in recovery between the Plako+/- LA and LV, 
although the Plako+/- LA has a much greater shift, likely due to the large 
standard deviations of the data set. 
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Figure 5.8. Flecainide effect on Plako+/- LA and LV time dependent sodium 
channel recovery. 
Channel recovery in control/=flecainide LA and LV cardiomyocytes from Plako+/- 
mouse hearts. A) Plako+/- LA curve of normalised sodium channel recovery 
(I/Imax) fitted to one-phase association with protocol shown inset (n=6/3 
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cells/mice). B) Plako+/- LA P50 of recovery (Plako+/- LA control=21.2 ± 3.126ms; 
n=6/3 cells/mice; Plako+/- LA plus flecainide=29.57 ± 5.097ms; n=6/3 cells/mice. 
C) Plako+/- LV curve of normalised sodium channel recovery (I/Imax) fitted to 
one-phase association with protocol shown inset (n=10/4 cells/mice). D) Plako+/- 
LV P50 of recovery (Plako+/- LV control=18.7 ± 3.797ms; n=10/4 cells/mice; 
Plako+/- LV plus flecainide=18.79 ± 3.196ms; n=10/4 cells/mice). E) Shift in 
recovery after flecainide addition (WT LA=9.124 ± 3.543ms; n=12/6 cells/mice; 
WT LV=1.354 ± 1.543ms; n=12/6 cells/mice; Plako+/- LA=8.367 ± 4.226ms; 
n=6/3 cells/mice and Plako+/- LV=0.09 ± 1.759ms; n=10/4 cells/mice). Error bars 
indicate ± S.E.M. Significance taken as *P<0.05 with paired Student t-test for (B 
and D) and two-way ANOVA followed by post-hoc multiple comparisons 
(Tukey’s) test (E). 
 
4.3.$Chapter$synopsis$and$discussion$
4.3.1.$Overview$of$main$findings$
The key findings of the chapter are described as follows: 
• There is no difference in mouse Plako+/- LA and LV INa density at any 
holding potential. 
 
• The activation and inactivation of mouse Plako+/- LA and LV sodium 
channels differ, but differences are not as pronounced as between WT 
LA and LV. Also, unlike between WT chambers, there is no difference in 
sodium channel recovery time. 
 
• Flecainide inhibition does not differ between Plako+/- LA and LV sodium 
channels, as inhibition is greater in Plako+/- LV compared to WT LV 
sodium channels. 
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4.3.2.$ Physiological$ INa$ density$ and$ inactivation$ of$ LA$ and$ LV$ in$ the$
Plako+/R$mouse$
As described in Chapter 3, there have been several studies comparing the 
biophysical properties of mammalian atrial and ventricular sodium channels, 
resulting in multiple publications stating chamber distinctions in the sodium 
channel physiology. Different activation, inactivation and recovery kinetics of the 
INa in LA and LV cardiomyocytes of guinea pig, canine, rat and rabbit (4, 5, 142, 
185, 186) have been shown. One of the conclusions from these studies is that 
the LA cardiomyocytes display greater peak INa than LV cardiomyocytes when 
generated from hyperpolarised holding potentials (4, 5, 142, 185, 186).  
 
Upon further analysis into the effect of the holding potential in WT LA and LV 
cardiomyocytes (Figure 3.2) INa density showed to be greatly affected by 
holding potential. In WT LA and LV chambers INa is greater when initiated from 
more negative potentials, compared to currents initiated from more 
physiological potentials, due to increased availability of the sodium channels. At 
-120mV holding potential WT LA INa is greater than WT LV INa (Figure 3.2B), in 
agreement with findings from other mammalian studies (4, 5, 142, 185, 186). 
However, at the -75mV holding potential WT LA INa is smaller than WT LV INa 
(Figure 3.2C). As discussed in Chapter 3, these findings are likely a 
consequence of differences in the inactivation kinetics between the WT LA and 
LV sodium channels (Figure 3.3). WT LA sodium channels inactivate at more 
negative voltages than WT LV sodium channels, so are less available at more 
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physiological positive holding potentials (Figure 3.3A). However, Plako+/- LA and 
LV INa distinctions at different holding potentials do not coincide with the WT 
counterparts. There is no significant difference in the INa density of the Plako+/- 
LA or LV at the -120mV holding potential or the -75mV holding potential (Figure 
5.2). 
 
The lack of difference in peak INa between the WT and Plako+/- LV at the -
100mV (Figure 5.1E), -120mV (Figure 5.2B) and -75mV (Figure 5.2C) holding 
potentials opposes the observed increased INa at -120mV holding potential in 
plakophilin 2 deficient rat ventricles compared to their WT counterparts (178). 
This suggests that the effects of plakophilin deficiency cannot be interpreted 
directly to be the effects of plakoglobin deficiency and that the desmosomal 
proteins may interact with VGSCs differently. 
 
Likewise, it was suggested that there would be a proarrhythmic reduction in INa 
in the plakoglobin deficient ventricles, as heart samples from ARVC patients 
with reduced plakoglobin also had reduced LV and RV Nav1.5 expression at the 
intercalated disks (179, 180). However, Figure 5.BC reveals that there is no 
difference in INa density between WT LV and Plako+/- LV INa at -120mV holding 
potential, when all sodium channels would be available for activation. 
Therefore, this disputes the suggestion that a reduced ventricular INa may be 
responsible for the increased arrhythmia vulnerability in ARVC patients due to 
slowed conduction (179, 180). 
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There may be upregulation of other sodium channel isoforms contributing to the 
INa in plakoglobin deficient hearts, as current density is not altered. If so, 
decreased INa density would not be a mechanism underlying ARVC 
arrhythmogenesis in plakoglobin deficient patients. Nevertheless, it must also 
be assessed whether the observed reduction in LV and RV Nav1.5 expression 
at the intercalated disks in ARVC plakoglobin deficient patients is conserved in 
the mouse model. If Nav1.5 expression is also reduced in the ventricles of the 
plakoglobin deficient mouse, measurement of the expression of other sodium 
channel isoforms would be necessary in order to explain absence of change in 
peak INa. 
 
There is a significant negative shift in the inactivation of Plako+/- LA sodium 
channels compared to those of the Plako+/- LV (Figure 5.3A), but the difference 
is visibly less than that seen between the WT counterparts (Figure 5.3D). 
Although the WT LV and Plako+/- LV inactivation curves overlap, suggesting no 
difference in inactivation kinetics (Figure 5.3C), the Plako+/- LA inactivation 
curve is shifted slightly positive to that of the WT LA inactivation curve (Figure 
5.3B), although there is no significant difference in the inactivation V50, this 
shift is clearly visible (figure 5.3D). 
 
Therefore, this slight positive shift in Plako+/- LA sodium channel inactivation 
could account for the greater INa density at -75mV compared to the WT LA, 
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although this is not significant, likely due to data variability (Figure 5.2C). 
However, it could be expected that that Plako+/- LA display greater INa in vivo. 
Therefore, amplified INa could be a causal factor of the increased atrial 
arrhythmia generation in endurance trained mice with plakoglobin deficiency 
(259, 260) as there could be increased atrial AP duration of Plako+/- LA 
cardiomyocytes compared to WT LA cardiomyocytes. 
 
Biophysical studies of a gain-of-function Nav1.5 mutation in tsA201 cells has 
shown that AF generation is enhanced as a result of increased cellular 
excitability due to a 5.13mV positive shift in inactivation (261). However, the 
difference in inactivation between Plako+/- LA and WT LA is only 2.19mV, and 
not significant (Figure 5.3D). Nevertheless, a slight positive shift in channel 
inactivation could result in enhanced INa, leading to calcium overload conditions 
(262) and exercise increases cyclic adenosine monophosphate levels, thus 
leading to intracellular calcium overload (263). Therefore, endurance trained 
Plako+/- hearts could be particularly susceptible to calcium overload and the 
resulting DADs (202). This could lead to increased vulnerability to stress-
induced triggered activity and contribute to AF development in plakoglobin 
deficient athletes undergoing endurance training. 
 
As there is no difference in the inactivation kinetics between WT and Plako+/- LV 
(Figure 5.3C) this conflicts with published findings that describe a plakophilin 2-
dependent negative shift in inactivation in ventricular sodium channels, 
 
 
176 
compared to the WT counterparts (178). This again supports the notion that the 
effect of plakoglobin deficiency on sodium channels differs to the effect of 
plakophilin deficiency and that the desmosomal proteins may interact with 
VGSCs differentially. 
 
4.3.3.$ Sodium$ channel$ activation$ differences$ of$ the$ LA$ and$ LV$ in$ the$
Plako+/R$mouse$
Figure 3.1E and 5.1F show the -3.77mV shift in the V50 activation of the WT LA 
sodium channels compared to that of the WT LV sodium channels, supporting 
findings in rabbit LA and LV cardiomyocytes (5). This negative shift in V50 
activation potential of the LA sodium channels suggests an enhancement of 
excitability and therefore arrhythmia generation in WT LA cardiomyocytes 
compared to WT LV cardiomyocytes, as described in Chapter 3. 
 
However, in the Plako+/- counterparts, the -2.44mV shift in the V50 activation of 
the Plako+/- LA sodium channels compared to that of the Plako+/- LV sodium 
channels is not significant (Figure 5.1F). The Plako+/- LA V50 activation is 
significantly negatively shifted compared to that of the WT LV. Therefore, it can 
be presumed that the potential enhancement of excitability and therefore 
arrhythmia generation in Plako+/- LA cardiomyocytes compared to WT LV 
cardiomyocytes is still possible, detailed greatly in Chapter 3 (241). The lack of 
difference between the Plako+/- chambers is due to the -2.22mV negatively 
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shifted LV Plako+/- activation V50 compared to that of WT LV, however, this not 
significant. Nevertheless, the shift in LV Plako+/- activation V50 could suggest 
an enhancement of excitability and therefore arrhythmia generation, but also an 
enhanced sensitivity to sodium channel inhibition by flecainide (264), compared 
to WT LV. This would offer further explanation for the enhanced ventricular 
arrhythmia occurrence in ARVC patients with plakoglobin deficiency (251, 252). 
  
4.3.4.$No$difference$ in$ sodium$channel$ recovery$between$ LA$and$ LV$ in$
the$Plako+/R$mouse$
In Chapter 3, WT LA sodium channel P50 for recovery time is 6.83ms slower 
than WT LV sodium channel recovery (Figure 3.4B). This could suggest that the 
WT LV are more susceptible to channel reopening during repolarisation due to 
faster recovery, with the resultant arrhythmic triggers described previously. On 
the other hand, the slower recovery of WT LA sodium channels could result in 
decreased INa, leading to decrease in AP amplitude and conduction velocity 
(98). A reduction in conduction velocity is also associated with arrhythmia 
generation, so a slower recovery time of the sodium channels may also be 
considered proarrhythmic. 
 
Figure 5.4A reveals that there is no difference in recovery kinetics between 
Plako+/- LA and LV, suggesting that neither Plako+/- chamber is more 
susceptible to arrhythmia than other due to distinctions in recovery kinetics. 
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Figure 5.4B shows that Plako+/- LA recovery curve is left shifted compared to 
that of WT LA, suggesting that Plako+/- LA sodium channels recovery quicker. 
This establishes why no difference is observed between the Plako+/- LA and LV 
recovery. However, the P50 recovery in Figure 5.4D reveals that the 3.37ms 
difference in recovery time is not significant between WT and Plako+/- LA. 
Although the difference is not significant it is evident that recovery is only 
different between the WT and Plako+/- counterparts in the LA, emphasising that 
plakoglobin deficiency has a greater effect on LA sodium channel recovery 
kinetics than those of the LV. 
 
The effect of a slower recovery of sodium channels in the atria compared to 
ventricles in WT or the Plako+/- hearts cannot be clearly determined. Further 
studies, examining the effects of these biophysical characteristics under 
physiological (increased heart rate) and pathophysiological stressors (ischemia, 
fibrosis) are required to gain a greater understanding of the impact of 
modulation of recovery kinetics on heart function and arrhythmia predisposition 
in the different chambers of the heart. 
 
4.3.5.$ Flecainide$ sodium$channel$ inhibition$of$ LA$and$ LV$ in$ the$Plako+/R$
mouse$
No significant difference in peak INa (Figure 5.1E), activation (Figure 5.1F), 
inactivation (Figure 5.3D) and recovery (Figure 5.4D) was found between 
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Plako+/- LA and LV chambers compared to their WT counterparts. As there was 
no reduction in INa peak at physiological holding potentials in the Plako+/- LA and 
LV compared to WT counterparts (Figure 5.2C) it suggests that reduced INa is 
not causative of the arrhythmia susceptibility of plakoglobin deficient patients. 
Therefore, conduction is unlikely to be slowed in plakoglobin deficient hearts 
and sodium channel blocking drugs, such as flecainide, may not be any more 
proarrhythmic in plakoglobin deficient hearts than ‘normal hearts’. Although 
there is no difference in sodium channel recovery kinetics between LA and LV 
Plako+/- sodium channels, there are differences in voltage dependence of 
inactivation and possibly activation that mirror the WT counterpart distinctions. 
Therefore, the differences in Plako+/- LA and LV sodium channel activation and 
inactivation kinetics may alter the susceptibility to flecainide, such as in the WT 
LA and LV (Figure 3.6).  
 
As with the WT LA compared to WT LV, Plako+/- LA sodium channels inactivate 
at more negative potentials compared to Plako+/- LV sodium channels (Figure 
5.3D). Open and inactivated channels are more susceptible to block from 
flecainide than deactivated closed state channels (227). Therefore, distinctions 
in sodium channel gating kinetics suggest that Plako+/- LA sodium channels 
would be inhibited more than Plako+/- LV sodium channels. However, sodium 
channels in both Plako+/- LA and LV are clearly inhibited by flecainide (Figure 
5.5D and 5.5E), with no detectable difference in % inhibition between the 
chambers (Figure 5.5F). This is due to the 10.21% greater inhibition of Plako+/- 
LV sodium channels compared to WT LV sodium channels (Figure 5.5F). This 
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suggests that flecainide may be suitable for also treating the ventricular 
arrhythmias that occur in ARVC patients with plakoglobin deficiency and would 
not be selective for atrial sodium channels. This supports findings that 
demonstrate that the addition of flecainide alone (265) or in combination with 
other drugs (sotalol/metoprolol) (266, 267) can be an effective treatment for 
ventricular arrhythmias in ARVC patients. 
 
Unlike in WT LV sodium channels, the addition of flecainide does not alter 
activation gating kinetics in Plako+/- LV sodium channels. Flecainide negatively 
shifts WT LV sodium channel activation (Figure 3.5H) whereas Plako+/- 
activation (Figure 5.6H) is unchanged. In the WT LV a negative shift in 
activation would result in more sodium channels being in an open state at 
physiological voltages and therefore more channels would be susceptible to 
further flecainide inhibition (227). In the Plako+/- LV, a lack of activation shift 
would mean that more sodium channels remain in the closed state at 
physiological voltages and are therefore less susceptible to flecainide inhibition 
but are also less likely to activate prematurely. 
 
However, as with WT LA and LV (Fiugre 3.7), flecainide addition results in a 
negative shift in inactivation of the Plako+/- LA and LV sodium channels (Figure 
5.8). The shifts in inactivation are comparable between the corresponding 
chambers in the WT (Figure 5.7E). The shift in Plako+/- LA sodium channel 
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inactivation is -1.625mV greater than the Plako+/- LV sodium channel activation 
but this is not significant, likely due to variation within both data sets.  
 
As shown in Chapter 3, WT LA sodium channel recovery time was increased 
when flecainide was added to the cells (Figure 3.7B). This could potentially 
reduce INa,late, meaning that flecainide safeguards the WT LA from prolongation 
of the AP plateau and the resultant arrhythmic triggers described previously 
because of this late current (223, 224). Additionally, with increase in channel 
recovery time the WT LA ERP would increase (221) and this could be protective 
against re-entrant AF (118). Conversely, neither Plako+/- LA or LV recovery time 
was significantly altered with flecainide addition. Therefore, the proposed 
cardioprotective mechanism that occurs as a result of slowed channel recovery 
would not occur with flecainide addition in Plako+/- hearts (Figure 5.8). However, 
the shift in Plako+/- LA recovery was comparable to the shift in WT LA recovery 
(Figure 5.8E) and may not have been significant due to pronounced data 
variability. 
 
Overall, flecainide does not appear to be atrial selective in the Plako+/- mouse, 
unlike in the WT mouse. Therefore, flecainide would not be an AF targeting 
drug for those with plakoglobin deficiency, as % inhibition of Plako+/- LV INa was 
significantly greater than % inhibition of WT LV INa and ventricular 
electrophysiology could be altered. This is likely primarily due the differences in 
channel gating kinetics of both the Plako+/- LA and LV compared to their WT 
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counterparts. Furthermore, as described in Chapter 3, the effects on the other 
ion channels, aside of the sodium channels, needs to be considered when 
assessing the effectiveness for AF treatment. However, ARVC patients 
predominantly present with ventricular arrhythmias over atrial arrhythmias (251, 
252). Therefore, the ventricular electrophysiology in ARVC patients would be 
abnormal and the greater inhibition of Plako+/- LV INa than WT LV INa with 
flecainide could be useful for supressing ventricular arrhythmias as well as atrial 
arrhythmias. 
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5.$ LangendorffRfree$ technique$ for$ mouse$ cardiomyocyte$
isolation$
5.1.$Chapter$introduction$and$overview$
The development of new clinical therapeutic approaches for treating 
cardiovascular disease is crucial. Therefore, model systems are essential to 
advance scientific understanding of the mechanisms, pathogenesis and 
progression of cardiovascular disease, alongside the testing of therapeutic 
approaches to restore cardiac function. The ideal model system is simply 
manipulated, reproducible, inexpensive, physiologically representative of the 
human model and ethically suitable (268).  
 
Mice models have the distinctive properties that make them valued and 
indispensable in cardiac research. Mice have relatively low maintenance cost, 
short gestation time and are often easier to handle than larger mammal models 
(269). Although there are obvious significant differences between mice and 
humans, 99% of human genes have direct murine orthologs (270) and 
genetically modified mice can be selected within a reasonably short time due to 
their high breeding rate (271). Additionally, mouse and human hearts share 
many similarities and both express proteins with comparable functions and 
roles (272). Therefore, the use of mouse models provides a wealth of valuable 
insight into human cardiac physiology and over the past decade the mouse 
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model has become the most popular model choice to study human 
cardiovascular disease (269). 
 
Animal models were initially only utilised for studying surgical and 
pharmacological interventions within the intact heart. Over time, advances in 
research lead to intact muscle preparations being used for experimental 
manipulation of the cardiac muscle (273). However, due to the large size of the 
intact muscle, in-depth electrophysiological examination proved difficult, as 
adequate control of membrane potential for voltage clamp experiments could 
not be achieved. These difficulties and the requirement for more in-depth 
electrophysiological data to progress cardiac research lead to the development 
of single cell isolation techniques. 
 
Research using isolated cardiomyocytes can provide crucial understanding of 
cellular and sub-cellular physiology. Isolated mouse cardiomyocytes are 
extensively used for the study of cardiac function, as demonstrated within this 
Thesis. However, high quality cardiomyocytes are essential to successful 
experimentation. Nevertheless, after almost 50 years of cardiomyocyte isolation 
(274-276), there is no simple universally used method that guarantees high 
yields of viable cells. Researchers often face problems isolating high quality 
healthy cardiomyocytes and difficulties in isolation can unpredictably occur, 
even in laboratories that routinely isolate cardiomyocytes. 
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Some research groups have isolated cardiomyocytes by mechanical 
homogenisation (275, 276) and mechanical agitation with enzymatic digestion 
of tissue in a petri dish (277, 278). Though, when cardiomyocyte viability was 
reported upon, these early examples of mechanical digestion often exhibited 
low yields of intact cells. Today most research groups rely on the Langendorff-
isolation method of retrograde perfusion via the aorta with enzymes (273). The 
Langendorff method was established in 1898 by Oscar Langendorff (279), 
mostly isolating cardiomyocytes from cat, dog and rabbit hearts. The general 
principal of this method is retrograde perfusion of the heart via a cannulated 
aorta (see Figure 6.1). This results in closure of the aortic valve and filling of the 
coronary arterial vasculature with perfusion buffer so that it passes through the 
vascular bed (280). 
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Figure 6.1. Schematic of a Langendorff apparatus. 
Basic schematic of the Langendorff system. The heart is retrogradely perfused 
with buffer solution via the cannulated aorta. The buffer solution is driven from 
the reservoir to the heat exchanger coil by the peristaltic pump. Drugs etc. can 
be administered via the bolus port. The solution is kept at 37°C. Image adapted 
from (280). 
 
The original Langendorff isolation method has been modified and has evolved 
over time to deliver cardiomyocytes with increased potential for research. 
O’Connell et al., adapted the method, so that a two-fold increased yield (1-1.5 
x106) of rod-shaped cardiomyocytes from a mouse heart was achieved, 
compared to previously published reports (281). Importantly, adaptations also 
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provided calcium tolerant cardiomyocytes that could be isolated for measuring 
contractile function and Ca2+ transients (281). MacDougall et al., also modified 
the traditional Langendorff method so that cardiomyocytes could be isolated 
from the rat heart and myocardium could be processed/stored from the same 
heart. This modification resulted in the ethically, logistically and economically 
beneficial reduction of the number of animals required for research (282). 
 
Nevertheless, even after many evolutions, research progress has been 
hindered by difficulties concerning the isolation of high-quality cardiomyocytes. 
The Langendorff cardiomyocyte isolation method demands specific commercial 
or custom-made equipment (as seen is Figure 6.1) with extensive training for 
the delicate and challenging technique. Additionally, Langendorff isolations face 
issues of sterility and often require anticoagulant pre-injection into animals, 
potentially affecting data outcomes (283, 284). These issues often cause 
significant financial, technical and logistical barriers to cardiac research. 
 
Together with our colleagues in Singapore, we have developed a novel, 
recently published, Langendorff-free alternative approach to mouse 
cardiomyocytes isolation, as described in the Material and Methods 2.4.2 of this 
Thesis. A schematic overview of the injection-based isolation method is shown 
in Figure 6.2 (183). This method works by injection of digestion buffers directly 
into the ventricles of an adult mouse heart ex vivo and can conveniently 
produce high yields of functionally healthy cardiomyocytes, without expensive 
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equipment. Additionally, this isolation method can be performed in sterile 
conditions for culturing purposes and does not require heparin injection. 
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Figure 6.2. Injection-based isolation method. 
A summary of the injection-based cardiomyocyte isolation method as described 
in the text of this thesis. Figure extracted from (183). 
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The reproducible yields of ≤1 million 81±6% viable isolated cardiomyocytes per 
LV with the injection method are comparable to those of successful Langendorff 
isolations (183, 281). Since this injection-based cardiomyocyte isolation method 
was published, a vast amount of positive feedback has been received and 
several research groups have adopted this protocol with extensive number of 
citations (285-301). In order to establish the suitability of injection isolated 
cardiomyocytes for research, the functionality and morphology of the cells must 
be demonstrated and compared to published findings and cardiomyocytes 
isolated via the traditional Langendorff-based method. 
 
The aims of this investigation are summarised below: 
1. To compare the functionality of the injection isolated cardiomyocytes to 
published findings and directly to cardiomyocytes isolated using the 
Langendorff method. This will be done by assessing the contractile 
properties, calcium handling, sodium channel gating kinetics and 
adrenergic responses. 
 
2. To assess calcium handling, stress-dependent hypertrophic signalling 
cascades and sodium channel gating kinetics of the injection isolated 
cardiomyocytes compared to those isolated using the Langendorff 
method. 
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5.2.$Protocol$optimisation$
This work was performed and published by Ackers et al., (183). These 
experiments were conducted on C57/BL6 mice aged 8-12 weeks. 
For optimisation experiments crude digestion product was monitored with 
percentage of viable rod-shaped cardiomyocytes quantified using a 
hemocytometer. 
 
In the injection-isolation protocol, mouse hearts are perfused with divalent 
cation chelating EDTA in the buffers. Preclearance of the heart in vivo, with 
EDTA (injected into the right ventricle) inhibits contraction, prevents coagulation 
and weakens extracellular connections (274, 302-304) (see materials and 
methods chapter for details). In three independent experiments peak rod-
shaped cardiomyocyte yields were tested in the presence of different pH. Peak 
rod-shaped cardiomyocyte yields were achieved with the dissociation buffer at 
pH 7.8 (Figure 7.1A) and 5mmol/L EDTA buffer concentration (Figure 7.1B). 
Under these conditions the injection method provided reproducible yields of ≤1 
million 81±6% cardiomyocytes (183), comparable to yields from Langendorff-
isolation (281, 305, 306). 
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Figure 7.1. EDTA and pH optimisation. 
A) Optimisation of dissociation buffer pH. B) Optimisation of EDTA 
concentration. Data shows mean ± S.D, n=3 independent experiments. 
 
5.3.$Functionality$of$injectionRisolated$cardiomyocytes$
During isolation of cardiomyocytes there is a risk of cellular damage and/or 
activation of stress response pathways, potentially altering in vivo or 
downstream transcriptional profiles. Therefore, experiments were performed to 
assess the functional characteristics of the injection-isolated cells. 
 
 
B
A
 
 
193 
5.3.1.$Cell$and$sarcomere$length$of$injection$isolated$LV$cardiomyocytes$
Sian-Marie O’Brien isolated the cardiomyocytes and Dr Davor Pavlovic 
performed the calcium and cell/sarcomere length experiments. These 
experiments were conducted on C57/BL6 mice aged 8-12 weeks. 
 
Frequency response was measured in injection-isolated cardiomyocytes. 
Representative traces of electrically paced injection isolated LV cardiomyocytes 
exhibit characteristic (307-311) frequency-dependent changes in calcium 
transients (Figure 7.2A) and sarcomere length (SL) (Figure 7.2B). This is 
demonstrated in Figure 7.2C, diastolic Ca2+ transient amplitude increases in a 
frequency-dependent manner and is significantly greater at 4Hz frequency than 
at 1Hz. Figure 7.2D shows that Ca2+ transient decay (tau) is significantly less at 
the 3Hz frequency than at 1Hz. This is in accordance with other mouse data 
that is contrary to data from other mammals (312, 313). SL shortening is 
significantly reduced at 3Hz and 4Hz frequency than at 1Hz. 
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Figure 7.2. Frequency response of LV injection-isolated cells. 
Ca2+ transients and SL were measured following pacing at varying frequencies 
(1-4Hz). A) Raw Ca2+ transients B) Raw SL. C) Diastolic Ca2+. D) Ca2+ transient 
decay (τ). E) % SL shortening. C-E (n=≥9/3 cells/mice). Error bars indicate ± 
S.E. significance taken as *P<0.05 with one-way ANOVA followed by Dunnett 
multiple comparisons test. 
 
5.3.2.$Adrenergic$response$of$injectionRisolated$LV$cardiomyocytes$
Sian-Marie O’Brien isolated the cardiomyocytes and Dr Davor Pavlovic 
performed the calcium and cell/sarcomere length experiments. These 
experiments were conducted on C57/BL6 mice aged 8-12 weeks. 
 
Adrenergic responses with the addition of +1 µmol/l isoproterenol (ISO) were 
assessed in injection-isolated cardiomyocytes. Figure 7.3A shows 
representative raw traces from an injection-isolated LV cardiomyocyte. Addition 
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of +1 µmol/l ISO amplified both Ca2+ transients (top) and SL shortening 
(bottom). Figure 7.3B shows a representative Ca2+ transient raw trace of 
electrically paced injection isolated LV cardiomyocyte, with control shown in 
black and +1 µmol/l ISO in red. ISO clearly increased Ca2+ transient amplitude 
(left panel) and resulted in a faster Ca2+ transient decay (right panel) when 
normalised. The representative trace of a single beat SL shortening, with 
control shown in black and with +1 µmol/l ISO in red (Figure 7.3C) 
demonstrates that SL length is clearly increased with the addition of ISO. 
Increasing doses of ISO increased Ca2+ transient amplitude (Figure 7.3D), 
decreased Ca2+ transient decay (τ) (Figure 7.3E) and increased SL shortening 
in a dose dependent-manner (Figure 7.3F). These findings are in accordance 
with previously published data (314-316).  
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Figure 7.3. Adrenergic response of LV injection-isolated cells. 
Adrenergic responses with the addition of (ISO). A) Representative raw traces 
of Ca2+ transient (top) and SL shortening (bottom). The period of 1 µmol/l ISO 
addition is marked in the figure. B) Representative raw calcium transient native 
(left) and normalised (right) trace of electrically paced injection isolated LV 
cardiomyocyte, with control shown in black and +1 µmol/l ISO in red. C) 
Representative SL trace of injection isolated LV cardiomyocyte, with control 
shown in black and +1 µmol/l ISO in red. D) Ca2+ transient amplitude E) Ca2+ 
transient decay (τ) and F) % SL shortening, with increasing dose of ISO (n=≥9/3 
cells/mice). Error bars indicate ± S.E. significance taken as *P<0.05 with one-
way ANOVA followed by Dunnett multiple comparisons test. 
 
5.3.3.$ InjectionRisolated$ LV$ cardiomyocyte$ sodium$ channel$ IV$ and$
activation$
Cardiomyocyte isolation and patch clamp experiments were conducted by Sian-
Marie O’Brien and Dr Andrew Holmes. These experiments were conducted on 
C57/BL6 mice aged 8-12 weeks. 
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As described previously, activation of sodium channels drives the upstroke of 
the AP, determining the propagation of electrical impulses throughout the 
myocardium and is a target of AADs. Here it is assessed whether injection-
isolated cardiomyocytes displayed typical INa compared to published data. 
Experiments were performed on Langendorff and injection isolated WT mouse 
LV cardiomyocytes to compare the sodium channel I/V relationship, using the 
relevant I/V patch clamp protocol described in the materials and methods 
(Table 1.5). This protocol enabled assessment of the voltage/current 
relationship and sodium channel activation. 
 
Figure 7.4A shows a typical raw representative trace of the INa I/V curve from a 
single injection-isolated LV cardiomyocyte with the patch clamp protocol shown 
inset. The mean current-voltage relationship of INa density in injection-isolated 
LV cardiomyocytes (n=8/3 cells/mice) (Figure 7.4B) confirms that the peak INa is 
achieved at -30mV, as widely published by others (4, 46, 57, 317). Figure 7.4C 
shows a raw representative trace of the INa voltage-dependent steady-state 
inactivation of a single injection isolated LV cardiomyocyte, with the patch 
clamp protocol shown inset. The injection-isolated mouse LV cardiomyocytes 
sodium channels have comparable inactivation kinetics (Figure 7.4D) to 
published data using Langendorff isolated cardiomyocytes (n=8/3 cells/mice) (4, 
46, 57, 317).  
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Figure 7.4. Injection isolated LV cardiomyocyte I/V relationship and 
sodium channel inactivation. 
INa I/V curve and channel inactivation in injection-isolated LV cardiomyocytes 
from WT mouse hearts. A) Representative raw trace of the INa patch clamp 
protocol on the right. B) Current-voltage relationship of INa density of injection-
isolated LV cardiomyocytes (n=8/3 cells/mice). C) Representative trace of the 
INa voltage-dependent steady-state inactivation, patch clamp protocol shown 
inset. D) Curve of normalised INa inactivation (I/Imax) fitted to the Boltzmann 
function (n=8/3 cells/mice). 
 
5.4.$ Comparison$of$function$and$signalling$characteristic$between$
injectionRbased$and$LangendorffRbased$isolation$techniques$
Analysis of contractile response, Ca2+ handling, INa properties and stress 
markers between cardiomyocytes isolated with injection-isolation and 
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Langendorff-isolation is essential to directly compare the functionality of 
cardiomyocytes using the novel method. 
 
5.4.1.$ Comparison$ of$ injection$ and$ Langendorff$ isolated$ LV$
cardiomyocyte$cell$and$sarcomere$length$
Sian-Marie O’Brien isolated the cardiomyocytes and Dr Davor Pavlovic 
performed the calcium and cell/sarcomere length experiments. 
 
Resting morphology was compared between injection-isolated cardiomyocytes 
and Langendorff isolated cardiomyocytes. There was no difference in resting 
cell length between Langendorff (n=19/3 cells/mice) and injection (n=19/3 
cells/mice) isolated LV cardiomyocytes (Figure 7.5A). However, the resting SL 
of Langendorff isolated LV cardiomyocytes (n=19/3 cells/mice) was significantly 
less than in injection isolated LV cardiomyocytes (n=19/3 cells/mice) (Figure 
7.5B). 
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Figure 7.5. Diastolic cell length and sarcomere length of Langendorff and 
injection isolated cells. 
Diastolic cell length and SL was measured were measured in Langendorff and 
injection isolated cardiomyocytes. A) Resting cell length of isolated LV 
cardiomyocytes (Langendorff=116.1 ± 5.055mM; n=19/3 cells/mice; 
injection=113.3 ± 5.4mM; n=19/3 cells/mice). B) Resting sarcomere length of 
isolated LV cardiomyocytes (Langendorff=1.707 ± 0.03801µM; n=19/3 
cells/mice; injection=1.823 ± 0.02828µM; n=19/3 cells/mice) *p<0.05. Error bars 
indicate ± S.E.M. significance taken as *P<0.05 with unpaired Student t-test. 
$
5.4.2.$ Pacing$ effect$ on$ injection$ and$ Langendorff$ isolated$ LV$
cardiomyocytes$
Sian-Marie O’Brien isolated the cardiomyocytes and Dr Davor Pavlovic 
performed the calcium and cell/sarcomere length experiments. 
 
Preservation of diastolic Ca2+ and tight control of Ca2+ release and uptake is 
fundamental to coordinated myocardium contraction. Therefore, calcium-
handling properties and SL at different pacing frequencies (1-3Hz) were 
compared between injection-isolated cardiomyocytes and Langendorff- isolated 
cardiomyocytes. There was no difference in diastolic Ca2+ between the 
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Langendorff and injection isolated cardiomyocytes at 1Hz, 2Hz or 3Hz 
(Langendorff n=16/3 cells/mice; injection n=16/3 cells/mice) (Figure 7.6A). 
There was no difference in Ca2+ transient amplitude between the Langendorff 
and injection isolated cardiomyocytes at 1Hz, 2Hz or 3Hz (Langendorff n=16/3 
cells/mice; injection n=16/3 cells/mice)  (Figure 7.6B). There was also no 
difference in Ca2+ decay constant (τ) between the Langendorff and injection 
isolated cardiomyocytes at 1Hz, 2Hz or 3Hz (Langendorff n=16/3 cells/mice; 
injection n=16/3 cells/mice)  (Figure 7.6C). Additionally, there was no difference 
in % of SL shortening in the Langendorff and injection isolated cardiomyocytes 
at 1Hz, 2Hz or 3Hz (Langendorff n=16/3 cells/mice; injection n=16/3 cells/mice) 
(Figure 7.6D). 
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Figure 7.6. Pacing effect on Langendorff and injection isolated cells. 
Ca2+ transients and sarcomere length were measured following pacing at 
varying frequencies (1-3Hz) in Langendorff and injection isolated 
cardiomyocytes. A) Diastolic Ca2+ in LV isolated cardiomyocytes at 1Hz 
(Langendorff=0.885 ± 0.01232 F1/F0; n=16/3 cells/mice; injection=0.8794 ± 
0.009059 F1/F0; n=16/3 cells/mice), at 2Hz (Langendorff=0.9044 ± 0.01525 
F1/F0; n=16/3 cells/mice; injection=0.9038 ± 0.008107 F1/F0; n=16/3 
cells/mice), at 3Hz (Langendorff=0.9363 ± 0.01217 F1/F0; n=16/3 cells/mice; 
injection=0.92 ± 0.008563 F1/F0; n=16/3 cells/mice). B) Ca2+ transient 
amplitude in LV isolated cardiomyocytes at 1Hz (Langendorff=0.08019 ± 
0.004004 F1/F0; n=16/3 cells/mice; injection=0.08163 ± 0.006124 F1/F0; 
n=16/3 cells/mice), at 2Hz (Langendorff=0.07400 ± 0.003949 F1/F0; n=16/3 
cells/mice; injection=0.07744 ± 0.004603 F1/F0; n=16/3 cells/mice) and at 3Hz 
(Langendorff=0.05744 ± 0.003623 F1/F0; n=16/3 cells/mice; injection=0.06632 
± 0.003106 F1/F0; n=16/3 cells/mice). C) Ca2+ decay constant (τ) in LV isolated 
cardiomyocytes at 1Hz (Langendorff=0.202 ± 0.009071s; n=16/3 cells/mice; 
injection=0.2095 ± 0.005273s; n=16/3 cells/mice), at 2Hz (Langendorff=0.1653 
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± 0.01081s; n=16/3 cells/mice; injection=0.1779 ± 0.006605s; n=16/3 
cells/mice) and at 3Hz (Langendorff=0.1491 ± 0.009074s; n=16/3 cells/mice; 
injection=0.1626 ± 0.006637s; n=16/3 cells/mice). D) % of SL shortening in LV 
isolated cardiomyocytes at 1Hz (Langendorff=8.619 ± 0.6069%; n=16/3 
cells/mice; injection=8.006 ± 0.3211%; n=16/3 cells/mice), at 2Hz 
(Langendorff=7.388 ± 0.4517; n=16/3 cells/mice; injection=7.319 ± 0.3737; 
n=16/3 cells/mice) and at 3Hz (Langendorff=6.281 ± 0.2687; n=16/3 cells/mice; 
injection=5.806 ± 0.359; n=16/3 cells/mice). Error bars indicate ± S.E.M. 
significance taken as *P<0.05 with two-way ANOVA followed by post-hoc 
multiple comparisons (Bonferroni) test. 
 
5.4.3.$ Adrenergic$ response$ of$ injection$ and$ Langendorff$ isolated$ LV$
cardiomyocytes$
Sian-Marie O’Brien isolated the cardiomyocytes and Dr Davor Pavlovic 
performed the calcium and SL experiments. 
 
Adrenergic responses with the addition of 1 µmol/l ISO were compared between 
injection and Langendorff isolated cardiomyocytes by assessing the calcium-
handling properties and SL. There was no difference in the percentage of SL 
shortening with the addition of 1 µmol/l ISO between Langendorff and injection 
isolated cardiomyocytes (Figure 7.7A) (Langendorff n=16/3 cells/mice; injection 
n=16/3 cells/mice). In both Langendorff and injection isolated cardiomyocytes 
Ca2+ decay constant (τ) was comparably significantly decreased by the addition 
of 1 µmol/l ISO (Figure 7.7B). This again demonstrates that injection-isolated 
cardiomyocytes display standard adrenergic responses and are suitable for 
biochemical signaling experiments. 
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Figure 7.7. Adrenergic responses of Langendorff and injection isolated 
cells. 
Adrenergic responses with the addition of +1 µmol/l ISO in Langendorff and 
injection isolated cardiomyocytes. A) percentage of SL shortening with the 
addition of +1 µmol/l ISO (Langendorff n=16/3 cells/mice; injection n=16/3 
cells/mice). B) Ca2+ decay constant (τ) (control Langendorff=0.182 ± 0.01056s; 
n=16/3 cells/mice; 1 µmol/l ISO Langendorff=0.1533 ± 0.01092s; n=16/3 
cells/mice; control injection=0.1751 ± 0.007762s; n=16/3 cells/mice; 1 µmol/l 
ISO injection=0.15 ± 0.006755s; n=16/3 cells/mice). Error bars indicate ± 
S.E.M. significance taken as *P<0.05 with two-way ANOVA followed by post-
hoc multiple comparisons (Bonferroni) test. 
 
5.4.4.$ Injection$ and$ Langendorff$ isolated$ LV$ cardiomyocyte$ INa$ IV$ and$
activation$
Experiments were performed on Langendorff and injection isolated WT mouse 
LV cardiomyocytes to compare the sodium channel I/V relationship, using the 
relevant I/V patch clamp protocol described in the materials and methods 
(Table 1.5). The currents were measured from a holding potential of -100mV up 
to +10mV in 5mV increments and normalised to cell capacitance. This protocol 
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enabled assessment of the voltage/current relationship and sodium channel 
activation. 
 
Figure 7.8A shows raw representative traces of the INa from injection isolated 
LV cardiomyocytes with the patch clamp protocol shown inset. The current-
voltage relationship of the sodium channels of Langendorff isolated LV 
cardiomyocytes (n=8/4 cells/mice) and injection isolated LV cardiomyocyte 
(n=5/3 cells/mice) is shown in Figure 7.8B. Sodium channels have a peak 
current potential of -30mV, at which INa amplitude was comparable in LV 
cardiomyocytes isolated with both methods, Langendorff (Figure 7.8C). 
 
The I/V curve data was fitted to a Boltzmann function to obtain the voltage 
dependence of the conductance activation of sodium channels using the initial 
downward slope of the curve (as described in the material and methods). This 
allows comparison of the voltage potential at which half of the sodium channels 
were activated (V50) in the Langendorff and injection LV isolated 
cardiomyocytes (Figure 7.8D). The V50 of LV cardiomyocytes isolated with both 
methods was comparable. 
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Figure 7.8. Langendorff and injection isolated LV cardiomyocyte I/V 
relationship and sodium channel activation. 
INa I/V curve and channel activation in Langendorff and injection LV 
cardiomyocytes from WT mouse hearts. A) Representative raw trace of the INa 
from injection isolated LV cardiomyocytes with the patch clamp protocol on the 
right. B) Current-voltage relationship of INa density, Langendorff (n=8/4 
cells/mice) and injection (n=5/3 cells/mice) isolated LV cardiomyocytes. C) INa 
peak density at a step from -100mV to -30mV in Langendorff (-30.67 ± 
2.841pA/pF; n=8/4 cells/mice) and injection (-31.51 ± 5.899pA/pF; n=5/3 
cells/mice) isolated LV cardiomyocytes. D) V50 of activation fitted to the 
Boltzmann distribution in Langendorff (-45.52 ± 1.209mV; n=8/4 cells/mice) and 
injection (-44.1 ± 2.829mV; n=5/3 cells/mice) isolated LV cardiomyocytes. Error 
bars indicate ± S.E.M. significance taken as *P<0.05 with unpaired Student t-
test. 
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5.4.5.$ Injection$ and$ Langendorff$ isolated$ LV$ cardiomyocyte$ sodium$
channel$inactivation$
Experiments were performed on Langendorff and injection isolated WT mouse 
LV cardiomyocytes to compare the potential at which the sodium channels 
inactivate (are no longer available), using the relevant steady-state inactivation 
patch clamp protocol described in the materials and methods chapter (Table 
1.5). The voltage dependence of steady-state inactivation (channel availability, 
I/Imax) was determined form this protocol, as shown in Figure 7.9A and fitted to 
the Boltzmann function. 
 
The Langendorff and injection isolated WT mouse LV cardiomyocytes sodium 
channels have comparable inactivation kinetics, as shown in Figure 7.9A; 
Langendorff isolated LV cardiomyocytes (n=8/4 cells/mice) and injection 
isolated LV cardiomyocyte (n=5/3 cells/mice). This is confirmed in Figure 7.9B 
V50 for inactivation. 
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Figure 7.9. Langendorff and injection isolated LV cardiomyocyte sodium 
channel inactivation. 
Channel steady-state inactivation in Langendorff and injection LV 
cardiomyocytes from WT mouse hearts. A) Curve of normalised INa inactivation 
(I/Imax) fitted to the Boltzmann function in Langendorff (n=8/4 cells/mice) and 
injection (5/3 cells/mice). B) V50 of inactivation fitted to the Boltzmann 
distribution in Langendorff (-84.08 ± 1.116mV; n=8/4 cells/mice) and injection (-
80.5 ± 2.721mV; n=5/3 cells/mice). Error bars indicate ± S.E.M. significance 
taken as *P<0.05 with unpaired Student t-test. 
 
5.4.6.$ Injection$ and$ Langendorff$ isolated$ LV$ cardiomyocyte$ signalling$
cascades$
Sian-Marie O’Brien isolated the cardiomyocytes and Dr Davor Pavlovic 
performed the signalling experiments. 
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Biomechanical stress and calcium overload during cardiomyocyte isolation can 
result in activation of hypertrophic signaling cascades (318) and detrimental 
PKC-α activation (319). To assess the effect of Ca2+ and stress-dependent 
hypertrophic signaling cascades between the Langendorff-based and injection-
based isolation methods, the protein expression and localisation of protein 
kinase C alpha (PKC-α), phosphorylation of extracellular signal-regulated 
kinase (ERK)1/2 and phosphorylation of PLM at PKC residues, was measured 
and compared in cardiomyocytes isolated from both methods. There was no 
difference detected in PKC-α, with cytosolic (inactivate) and membrane (active) 
fractions evenly distributed in the cardiomyocytes (Langendorff cyt n=8; 
Langendorff mem n=8; injection cyt n=8; injection mem n=8) (Figure 7.10A). 
Likewise, ERK1/2 phosphorylation was no different in cardiomyocytes isolated 
with both methods (Langendorff n=13; injection n=13) (Figure 7.10B). 
Additionally, there was no change detected in the expression or Ser63 
phosphorylation of the cardiac stress protein PLM (Langendorff n=9; injection 
n=9) (Figure 7.10C), a downstream target of PKC-α. Experiments performed 
here clearly demonstrate that the injection-isolation method does not negatively 
affect cardiac intracellular signalling. 
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Figure 7.10. Stress signalling cascade associated protein expression in 
Langendorff and injection isolated LV cardiomyocytes. 
Expression of PKC-α, ERK1/2, PLM and PLM phosphorylation at ser63 in 
cardiomyocytes isolated using Langendorff (L) or injection (I) protocols. A) PKC-
α expression and cytosolic (cyt) / plasma membrane (mem) localisation, with 
PMA administration as positive control (Langendorff cyt=43.63 ± 4.732AU; n=8; 
Langendorff mem=56.38 ± 4.732AU; n=8; injection cyt=51.49 ± 4.457AU; n=8; 
injection mem=48.51 ± 4.457AU; n=8). B) ERK1/2 expression and 
phosphorylation (pERK) (Langendorff=1.489 ± 0.09997AU; n=13; 
injection=1.568 ± 0.118AU; n=13). C) PLM expression and phosphorylation at 
ser63 (Langendorff=1.278 ± 0.08811AU; n=9; injection=1.374 ± 0.1174AU; 
n=9). Error bars indicate ± S.E.M. significance taken as *P<0.05 with one-way 
ANOVA (A) and unpaired Student t-test (B-C). 
$
5.5.$Chapter$synopsis$and$discussion$
5.5.1.$Overview$of$main$findings$
The key findings of the chapter are described as follows: 
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• Injection-isolated LV cardiomyocytes display characteristic changes in 
Ca2+ transients, Ca2+ decay and SL shortening in response to changes in 
pacing frequency and addition of isoproterenol. No differences were 
observed when directly compared to Langendorff isolated LV 
cardiomyocytes. 
 
• Injection-isolated LV cardiomyocytes have greater resting SL but the 
same levels of diastolic Ca2+ as those isolated using the Langendorff 
method. 
 
• Injection-isolated LV cardiomyocytes exhibited the standard INa voltage 
relationship and kinetics and directly compared to those of Langendorff 
isolated LV cardiomyocytes. 
 
• Langendorff and injection isolation protocols similarly affect stress-
signalling cascades. 
 
5.5.2.$Protocol$optimisation$
Isolated mouse cardiomyocytes are essential for investigation into cardiac 
physiology and pathobiology. Nevertheless, the progress of research relying 
upon isolated cardiomyocytes is hindered by technical and logistical 
complications associated with the Langendorff-based isolation method. The 
novel injection-isolation approach described here is a convenient method to 
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isolate high yields of viable, Ca2+ tolerant cardiomyocytes from the adult mouse 
heart (183). 
 
Langendorff-based cardiomyocyte isolation usually requires pre-injection of 
animals with an anticoagulant, such as heparin. However, heparin has proven 
to be detrimental to downstream PCR based analysis (283, 284). EDTA was 
examined as a substitute for heparinisation, and as a means of rapidly reducing 
calcium and thereby reducing calcium overload and calcium overload induced 
apoptosis.  There are however concerns that high concentration of EDTA may 
be damaging to cardiomyocytes as lack of Ca2+ results in separation of 
membrane superficial laminae (303, 304). However, initial perfusion of the heart 
with Ca2+ free solution is usually imperative for effective cardiomyocyte isolation 
(320). Therefore, use of low concentrations of EDTA, or the higher Ca2+ affinity 
analogue EGTA, is widely reported in cardiomyocyte isolations (228, 321-323). 
The initial chelation of divalent cations with EDTA appears to have several 
benefits, aside of the release of intracellular connections, including 
anticoagulation and cessation of cardiomyocyte contraction (274, 302). The 
efficacy of EDTA for isolation of viable cardiomyocytes is evident in Figure 7.1B, 
as the high pre-clearing 5 mmol/L EDTA concentration produces the greatest 
yields of rod-shaped cardiomyocytes. The higher 25 mmol/L concentration may 
have presented with a slightly lower yield of cardiomyocytes possibly due to 
disruption of the cell membranes, effecting cardiomyocytes viability (303).  
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Generally, cardiomyocyte isolation protocols rely on dissociation buffers within a 
physiological pH range (7.0-7.4) (273, 280, 306, 324, 325). However, little 
evidence has been provided as to whether that pH range produces the highest 
yield of viable rod-shaped cardiomyocytes. In this study a pH of 7.8 proves 
optimal for the described injection-isolation protocol (Figure 7.1A). It is possible 
that more alkaline pH increases the affinity of EDTA for divalent cations, offsets 
acidification via the potential production of lactate in the myocardium (326), or 
improves glucose utilisation due to increased phosphofructokinase activity 
(327). 
 
5.5.3.$ Comparable$ contractile$ and$ calcium$ handling$ properties$ of$
injection$and$Langendorff$isolated$LV$cardiomyocytes$
In order to establish whether cardiomyocytes isolated via the injection method 
are suitable for research calcium-handling properties must be comparable with 
published findings from Langendorff isolated cardiomyocytes. Therefore, 
experiments were performed to analyse the Ca2+ handling properties and 
adrenergic responses of the injection-isolated cardiomyocytes. 
 
Post injection isolation and calcium reintroduction, LV cardiomyocytes remained 
quiescent and adhered to laminin-coated culture surfaces, with the typical 
angular morphology and expected organised sarcomeric patterns of LV cells 
isolated using the Langendorff technique (183). Injection isolation did not alter 
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resting cell length compared to Langendorff isolated cardiomyocytes (Figure 
7.5A). This assures that with the injection method the ventricles did not undergo 
any additional ischemic damage than those of the Langendorff perfused heart 
during isolation, as change in cell length can be associated with cardiac tissue 
ischemia (328). 
 
However, the resting SL was significantly greater in the injection-isolated 
cardiomyocytes (Figure 7.5B). SL is a significant determinant and indicator of 
cardiac mechanics as it is a function of Ca2+ binding. Diastolic Ca2+ is an 
indicator of cell stress and the greater the diastolic Ca2+, the lower SL (329). 
Therefore, SL has been described as shortened under ischemic conditions 
(330) and the greater SL in injection-isolated cardiomyocytes suggests they 
could be healthier than the Langendorff isolated cardiomyocytes. Nevertheless, 
these differences were not sustained during field stimulation of the 
cardiomyocytes. When electrically paced the cardiomyocytes exhibited 
characteristic frequency-dependent changes in Ca2+ handling and SL 
shortening (Figure 7.2) (307-311) and did not differ from the cardiomyocytes 
isolated by the standard Langendorff method (Figure 7.6).  
 
Furthermore, injection-isolated cardiomyocytes responded to adrenergic 
stimulation in a dose-dependent manner in accordance with other studies (314-
316)  (Figure7.3) and showed no difference in % SL shortening or Ca2+ decay in 
direct comparison with Langendorff isolated cardiomyocytes (Figure 7.7). 
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Overall, based on these findings it can be assured that injection-isolated 
cardiomyocytes display standard Ca2+ handling properties, contractile 
characteristics and adrenergic responses. 
 
5.5.4.$ Comparable$ INa$ of$ injection$ and$ Langendorff$ isolated$ LV$
cardiomyocytes$
In order to establish the suitability of LV cardiomyocytes isolated by the injection 
method for patch clamp studies and assess functionality, sodium channel 
kinetics and current density were measured and compared with Langendorff 
isolated cardiomyocyte counterparts.  
 
Injection-isolated cardiomyocytes displayed characteristic INa I/V relationship 
(Figure 7.4B) and inactivation kinetics (Figure 7.4D) compared to previously 
published LV cardiomyocyte data (4, 46, 54, 57, 317). Likewise, there was no 
difference in peak INa (Figure 7.8C), activation kinetics (Figure 7.8D) or 
inactivation kinetics (Figure 7.8B), in direct comparisons between Langendorff 
and injection isolated LV cardiomyocytes. Therefore, it can be concluded that 
the INa density, activation and inactivation kinetics of the injection-isolated 
cardiomyocytes are as expected and this data supports that these cells can be 
used for patch clamping experiments. 
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5.5.5.$Comparable$signalling$cascade$effects$of$injection$and$Langendorff$
isolated$LV$cardiomyocytes$
In order to assess signalling cascades in injection and Langendorff isolated 
cardiomyocytes, the expression of biochemical stress and Ca2+ overload protein 
indicators were analysed.  
 
Despite some differences in resting SL between Langendorff and injection 
isolated cardiomyocytes (Figure 7.5B), PKC-α, ERK1/2 and PLM expression 
was equal in cardiomyocytes isolated from both methods (Figure 7.10). 
Therefore, data presented here establishes that the injection-isolation method 
does not negatively affect cardiac intracellular signalling any more than the 
Langendorff isolation method. 
 
Furthermore, as the injection method negates the need for Langendorff 
perfusion apparatus, it enables simpler and cheaper isolation with the ability to 
maintain a sterile environment if isolated cells are required for culturing. 
Additionally, the injection method does not require the precise identification and 
difficult cannulation of the small mouse aorta, so the likelihood of errors 
occurring from incorrect mounting of the heart, introduction of air, blood 
coagulation and ischemia are reduced. Overall, the novel Langendorff-free 
isolation protocol has proven to be a valuable method for obtaining mouse 
cardiomyocytes that are comparable in physiological health and responsiveness 
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to published findings and those that have been isolated with the Langendorff 
method. Therefore, injection isolation offers a novel and convenient method for 
obtaining mouse cardiomyocytes and data presented here can provide 
reassurance to current or perspective users of this method. 
 
5.5.6.$Potential$injectionRisolation$method$limitations$
Although injection-isolation produces high yields of viable cardiomyocytes with 
comparable functionality to Langendorff isolated cardiomyocytes, there may be 
some limitations to the method. Firstly, in the injection-isolation method, 
reduction in resistance to injection pressure and loss of heart rigidity serve as 
benchmarks for assessing digestion completion.  However, experience of the 
technique may be required in order to recognise these benchmarks and 
researchers may find it difficult to establish when digestion is complete and halt 
the experiment with over or under digested tissue. However, complete digestion 
is also difficult to definitively determine with the Langendorff-isolation method, 
as acceleration of perfusion rate under constant pressure does not always 
serve as an accurate benchmark and likewise requires method experience 
(331). 
 
Another possible limitation of the injection method is that it may not be useful for 
research in infarcted hearts. Infarcted hearts have areas of thin scar tissue that 
can be ruptured (332), suggesting that the injection-isolation method may be 
too harsh for such tissue. Therefore, practical assessment of the injection-
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isolation method on infarcted mouse hearts is imperative in order to establish 
the methods suitability under those circumstances. 
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6.$Overall$discussion$
6.1.$General$outcomes$$
The primary aim of this thesis was to assess sodium channel biophysical 
properties in the atria compared to the ventricles, interpreting the physiological 
significance of chamber electrophysiological distinctions. These investigations 
were performed using isolated LA and LV cardiomyocytes and also examined 
the inhibition efficacy of flecainide as a sodium channel blocking AAD between 
the different chambers. 
 
The main outcomes of this thesis are summarised below: 
• Mouse LA INa density was smaller than LV INa density at physiological 
RMP, due to chamber distinctions in channel voltage dependence of 
inactivation. The mechanism causative of the distinctions in gating 
kinetics has been suggested to be due to chamber differences in 
expression of Navβ2 and Navβ4 (4, 5, 142, 185, 186) and these 
differences are also observed between mouse LA and LV within this 
study. However, human diseased LA and LV presented opposing Navβ2 
expression distinctions. 
. 
• Flecainide demonstrated more potent inhibition of LA sodium channels 
than LV sodium channels likely due to distinctions in channel gating 
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kinetics. Additionally, the difference in inhibition efficacy would be 
expected to be even greater in vivo due to distinctions in physiological 
RMP between the chambers. 
 
• There was no physiological difference between mouse Plako+/- LA and 
LV INa density. This is likely due to the chamber distinctions in channel 
gating kinetics being evident but reduced between Plako+/- LA and LV, 
compared to WT counterparts. Additionally, there was enhanced 
flecainide INa inhibition in the Plako+/- LV compared to WT LV, with no 
difference in flecainide efficacy between the Plako+/- chambers. 
 
• The novel injection-based isolation method described in this thesis 
provided cardiomyocytes that were comparable to those isolated using 
the Langendorff-based method. This established a convenient mouse 
cardiomyocyte isolation method. 
 
6.2.$Physiological$ relevance$of$ INa$distinctions$between$ the$ LA$and$
LV$ $
A key finding in this study is that mouse LA INa density is smaller than LV INa 
density at physiological holding potentials, due to differences in the inactivation 
gating kinetics between the chambers that has also been described by others 
(4, 5, 142, 185, 186). The relationship between channel inactivation kinetics and 
effect on current density at physiological holding potentials has not previously 
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been acknowledged when comparing INa between mammalian LA and LV. 
Former studies have described LA INa density as greater than that of the LV (4, 
5, 142, 185, 186), without recognising that experiments which rely on 
hyperpolarised potentials do not provide in vivo representation. 
 
Therefore, patch clamp experiments measuring INa at hyperpolarised potentials 
offer physiologically irrelevant information in terms of INa density, as holding 
potential greatly alters channel gating kinetics and absolute currents. This also 
dispels the lack of correlation with Vmax findings; supporting the established 
understanding that Vmax is greater in the mammalian LV than LA (31-34, 193, 
194). Greater understanding of physiological LA INa is vital in order to improve 
pharmacological AF therapy and highlights the importance of consideration of 
physiological conditions. 
 
6.3.$Importance$of$LA$INa$distinctions$as$potential$atrialRspecific$drug$
target$
AF is the most common sustained cardiac arrhythmia in clinical practice (99), 
suggesting that the atria are more susceptible to arrhythmia than the ventricles. 
In depth understanding of atrial sodium channel distinctions could prove key to 
understanding the atria’s increased susceptibility to arrhythmia. This thesis 
highlights several atrial sodium channel kinetic distinctions that may enhance 
arrhythmia occurrence within the atria. 
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Physiologically smaller LA INa may lead to reduced CV, which as previously 
described, can be proarrhythmic (1). Secondly, the negatively shifted 
inactivation of LA sodium channels suggests that depolarisation of the RMP as 
a result of medication, ischemia or hypoxia (212), would have a greater impact 
on reducing atrial peak INa. This again could lead to reduction in CV, potentially 
leading to arrhythmia generation (213). Additionally, the negatively shifted 
sodium channel activation of the atria compared to the ventricles, could indicate 
that the atrial sodium channels are more sensitive to untimely depolarisation of 
membrane potential. Therefore, atrial sodium channels may be more 
susceptible to premature activation and subsequent arrhythmias (216). Finally, 
the slower recovery time of the sodium channels may also be considered 
proarrhythmic, also due to potentially slower CV (98). Therefore, 
pharmacological alteration of atrial sodium channel kinetics could reduce the 
likelihood of arrhythmia generation/propagation. Consequently, identifying the 
molecular determinants driving distinctive atrial sodium channel activation, 
inactivation and recovery, may reveal novel drug targets for treatment and/or 
prevention of AF. 
 
As described within this thesis, LA sodium channels may be less likely to 
reactivate prematurely as hyperpolarisation is required for sodium channels to 
convert from the inactivated state and be available for reactivation. Additionally, 
slower sodium channel recovery would hinder channel reopening during 
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repolarisation. Therefore, atria may display negligible or smaller INa,late 
compared to the ventricles and this may be considered as cardioprotective. 
However, this is contradicted by previous studies that have demonstrated 
ranolazine, an INa,late blocker, as an effective AF treatment (204-207). 
Consequently, further investigation is required in order to assess INa,late in the 
atrial and ventricular chambers. 
 
Due to the negative shift in LA sodium channel inactivation a greater proportion 
of the channels remain in the inactivated (closed) state compared to those of 
the LV. It is this property that perhaps makes LA sodium channels more 
sensitive to flecainide inhibition, as inactivated channels are more susceptible to 
blockade (7). 
 
Greater understanding of the VGSC gating kinetics could highlight a target for 
the development of atrial specific AADs that only inhibit sodium channels that 
display atrial specific kinetic properties. As it was determined in this study and 
by others (4, 5, 142, 185, 186), atrial sodium channels are distinctive in terms of 
kinetics so it is feasible that they could be specifically targeted. Existing studies 
with several AADs have found that sodium channels in atrial 
cardiomyocytes/tissue are more sensitive to blockade than ventricular sodium 
channels (4, 5, 142, 185), as with flecainide in this study. However, none of 
those studies were able to identify a drug that had no inhibitory effect on the LV 
sodium channels. Therefore, the properties that render the atrial sodium 
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channels more susceptible to blockade could be more specifically targeted, 
avoiding any inhibition of ventricular sodium channels. 
 
Furthermore, in this study it was confirmed that Navβ2 and Navβ4 expression is 
lower in the mouse LA than LV. This was supported by lower SCN4B mRNA 
expression and trend for lower SCN2B mRNA expression in the healthy human 
LA compared to the LV. This is comparable to protein expression findings 
reported by others in rat myocardial tissue and in healthy human tissue (4). 
Chen et al., presented data supporting a hypothesis that lower expression of 
Navβ2 and Navβ4 subunits in atrial cardiomyocytes may be responsible for the 
negative shift in activation, negative shift in inactivation and slower recovery of 
the LA sodium channels (4). Therefore, Navβ2 and Navβ4 may be the molecular 
determinants driving distinctive atrial sodium channel gating kinetics and could 
potentially provide novel drug targets for treatment of AF in patients. 
 
However, it has been well documented that the co-expression of the other Nav 
β-subunits alongside Navβ2 and Navβ4 can cause further changes in channel 
gating kinetics (236, 238, 240, 241). Therefore, the effects of the other β-
subunits on sodium channel function, and how all of the β-subunits interact with 
each other should be considered. Additionally, there is a lot of inconsistency in 
published data on the role of the Navβ2 and Navβ4, with opposing information 
on whether/how the subunits affect sodium channel gating kinetics (4, 64, 232-
238). Consequently, more research is essential to form a definitive conclusion 
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on whether the lower expression of Navβ2 and Navβ4 in the LA is causative of 
kinetic distinctions and whether they are subsequently suitable atrial specific 
drug targets for AF treatment. Therefore, electrophysiological experiments 
examining the NaV1.5 current kinetics with and without the Navβ2 and Navβ4 
individually and in combination are imperative in order to make definitive 
conclusions on the regulation of sodium channels by the β-subunits. 
 
6.4.$Significance$of$greater$Navβ2$expression$in$diseased$human$LA$
This thesis reveals increased Navβ2 in diseased human LA compared to 
healthy human LA. According to the hypothesis that lower expression of Navβ2 
in the LA results in distinctive sodium channel gating kinetics compared to the 
LV (4), the diseased human LA may present with a more ventricular sodium 
channel phenotype. 
 
Consequently, diseased atrial sodium channels may activate and inactivate at 
more positive potentials and have faster recovery. More positive activation 
could result in a reduction in the excitability of diseased LA cardiomyocytes and 
could be cardioprotective against premature initiation of sodium channels with 
minor depolarisation, inhibiting arrhythmia generation (216). However, a 
positive shift in activation could also lead to reduced INa as the threshold 
potential for activation is increased, with the proarrhythmic reduction in CV (1). 
Nevertheless, there may also be a positive shift in inactivation if the diseased 
LA present with a more LV phenotype. This could result in an increased INa 
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density in vivo, increasing CV and reducing the likelihood of arrhythmia 
generation (1). Proarrhythmic INa,late may also be increased or decreased in 
diseased atria compared to healthy atria, if increased Navβ2 expression does 
alter gating kinetics. Overall, due to the many electrophysiological possibilities, 
further research is fundamental in order to directly compare the sodium channel 
gating kinetics between healthy and diseased LA. 
 
6.5.$ Importance$of$no$difference$ in$ INa$density$between$Plako+/R$LA$
and$LV$
The observed smaller peak INa in WT LA compared to WT LV at a physiological 
holding potential is not apparent between the Plako+/- LA and LV. Plako+/- LA INa 
initiated from -75mV is no different to that of the Plako+/- LV, also no differences 
were observed at any other holding potential. The slight positive shift in Plako+/- 
LA sodium channel inactivation compared to that of the WT LA, could account 
for the lack of difference seen in the INa density between the Plako+/- LA and LV. 
Therefore, amplified INa could be a causal factor of the increased atrial 
arrhythmia generation in endurance-trained mice with plakoglobin deficiency 
(259, 260). A slight increase of INa in the Plako+/- LA could result in enhanced 
INa,late which, combined with exercise and resulting increased cyclic adenosine 
monophosphate levels, could lead to intracellular Ca+ overload (262, 263). This 
could potentially predict increased AF vulnerability due to stress-induced 
triggered activity in plakoglobin deficient athletes. 
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Furthermore, no peak INa difference was observed between WT and Plako+/- LV. 
This opposes the theory that ARVC patients with plakoglobin deficiency and 
associated reduction in LV Nav1.5 expression (179, 180) would experience a 
proarrhythmic reduction of INa. Consequently, it must also be assessed whether 
the reduction in LV and RV Nav1.5 expression, observed in ARVC plakoglobin 
deficient patients, is conserved in the mouse model. Alternatively, upregulation 
of other sodium channel isoforms may contribute to the INa in plakoglobin 
deficient hearts, as current density is not altered. Therefore, if Nav1.5 
expression is reduced in mouse Plako+/- ventricles compared to WT ventricles, 
the expression of other sodium channel isoforms must also be assessed, in 
both the Plako+/- mouse and plakoglobin deficient ARVC patients.  
 
6.6.$Flecainide$has$no$differential$inhibition$between$Plako+/R$LA$and$
LV$
Unlike between WT LA and LV, there is no difference in % inhibition of INa 
between Plako+/- LA and LV. This is due to 10.21% greater inhibition of Plako+/- 
LV sodium channels compared to WT LV sodium channels. This is likely 
primarily due the reduced differences in channel gating kinetics between the 
Plako+/- LA and LV, compared to between WT counterparts. Whether, altered 
expression of beta subunits plays a role in flecainide sensitivity is unclear and 
should be examined in future studies. Although ARVC patients can present with 
increased AF risk (258), ventricular arrhythmias are the primary clinical 
observation. Therefore, ARVC patients with plakoglobin deficiency would 
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benefit from the greater inhibition of LV INa with flecainide, as both ventricular 
and atrial arrhythmias could be supressed simultaneously to the same degree. 
 
6.7.$ Impact$ of$ a$ simplified$ LangendorffRfree$ isolation$method$ that$
produces$high$yields$of$viable$mouse$cardiomyocytes$
The injection method enables simpler and cheaper cell isolation, with the ability 
to maintain a sterile environment, where isolated cells are required for culturing. 
Additionally, as the Langendorff apparatus is not utilised in this method, the 
likelihood of errors resulting from incorrect cannulation and/or mounting of the 
heart, introduction of air, blood coagulation and ischemia are also reduced 
(183). 
 
An important conclusion of this study is the capability of the injection-isolation 
method to supply high yields of viable cardiomyocytes. The novel Langendorff-
free isolation protocol has proven to be a valuable method for obtaining mouse 
cardiomyocytes that are comparable in physiological health and 
responsiveness. Crucially, the injection-isolated cardiomyocytes displayed; 
typical Ca+ handling properties, responses to electrical stimulation, amenability 
to patch clamping and stress-dependent hypertrophic signalling cascades, 
compared to published data and in direct comparison with Langendorff isolated 
cardiomyocytes. Therefore, the data presented within this study can provide 
reassurance to current or perspective users of this isolation method. Overall, 
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the injection-isolation method removes technical and logistical obstacles to 
cardiac studies, potentially expanding and accelerating innovative research 
within this field. Whether the methodology can be applied for isolation of cells 
from the post-infarcted hearts with large scars, thin myocardium that is 
susceptible to rupture due to high pressure needs to be examined.   
 
6.8.$Study$limitations$
6.8.1.$General$limitations$
All experiments described within this thesis were performed in vitro, in isolated 
cardiomyocytes or cardiac tissue following surgical isolation of the intact heart 
from the mouse. Therefore, the heart could have been exposed to short periods 
of ischemia, hypoxia, acidosis and protein degradation, potentially affecting 
experimental outcomes (333-336). In order to limit the likelihood of tissue/cell 
impairment, isolation was carried out as rapidly as possible. 
 
Additionally, the majority of the data within this thesis was obtained using a 
mouse model. The mouse cardiac electrophysiology (i.e. heart rate, absence of 
IKr and IKs and contractility force frequency) differs to that of the human heart. 
Therefore, translational aspects must be interpreted with caution. However, 
human heart tissue availability is very limited and exhibits great variability (337) 
and the mouse model does offer many benefits described within this study. 
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6.8.2.$Patch$clamp$limitations$
Attention to temperature and patch clamp protocol conditions is important when 
designing experiments, in order to determine accurate INa properties. It is 
beneficial to measure sodium channel properties using hyperpolarised 
potentials in patch clamp protocols as current is amplified and distinctions are 
easier to observe/analyse. This is shown in Figure 3.2 of this thesis, where INa 
density decreases as the holding potential becomes depolarised. However, as 
also demonstrated within this thesis, holding potential of cardiomyocytes has a 
great effect on the current kinetics observed. Therefore, it would be beneficial to 
measure peak INa, inactivation, activation and recovery kinetics of the channels, 
with patch clamp protocols that are more representative of in vivo 
electrophysiological conditions. For example, when assessing the I/V 
relationship, the holding potential of the cardiomyocytes could be paired to 
physiological holding potential in vivo, -80 to -90mV for LV and -60 to -80mV for 
LA cardiomyocytes (19, 20). This would provide physiologically relevant voltage 
dependence of activation data. 
 
Similarly, when quantifying the voltage dependence of inactivation and recovery 
time, the potential that is used to stimulate peak INa could originate from a 
holding potential that is representative of cardiomyocytes in vivo RMP. 
Therefore, it would be advantageous to this study and all INa patch clamp 
studies, that physiologically relevant protocols were also completed. However, 
this would serve as a great logistical obstacle as it would require experiments to 
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be much longer and it is difficult to ensure cardiomyocytes remain healthy over 
prolonged electrophysiological experimentation. This would likely require more 
experiments to be run in order to achieve a substantial data set, proving a 
logistical and financial burden to this study. 
 
Likewise, it has been demonstrated that temperature has an effect on the gating 
kinetics of VGSCs (338-340), potentially inducing differing effects on VGSCs 
between the LA and LV chambers. Consequently, it would be preferable for 
experiments to be completed at physiological temperature (36.5–37.5°C), 
requiring water baths to heat patch clamp solutions. However, patch clamp 
experiments within this thesis were carried out at room temperature and this 
must be considered a limitation of this study. 
 
6.8.3.$Western$blot$limitations$
There was limited choice of Nav1.5 antibodies, with the only antibody that 
worked (Alomone, ASC-005) consistently displaying multiple bands on the 
blots. Similarly, no measurement of Navβ1 or Navβ3 expression was made, as 
antibodies consistently did not yield any data. 
 
Additionally, due to time constraints and difficulty with method optimisation, 
neither Nav1.5 or Navβ4 expression was measured in diseased human LA and 
LV. Likewise, limited human healthy LV tissue means that it was not possible to 
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compare Nav1.5 or β-subunits between diseased LV and healthy LV or healthy 
LA. 
 
6.9.$Future$experiments$
6.9.1.$Electrophysiology$experiments$
In view of the results from this thesis a key investigation would be to perform 
additional patch clamp experiments measuring INa and flecainide inhibition in 
mouse LA and LV cardiomyocytes under more physiological conditions. This 
would include ensuring patch clamp solutions were kept at 36.5–37.5°C and 
chamber specific in vivo RMP was considered when designing all protocols (as 
described above). This would provide more physiologically relevant data. 
 
It would also be interesting to measure the INa in the LA and LV from a diseased 
mouse model. This would assess whether the increased expression of Navβ2 
observed in diseased human LA affects channel gating kinetics as suggested. 
Additionally, examining flecainide inhibition would be beneficial in order to 
access whether increase in LA Navβ2 would reduce drug efficacy, if channels 
do exhibit LV gating kinetics. Firstly, additional Western blot experiments would 
be required in order to determine whether Navβ2 expression is increased in the 
diseased mouse LA compared to WT LA in accordance with human data. 
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Patch clamp experiments measuring INa,late in WT LA and LV cardiomyocytes 
would also offer insight into whether differences in channel gating kinetics result 
in differential INa,late, as hypothesised above. If sizeable INa,late was measured in 
both chambers, the addition of a INa,late inhibitor, such as ranolazine, would also 
reveal whether differences in gating kinetics affect drug efficacy. 
 
Experiments measuring INa in HEK293 cells expressing Nav1.5 with different 
combinations of the Navβ-subunits and then each Navβ-subunit individually, 
would provide definitive information of the effect of each of the subunits on 
gating kinetics and also consider interactions between the subunits. This would 
aim to determine whether differential expression of Navβ2 and Navβ4 between 
the LA and LV does regulate differences in channel gating kinetics. 
 
6.9.2.$Molecular$experiments$
Measurement of Navβ1 and Navβ3 in WT LA and LV would offer a more 
conclusive study on the comparisons of the β-subunits. Likewise, expression of 
Navβ1 and Navβ3 between human diseased LA and LV would also make the 
study more comprehensive. Additionally, it is essential that Navβ1, Navβ3 and 
most notably Navβ4 expression be compared between the healthy human LA 
and diseased LA, preferably also compared in diseased and healthy human LV 
samples, in order to complete the data set. 
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As described above, Western blot experiments would be required in order to 
determine whether Navβ2 expression is increased in the diseased mouse LA 
compared to WT LA in accordance with the human data.  
 
Measurement of the expression of Nav1.5 in Plako+/- ventricles compared to WT 
ventricles would establish whether the observed reduction in ventricular Nav1.5 
expression in plakoglobin deficient ARVC patients is conserved in the mouse 
model (179, 180). If expression of Nav1.5 is reduced in the Plako+/- mouse 
model, measurement of other sodium channel isoforms could aim to understand 
the lack of difference in INa between WT and Plako+/- LV.  
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